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2. Summary  2. Summary  2.1 Summary  Retinoblastoma is the most common intraocular malignancy of infancy which is thought to originate from progenitor cells of the developing retina.The modern therapeutic approaches for retinoblastoma treatment including radiotherapy have very high success rates if the tumour is diagnosed at an early time point. But these therapies, especially radiotherapy, have side effects such as damage to healthy tissues and increasing the risk of induction of secondary tumours. As the radiotherapy has to be performed in a very young age and the risk of the therapy's side effects persist over lifetime, the quality of the patients' lives is strongly impaired. The risk of developing secondary tumours after radiotherapy is particularly high for patients with a family history of retinoblastoma, which leads to a deterioration in the quality of these patients’ lives. In this context, the aim of our project was to analyse a new option for the prevention of side effects of radiotherapy of the retinoblastoma through the use of the radioprotector ortho-phospho-L-tyrosine (pTyr). Three main questions had to be answered:  1. Is there a relevant retinoblastoma-mouse-model which can be used for radiotherapy?  2. Can the application of pTyr protect tissues that are damaged by irradiation during radiotherapy and prevent the induction of secondary tumours?  3. Does the application of pTyr interfere with the radiotherapy? To answer question 1., the retinoblastoma mouse models described in the literature were analysed. Since none of them fully met our requirements, we decided to establish a new retinoblastoma-xenograft-mouse model by performing intravitreal injections of human Y79 cells in immunodeficient nude mice. The growth of the xenograft tumours in the eyes was monitored in vivo by scanning laser ophthalmoscopy (SLO) and optical coherence tomography (OCT). These results were compared to the results of the corresponding histological analysis. The in vivo and histological results showed a good correlation. The xenograft-tumours in the mouse-model showed very similar growth, histological and ultrastructural characteristics to Rb patients’ tumours and therefore our model can be used for the study of retinoblastoma.  To answer the second question, Rb+/- mice as a model for patients who have defects in the homologue human RB1 gene were used. These patients have a higher risk of developing a retinoblastoma and other tumours like sarcomas, additionally they are prone to radiotherapy-induced tumours. The animals were irradiated in a retinoblastoma radiotherapy-like procedure with and without a pTyr pre-treatment (100 mg/kg bodyweight, 16 hours before irradiation). A bleaching of the hair coat in the irradiated area started five weeks after irradiation in the animals which were not treated with pTyr. However, in the pTyr pre-treated animals the bleaching started later, about eight weeks after irradiation, and was significantly weaker. Importantly our in vivo (OCT) as well as our histological results have shown that pTyr protects the retina, which is a radiosensitive tissue, against the radiation-induced damage: the irradiation induced degenerative changes in the retina, such as thickness reduction, and loss of photoreceptors were significantly higher in the non-pTyr pretreated animals as compared to the pTyr-treated ones three, six and nine months after irradiation. No induced tumours or distant metastasis were found for any of the analysed mice. Since it is known that in retinoblastoma patients induced tumours are mostly diagnosed some 30 years after radiotherapy, the maximum lifespan of 16 months of our mice might be too short for the side effects to appear.  Finally, in order to check if the application of pTyr would interfere with radiotherapy, the ability of pTyr to protect Y79 cells in vitro and in vivo was tested. For the in vitro 
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2. Summary  testing Y 79 cell cultures were irradiated with and without pTyr pretreatment and their survival was analysed using different “limited dilution assays”. No significant radioprotection of pTyr on Y79 cells was detected.  For the in vivo analysis of the radioprotection of Y79 cells by pTyr, our new established nude mouse model was used for a radiotherapeutic experiment with and without pTyr pre-treatment. The radiotherapy was successful as 80% of the mice which were not pre-treated with pTyr, stayed tumour-free for at least nine months after radiotherapy. However, in all pTyr pretreated animals a retinoblastoma reappeared. It has become apparent, that pTyr is a potent radioprotector for Y79-xenografts in contrast to Y79 cell cultures. This makes pTyr contraindicated for the radiotherapy of retinoblastoma. However, the radioprotective abilities of pTyr might make it interesting for the radiotherapy of other cancers, especially those with p53 mutations.  2.2 Zusammenfassung  Das Retinoblastom ist der häufigste intraokulare Tumor im Kindesalter. Moderne Therapien für Retinoblastom-Patienten wie z.B. die Strahlentherapie führen bei frühzeitiger Erkennung des Tumors mit sehr hoher Wahrscheinlichkeit zur Heilung. Allerdings hat die Strahlentherapie Nebenwirkungen wie z.B. Normalgewebsschädigungen und ein erhöhtes Risiko für das Entstehen von Sekundärtumoren. Da die Therapie im sehr frühen Lebensalter stattfindet und das Risiko der Folgeschäden der Therapie ein Leben lang bestehen bleibt, wird die Lebensqualität der Patienten dadurch nachhaltig beeinträchtigt. Das Risiko ist besonders hoch für Patienten mit familiärer Retinoblastomvorbelastung. Vor diesem Hintergrund war es das Ziel unseres Projektes einen Ansatz zur Prävention dieser therapiebedingten Nebenwirkungen für die Strahlentherapie des Retinoblastoms durch den Einsatz des Normalgewebs-spezifischen Radioprotektors Ortho-phospho-L-tyrosin (pTyr) zu untersuchen. Dabei sollten drei wichtige Fragen geklärt werden:  1. Gibt es ein passendes radiotherapeutisch einsetzbares Retinoblastom-Mausmodell?  2. Kann pTyr Radiotherapie-bedingte Nebenwirkungen und die Entstehung von Sekundärtumoren verhindern?  3. Wird durch pTyr Gabe eine Beeinträchtigung des Erfolges der Strahlentherapie verursacht? Um die erste Frage zu beantworten, wurde zunächst die Literatur nach Retinoblastom-Modellen durchsucht. Da keines der beschriebenen Modelle unseren Vorstellungen voll entsprach, wurde beschlossen ein neues eigenes Modell zu etablieren. Dazu wurden humane Y79 Tumorzellen intravitreal in immundefiziente Nacktmäuse injiziert. Das Wachstum der Xenograft-Tumore in den Augen wurde in vivo mit Hilfe von scanning laser ophthalmoscopy (SLO) und optical coherence tomography (OCT) untersucht und die Resultate mit denen der entsprechenden histologischen Untersuchungen verglichen. Die Resultate der in vivo Untersuchungen konnten gut mit den Resultaten der histologischen Untersuchungen korreliert werden. Das Wachstum der Xenograft-Tumore in unserem neu etablierten Retinoblastom-Nacktmausmodell, sowie deren zelluläre und ultrastruckturellen Charakteristika waren dem menschlicher Retinoblastome sehr ähnlich. Somit ist unser Modell gut für Untersuchungen zum Wachstum und Entwicklung des Retinoblastoms geeignet. Somit sind die von uns verwendeten in vivo Verfahren für die Detektion und morphologische Beschreibung von Retinoblastomen im frühen Entwicklungsstadium einsetzbar.  Um die zweite Frage zu klären wurden Rb+/- Mäuse eingesetzt. Diese dienten als Modell für Patienten mit Defekten im homologen RB1 Gen, die ein höheres Risiko haben ein Retinoblastom und Sekundärtumore nach einer Strahlentherapie zu 
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2. Summary  entwickeln. Die Mäuse wurden mit und ohne pTyr-Vorbehandlung in einer eine Retinoblastom-Radiotherapie simulierenden Art bestrahlt. Die erste feststellbare Reaktion der Mäuse auf die Bestrahlung war eine Veränderung des Fells im bestrahlten Bereich von schwarz zu grau/weiß. Bei allen nicht mit pTyr behandelten Tieren erfolgte diese Reaktion ca. 5 Wochen nach der Behandlung. Diese ist bei den mit pTyr behandelten Tieren später (ca. 8 Wochen nach Behandlung) und signifikant weniger stark ausgeprägt erfolgt. Fell und Hautveränderungen sind bekannte Begleiterscheinungen nach Bestrahlungs- und Radiotherapeutischen Versuchen bei Mäusen. Eine weitere wichtige Frage unserer Untersuchung war, ob die Retina, die ein bestrahlungsempfindliches Gewebe darstellt, durch die pTyr Behandlung vor Strahlenschäden geschützt werden kann. Sowohl unsere in vivo als auch unsere histologischen Untersuchungen lassen eine schützende Wirkung von pTyr auf bestrahltes Gewebe erkennen, da die degenerativen Retinaveränderungen in den mit pTyr vorbehandelten Tieren 3, 6 und 9 Monate nach Bestrahlung deutlich schwächer ausgeprägt waren als in den nicht mit pTyr vorbehandelten. Im Beobachtungszeitraum dieses Versuches konnten keine induzierten Tumore beobachtet werden. Wir gehen davon aus, dass diese sich erst zu späteren Zeitpunkten manifestieren würden. Bei Retinoblastom-Patienten, die mit Radiotherapie behandelt wurden, werden Therapie-induzierte Tumore meist erst ungefähr 30 Jahre nach der Behandlung diagnostiziert.  Um zu testen, ob pTyr die Radiotherapie beeinträchtigt, wurden in vitro und in vivo Studien zur Radioprotektion von pTyr auf Y79 Zellen durchgeführt. Für die in vitro Untersuchung wurden Y79-Tumorzellkulturen mit und ohne pTyr Vorbehandlung bestrahlt und das Überleben der Zellen mittels „limited dilution assays“ analysiert. Es konnte keine signifikante Radioprotektion von pTyr in Y79 Zellen in unseren in vitro Studien nachweisen werden.  Um die Radioprotektion von pTyr auf Y 79 Zellen in vivo zu untersuchen, wurde unser neu etabliertes Xenograft-Retinoblastom-Nacktmausmodell eingesetzt. Die Mäuse wurden mit und ohne pTyr Vorbehandlung radiotherapeutisch behandelt, wobei das gleiche Bestrahlungs-Schema wie für die Bestrahlungen der Rb+/- Mäuse angewendet wurde. Der Erfolg der Radiotherapie mit und ohne pTyr-Vorbehandlung wurde untersucht.   Die Bestrahlungen haben die Y79 Krebszellen effektiv eliminiert. 80% der Mäuse, die nicht mit pTyr vorbehandelt wurden, sind über einen Zeitraum von mindestens neun Monaten Tumor-frei geblieben. pTyr hat sich allerdings als ein potenter Radioprotektor für Y79 Xenograft-Tumore erwiesen, im Gegensatz zu Y79 Zellkulturen. In allen mit pTyr behandelten Mäusen haben sich nach der Radiotherapie wieder Retinoblastome entwickelt, was den Einsatz von pTyr für die Radiotherapie des Retinoblastoms ausschließt.  pTyr könnte allerdings für den Einsatz in der Radiotherapie anderer Tumore, vor allem derer mit p53 Defekten in Frage kommen.   
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3. Introduction  3. Introduction  3.1 Retinoblastoma (Rb)  3.1.1 History of Rb  It seems that retinoblastoma (Rb) is a very old problem of human beings. There are hints that the ancient Mayans already suffered from Rb. Thus in the national museum of Mexico there is a stone sculpture of a head with Rb-like symptoms such as a hanging lip and a swollen eye, which is estimated to be 4000 years of age (fig. 1 A) (Gaitan-Yanguas, 1978).  The first person to report about patients with Rb-like symptoms in Europe was Pieter Pauws (Petrus Pawius of Amsterdam) a noted anatomist and later professor at the University of Leiden in 1597 (Kivela & Polkunen, 2003). James Wardrop, a famous Scottish surgeon, described an Rb-like disease- fungus haematodes, as an entity in 1809 and suggested enucleation as the preferred treatment (fig. 1 B) (Albert, 1987). Numerous famous ophthalmologists like Friedrich Wilhelm Ernst Albrecht von Graefe, pathologists like Rudolf Virchow, who claimed that Rb is of glial origin and used the term glioma of the retina, and many others made their contributions to the understanding and treatment of Rb (Pandey, 2014).  The name retinoblastoma for this kind of tumour was first suggested by the American ophthalmic pathologist, Friedrich Herman Verhoeff in the 1920’s, a term that was adopted by the American Ophthalmological Society in 1926 (Grossniklaus, 2014). He was also the first person to report about the first Rb patient who received radiotherapy (RT), whose eye was cured, who kept his vision and stayed tumour-free for over 50 years (Verhoeff, 1921, 1952).   
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3. Introduction    Fig. 1: Historical representations of retinoblastoma. (A): stone sculpture of a head with Rb-like symptoms such as a hanging lip and a swollen eye National museum of Mexico (ca. 2000 BC) (B): illustration from “Observations on fungus haematodes or soft cancer in several of the most important organs of the human body: containing also a comparative view of the structure of fungus haematodes and cancer: with cases and dissections” by Wardrop James (1809).  3.1.2 Aetiology and Epidemiology of Rb  A family history of Rb is a major risk factor for the development of the tumour. The genetic background for these kinds of Rb-tumours will be discussed in more detail in the Chapters 3.1.3 Biology of Rb and 3.1.4 RB1 gene.  Risk factors for the development of sporadic (without family history) Rb are poorly understood. There are hints that the exposure of the parents to pesticides (Kristensen et al., 1996), higher age of the parents (Moll et al., 1996) and in vitro fertilization (IVF) (Moll et al., 2003) are risk factors. Additionally, climate, race, socioeconomic development (Jemal et al., 2000), UV exposure (Hooper, 1999), and diet are discussed as risk factors (M. A. Orjuela et al., 2005). The human papilloma virus (HPV) protein E7 leads to Rbp degradation. HPV could be found in 36% of Rb tumours according to an epidemiological study with Mexican patients (Boyer et al., 1996; M. Orjuela et al., 2000), which makes a HPV infection of the mother a risk factor (Bhuvaneswari et al., 2012) because the virus can be transferred to the child. Additionally it was shown that Rb1 expression is negatively regulated in cells containing replicating genomic RNA from hepatitis C virus, a human virus strongly 
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3. Introduction  associated with hepatocellular carcinoma (Munakata et al., 2005). These studies suggest intriguing possible factors that may contribute towards the incidence of retinoblastoma, but further work to better elucidate the etiology of Rb is needed.  There is no clear gender-specific difference in the incidence of Rb. Global incidence data for retinoblastoma show an approximate 50-fold variation, which is highly atypical for a paediatric tumour. According to population-based registry data of the International Agency for Research in Cancer (IARC), incidence rates are generally similar in North America, Europe, and Australia; slightly higher rates are observed in Central and South America; a wide range of rates are reported in Asia with the highest in the Chennai region in India; and generally higher rates are observed in Africa (Parkin et al., 1988).  Great efforts are being made to investigate the variations in the incidence of Rb and risk factors for the development of the disease. The study of geographic and ethnic variations, factors that may differ between populations with different incidence rates for Rb may help to recognize the risk factors for Rb and those populations with a higher risk of developing Rb. This information could be used to inform the populations about the risk and develop monitoring programs.  3.1.3 Biology of Rb  Retinoblastoma is the most common intraocular malignancy of infancy which is thought to originate from progenitor cells of the developing retina (Aerts et al., 2016; Aerts et al., 2006). A controversial discussion about the exact cell type of the origin of Rb is still going on (Ajioka et al., 2007).  The tumour can grow within the retina (endophytic), extending into the vitreous body (fig. 2 A), or beneath the retina, subretinal (exophytic), which results in a detachment of the retina lying above it (fig. 2 B). There are also combined forms as well as diffuse infiltrating forms of retinoblastoma. In addition, the tumours can occur in just one part of the eye (unifocal) or in several places at once (multifocal) (fig. 2 C) (Balmer et al., 2006).  
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3. Introduction    Fig. 2: Illustrations of retinoblastoma. (A): Schematic picture of a human eye with a unifocal Rb tumour with an endophytic growth pattern. The tumour arises from the retina and grows into the vitreous (B): Gross photograph of a human eye with a unifocal Rb with an exophytic growth pattern. The tumour arises from the retina (arrows) and grows into the subretinal space (from clinical features, diagnosis, pathology P. Chevez-Barrioz, D.S. Gombos : Rodriguez-Galindo C, Wilson MW, eds. Retinoblastoma. New York: Springer; 2010:32). (C): Fundoscopic image of a multifocal Rb (from Bornfeld N, Schüler A., Bölöni R, Jurklies C, Wieland R, Sauerwein W, Lohmann D. (2006) Retinoblastom. Ophthalmologe 103:66)  Rb has an incidence of about 1/20000 live births. It is estimated that Rb affects 7000-8000 new patients worldwide yearly (Broaddus et al., 2009; Seregard et al., 2004). Survival rates vary dramatically worldwide. Untreated, mortality is 100%.  Rb occurs in different forms, depending on the site and direction of growth (fig. 2). Sixty percent of Rb are unilateral, afflicting one eye, with a median age at diagnosis of two years. Rb is bilateral, afflicting both eyes, in about forty percent of cases, with an earlier median age at diagnosis (one year) (Ayari-Jeridi et al., 2015). In very rare cases a trilateral Rb occurs. Here both eyes and the pineal or suprasellar region are afflicted (Antoneli et al., 2007; de Jong et al., 2014).  There is a clear link between the disease and the inactivation of a tumour suppressor gene- the Rb gene (RB1), which was first described by Knudson, who formed the so called “two-hit hypothesis”. According to this theory both alleles of the RB1 tumour suppressor gene must be inactivated to initiate Rb (Knudson, 1971) (fig. 3). 
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3. Introduction    Fig. 3: “2 hits hypothesis”. Retinoblastoma is initiated by the inactivation of RB1. The loss of both alleles of RB1 (I1 and I2, inactivation events: mutations, chromosomal loss, methylation of the Rb1 promotor region inactivation on RNA level), are necessary, but not sufficient, for retinoblastoma development. The first inactivation (first hit) can be due to either an inherited or sporadic mutation in a certain retinal cell, the second inactivation (second hit) of the other RB1 allele in that retinal cell, which is always sporadic, predisposes the formation of the benign tumour retinoma, while a number of additional mutational events eventually lead to retinoblastoma. (illustration modified from Genetics of Retinoblastoma and Genetic Counseling H. Dimaras, B. L. Gallie In: Rodriguez-Galindo C, Wilson MW, eds. Retinoblastoma. New York: Springer; 2010:42.)  Rb occurs in two forms, hereditary (40%) and non-hereditary (60%)The hereditary disease is caused by a constitutional mutation in the RB1 gene that predisposes to Rb and other cancers later in life and is transmitted as an autosomal dominant trait with high penetrance (90%). In its non-hereditary form, Rb is initiated by two somatic mutations in the RB1 gene in retinal cells.  All bilateral and multifocal unilateral forms of Rb are hereditary and part of a genetic cancer predisposition syndrome. All children with a bilateral or familial form, and 10 to 15% of children with a unilateral form, constitutionally carry RB1 gene mutations (Ayari-Jeridi et al., 2015; Jehanne et al., 2014).   3.1.4 RB1 gene  The RB1 gene in humans is located on chromosome 13q14. It is the first described tumour suppressor gene (TSG) (Murphree & Benedict, 1984). Various mechanisms have been found which lead to a loss of function of RB1: over 1000 mutations of the Rb1 gene (Richter et al., 2003), loss at chromosome 13 (site of Rb1) (Bunin et al., 1989), silencing by hypermethylation of the promotor of RB1 (Richter et al., 2003) and viral infections (M. Orjuela et al., 2000). These can initiate Rb formation. 
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3. Introduction   However, the initiation of some very rare forms (3-7%) of Rb without mutations in the RB1 gene is associated with amplifications of the MycN gene (Rushlow et al., 2013).  3.1.5 Rbp interactions and its role in cancer   The product of the RB1 gene, the retinoblastoma protein (Rbp), belongs to the group of the so called “pocket proteins”: This family includes three members, Rbp1/p105, p107 and Rbp2/p130, all of them are involved in cell cycle regulation. (Giacinti & Giordano, 2006).  The Rbp has various functions (fig. 4), it represses gene transcription by directly binding to the transactivation domain of E2F (E transcription factor) and by binding to the promoter of these genes as a complex with E2F. Rbp represses transcription also by remodeling chromatin structure through interaction with proteins such as hBRM ((Brahma homologue) also known as SMARCA2 - SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4), BRG1 ((Brahma-related gene 1) also known as SMARCA4), HDAC1 (Histone deacetylase 1) (Luo et al., 1998) and SUV39H1 (Suppressor of variegation 3-9 homolog), which are involved in chromatin remodelling, histone acetylation/deacetylation and methylation respectively, and interacts with different other non-chromatin remodeling proteins like APC/C (anaphase promoting complex/cyclosome), SKP2 (S-phase kinase-associated protein 2) and MDM2 (Mouse double minute 2). Loss of Rbp functions may lead to cell cycle deregulation and tumourigenesis (Burkhart & Sage, 2008).   
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3. Introduction    Fig. 4: Interactions of Rbp. (A): In the cytosol, Rbp binds to E2F/DP and prevents them from entering the nucleus and activating their target genes, this activity is controlled by the CycD1/CDK4 and CycE/CDK2 complexes, which phosphorylate Rbp, leading to the release of E2F/DP (B) Rbp/E2F is recruited to the promoter region of target genes and inhibits their transactivation, additionally this complex interacts with chromatin remodeling complexes (including HDAC (histone deactylase), DNMT1 (DNA methyltransferase 1), HP1A (heterochromatin protein 1A) and SUV39H1) to repress transcription of  target genes. (C) Rbp interacting with the chromatin remodelling machinery acts as a transcriptional co-factor for non-E2F transcription factors or other co-factors (o), such as the HIF1α (hypoxia-induced factor 1α), MYOD (myogenic factor D) and SP1 (specificity protein 1) transcription factors. (D) Rbp serves as a non-chromatin-associated co-factor with other proteins (oo), e.g. Rbp forms a complex with APC/C (anaphase promoting complex/cyclosome) and SKP2 (S-phase kinase-associated protein 2) promoting SKP2 degradation. Rbp binds and inactivates MDM2, an inactivator of p53 (illustration modified from (Burkhart & Sage, 2008))   Additionally, Rbp is involved in various mechanisms of tumour suppression (fig. 5). Rbp can suppress cancer development through its interactions with more than 100 different partners, including lineage-specific transcription factors, DNA-modifying enzymes and members of chromatin remodelling complexes (Chinnam & Goodrich, 2011; Viatour et al., 2003), by inducing differentiation, controlling cell-cycle arrest, maintaining genomic stability and inducing senescence (Takahashi et al., 2007) in response to oncogenic stresses. Furthermore, the absence of Rbp has been associated with increased tumour angiogenesis and metastasis (Gabellini et al., 2006), although the mediators of these functions are less well understood. 
13
3. Introduction  Surprisingly, the presence of Rbp has a partly pro-survival function because of its inhibition of cell death through apoptosis and, potentially, autophagy by interacting with APAF1 (apoptotic peptidase activating factor 1); BNIP3 (BCL2-interacting protein 3); CDH1 (cadherin 1); DNMT1 (DNA methylatransferase 1); HIF1α, (hypoxia-induced factor 1α); PCNA (proliferating cell nuclear antigen); VEGF (vascular endothelial growth factor) to mention a few, an overview is presented in (fig. 4). Of particular interest for this thesis was the Rbp/MDM2 (fig. 5, red circled) interaction which is involved in the p53 pathway, which will be discussed further (Burkhart & Sage, 2008).    Fig. 5: Overview of the numerous Rbp binding partners and transcriptional targets that might mediate its tumour suppressor ability. Presence of Rbp might prevent tumour formation by inducing differentiation, controlling cell-cycle arrest, maintaining genomic stability and inducing senescence in response to oncogenic stresses. The absence of Rbp has been associated with increased angiogenesis and metastasis. This figure depicts a simplified representation of the potential role of Rbp in tumour suppression. Each function is illustrated with some of the key protein binding partners and transcriptional targets associated with that function, but they are not meant to be comprehensive. APAF1, apoptotic peptidase activating factor 1; BNIP3, BCL2-interacting protein 3; CDH1, cadherin 1; DNMT1, DNA methylatransferase 1; HIF1α, hypoxia-induced factor 1α; PCNA, proliferating cell nuclear antigen; VEGF, vascular endothelial growth factor, MDM2 (red circled) (illustration modified from (Burkhart & Sage, 2008))    
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3. Introduction  3.1.6 Rb research  As confirmed by numerous historical references, Rb was always an object of scientific interest. Innovative surgical, radiotherapy (RT), chemotherapy (ChT) and other therapeutical methods were developed for the treatment of Rb. The biological, genetic and aetiological studies of Rb have widened and deepened our understanding of this tumour and tumours in general. This was the first tumour where a heredity predisposition for a cancer disease due to a genetic alteration was shown (Knudson, 1971).  Knowledge on the tumourigenesis and development of Rb has made a huge step forward with the development of suitable mouse models (Dyer et al., 2005; Macpherson, 2008; Villegas et al., 2013).  For example, using the transgenic LHBETATAG mouse with hereditary Rb, 26% of advanced Rb tumours have been shown to have hypoxic regions (Boutrid et al., 2008). As a result, hypoxic cells may serve as important targets for adjuvant therapies. Treatment with glycolytic inhibitors which decrease hypoxia as an adjuvant to chemotherapy has the potential to increase the efficacy of chemotherapy in advanced Rb (Boutrid et al., 2008). Recently, the chemotherapeutic effect of focal melphalan, a highly potent drug for Rb treatment (Muen et al., 2012; Schaiquevich et al., 2012) was investigated in the LHBETATAG murine model and it has shown a significant effect on reducing tumour burden, hypoxia and vasculature (Shah et al., 2014). The genetic background of the Rb incidence differs in mouse and human. So for the development of a Rb-tumour in a mouse, not only the RB1 gene has to be inactivated, but also another member of the Rb gene group (p107, p130) and/or the tumour suppressor gene p53 (Zhang et al., 2004). The advantage of xenograft models is the usage of human cells (Pacal & Bremner, 2006). These models are especially suitable for studying novel therapeutic approaches.  3.1.7 Diagnosis of Rb  Diagnosis of a retinoblastoma should be made as early as possible. Therefore, if either parent suffered from retinoblastoma, the first examination of the new-born child should already be performed at the age of two weeks. The first and often decisive leading symptom when diagnosing this condition is leucocoria, a white reflection in the pupil, if this is detected, then the cause should be identified as soon as possible. In addition, if strabismus is present, the child should be examined for Rb.  
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3. Introduction   The first measure to be taken in the diagnosis of retinoblastoma is inspection of the fundus. However, for a more detailed clarification of the exact shape, size and possible space occupied by the retinoblastoma, additional examinations with (high-resolution) ultrasound and magnet resonance imaging are often used.   Beyond this, well-established techniques like Fundoscopy, Wide-field Photography, Computer Tomography, Magnetic Resonance Imaging, Ultra Sound-based techniques (de Graaf et al., 2012), Scanning Laser Ophthalmoscopy (SLO) and Fluorescein Angiography (FA) were shown to be useful for the study of the tumour’s vessel system and its changes after treatment (Bianciotto et al., 2012; Wetzig, 1966): Using Auto-Fluorescence Fundoscopy, clinical features of Rb, especially calcifications, could be effectively analysed (Ramasubramanian et al., 2011).  Recently optical coherence tomography (OCT) is being used for the diagnosis and characterisation of ocular tumours, it is more precise with regard to surface changes to the macula, macular oedema and subfoveal fluid compared to a simple clinical examination or ultrasonography. Within a very short space of time, it has become highly regarded in clinical retinal diagnostics (Shields et al., 2004).  The introduction of OCT in diagnosis and monitoring of Rb patients allows visualization of foveal anatomy and microstructure. This allows a correct assessment and facilitates planning for visual rehabilitation (Rootman et al., 2013). In vivo methods like SLO/OCT have also been successfully used for detection and characterisation of tumours in mouse models by our group (Tschulakow et al., 2016) and Wenzel et al. (Wenzel et al., 2015).  For the successful treatment of patients with Rb, an early diagnosis is essential. The various aspects of the disease like grading, size, localisation etc. must be taken into account. The aim is to save the patient’s life and to cause as little damage as possible. In cases where the tumour has grown too big and the likelihood of restoring vision is low or there is a danger of metastasising, enucleation is still the only treatment option (Jehanne et al., 2014).  3.1.8 Radiotherapy and other treatment options for Rb treatment   Rb responds very well to radiotherapy (RT) and external beam radiotherapy was the first globe and vision saving therapy for Rb (Albert, 1987). However, in addition to the unavoidable risk of the RT, the genotype of the hereditary Rb patients predisposes the appearance of secondary malignancies. The RT further enhances the risk of RT- induced tumours occurring in the irradiated area (Mayorga et al., 2014). In these patients secondary tumours can already be triggered by exposure to natural 
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3. Introduction  radioactivity, X-rays or the cosmic radiation on high mountains or on board airplanes or during X-ray exposure for diagnostic purposes. Of course this means a reduction in the quality of life for these patients. The incidence of secondary tumours 50 years after diagnosis due to radiotherapy of retinoblastoma is 38% (Kleinerman et al., 2005). This explains why the trend has been to move away from radiotherapy (Abramson & Frank, 1998; Dommering et al., 2012; Rodjan et al., 2013; Vasudevan et al., 2010). This has favoured the use of other therapeutical approaches like cryo-, thermotherapy as well as systemic, periocular, intra-arterial or intravitreal chemotherapy and combined therapies such as chemosurgery (Ghassemi & Shields, 2012; Schueler et al., 2006; Temming et al., 2012; Yamane et al., 2004).   Although radiotherapy for the treatment of Rb is nowadays avoided as much as possible and is considered only as the last treatment option prior to enucleation, it is still considered necessary for patients with large tumours who are not candidates for chemosurgery, but who have visual potential. Approximately 80% of the Rb patients are still diagnosed at a locally advanced stage, and only 20-25% at an early stage. Additionally chemotherapy fails in more than two-thirds of eyes with advanced stages of Rb, requiring RT or enucleation (Kim & Park, 2015).  Strategies which could reduce the described side effects of RT and make RT safer are currently in the focus of extensive scientific investigations. High-tech RT like proton beam RT (Krengli et al., 2005; Mouw et al., 2014), intensity-modulated and fractionated stereotaxic RT (Combs et al., 2007) enables precise radiation delivery to the tumour while sparing the healthy tissues, improving the efficacy/toxicity ratio. Additionally, the side effects of the RT can be reduced by the usage of radioprotectors before and mitigators after RT (Bourgier et al., 2012). For these pharmacological agents, it is important to be active only in normal tissues and not to interfere with the RT.  3.2 Radioprotectors  There is an intensive search for radioprotectors which can protect the normal tissues from damage of the RT and prevent side effects like induced tumours, but do not interfere with the radiotherapy. Different radioprotective substances are in the focus of scientific interest like natural compounds (Kuntic et al., 2013), ethanol, trimethylglycine, beer (Rodriguez et al., 2013) and DMSO (Ashwood-Smith, 1967) to name but a few. A group of special interest are aminothiols, an important representative of this group is amifostine (WR-2721), which until now is the only radioprotector used for therapy in humans (Yuhas, 1970). Most of these substances 
17
3. Introduction  have a radical oxygen species (ROS) scavenging mode of action reducing the cellular damage caused by IR.  Another strategy is the activation of cellular radio resistance mechanisms like DNA repair and - protection (Chang et al., 2014; Sun et al., 2011), changes in the energy supply, downregulation of cellular breathing (Kam & Banati, 2013) or the induction of autophagy (Chaachouay et al., 2011; Y. S. Chen et al., 2011).  Activation of the ATM/ATR-pathway by radiation leads to cell cycle arrest, DNA-PK signalling and enhanced DNA repair. Activation of HER (human epidermal growth factor receptor) by radiation, leads to ERK1/2 and AKT signalling which suppresses apoptosis induction. Additionally, this signalling positively regulates cell cycle checkpoint response and DNA repair (Hein et al., 2014) (fig. 6). Of particular interest for the enhancement of cellular radio resistance is the EGFR (epidermal growth factor receptor) pathway.   
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3. Introduction  
  Fig. 6: Overview of radiation-induced signaling pathways that promote cell survival. Activation of ATM, ATR and DNA-PK signalling by DNA breaks leads to cell cycle arrest and DNA repair. Activation of HER, ERK1/2 and AKT signalling pathways by radiation suppresses apoptosis induction. HER, ERK1/2 and AKT signalling activation following radiation positively regulate cell cycle checkpoint response and DNA repair. Additionally, the Akt and Srk signalling activates the mitochondrial damage repair, suppresses mitochondrial metabolism and enhances autophagy (modified from (Hein et al., 2014)).  3.2.1 Epidermal growth factor receptor (EGFR)   EGFR or human epidermal growth factor receptor 1 (HER1) or erythroblastosis oncogene B (ErbB-1) is a member of the HER family. EGFR is often overexpressed in many human tumours, which leads to their enhanced proliferation aggressiveness and resistance to ChT (chemotherapy) and RT (radiotherapy) (Brand et al., 2011; D. J. Chen & Nirodi, 2007).  The receptor can be phosphorylated after binding of ligands like EGF (epidermal growth factor),TGFα (tumour growth factor alpha), Ammphiregulin, Betacellulin, HB-EGF (heparin binding EGF), Epiregulin (Rowinsky, 2004), after transactivation by G-protein coupled receptors (Bhola & Grandis, 2008) and after exposure to oxidative, hyperthermic, hypoxic stresses, UV-radiation and ionizing radiation (K. Dittmann et al., 2008). After phosphorylation, the receptor is internalized and starts the EGFR 
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3. Introduction  signalling (Rodemann et al., 2007). However, phosphorylated EGFR after having bound to growth factors, dimerizes and is then internalized into coated pits (fig. 7) initiates signalling via the phosphoinositol 3-kinase (PI3K) pathway, the signal transducer and activator of transcription (STAT-1, STAT-3, STAT-5) pathway, the Ras/MAPK (mitogen-activated protein kinase) pathway and activates specific enzymes, such as the phospholipase C-gamma and is then degraded in lysosomes (Alwan et al., 2003). Partly EGFR after EGF stimulation and Src, an activated downstream product of the EGFR pathway, are translocated into mitochondria. There they interfere with the cytochrome c oxidase subunit II (CoxII, MTCO2) which leads to a down-regulation of mitochondrial function. EGFR stabilizes COXII by binding it and prevents the activation of apoptosis (Demory et al., 2009) (fig.7).  Radiation-induced EGFR internalization is realized by caveolae formation and is associated with nuclear translocation (K. Dittmann, Mayer, et al., 2005; K. Dittmann et al., 2008). In the nucleus EGFR activates various mechanisms like DNA-PK driven DNA repair and chromatin relaxation via enhancement of acetylase TIP60 activity and building complexes with Ataxia telangiectasia mutated (ATM), promyelocytic leukemia protein (PML), histone H3 and hetero-chromatin binding protein (HP1) (K. Dittmann et al., 2011) (fig.7).   Partly phosphorylated EGFR after irradiation (IR) is translocated into mitochondria, where the receptor binds COXII and acts in a similar way to EGF stimulated EGFR (Nyati et al., 2006). EGFR and the sodium-dependent glucose transporter, SGLT1, were found in complex after radiation treatment, which was shown to increase the glucose uptake (K. Dittmann et al., 2013) and trigger a metabolic switch to increase lactate production (K. Dittmann et al., 2015) (fig. 7).  
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  Fig. 7: EGFR signalling. (A): After binding of growth factors like EGF, TGFα etc., the receptor can be phosphorylated and initialized in coated pits and starts signalling via Akt and ERK pathways which leads to the activation of radio resistance by activating anti-apoptotic and DNA-repair mechanisms, activating cell cycle arrest and autophagy. EGFR and Src also have a mitochondria regulating function: binding of COXII leads to the downregulation of the mitochondrial metabolism. After initialization, EGFR is degradated in lysosomes. (B): After irradiation, EGFR can be phosphorylated and is then initialized in caveolae which leads to an intranuclear transport. In the nucleus EGFR enhances chromatin remodelling, DNA-repair and autophagy, which leads to radio resistance. EGFR after IR is partly translocated to the mitochondria, where it acts as after stimulation with growth factors. EGFR also binds the SGLT glucose transporter increasing the glucose uptake.  (For the illustration numerous sources were used, please refer to Chapter 3.2.1 for reference).    
A B 
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3. Introduction  3.2.2 Ortho-phospho-L-tyrosine (pTyr)   Fig. 8: Formula: ortho-phospho-L-tyrosine (pTyr)  The application of the radio protector pTyr results in a multimodal mode of action. pTyr mediates activation of phosphokinase C epsilon (PKCε), which phosphorylates EGFR at the residue No. T654 and triggers nuclear EGFR accumulation (Wanner et al., 2008), which leads to enhanced DNA repair mechanisms (K. Dittmann et al., 2007), chromatine remodelling (K. Dittmann et al., 2013), a higher glucose uptake (K. Dittmann et al., 2013) and a shift from oxidative metabolism to lactate metabolism (K. Dittmann et al., 2015) in normal cells after treatment with radiation (fig. 8 B). Moreover, pTyr was shown to be predominantly radioprotective in cells with a WT (wild type) p53 phenotype (K. H. Dittmann et al., 2001) which indicates p53 stabilisation by pTyr (fig. 9). The p53 gene is a very important tumour suppressor gene, also known by its bynames "the guardian of the genome", “gatekeeper-gene” or “caretaker-gene”. It was found to be mutated in about half of all human cancers (Vogelstein et al., 2000). P53 has various tumour suppression functions like cycle arrest and apoptosis, genomic stability, and inhibition of angiogenesis (Harris & Levine, 2005). It is also involved in the in the internalization of EGFR in coated pits (Endo et al., 2008) and the downregulation of the oxidative phosphorylation, glycolysis and glucose intake by interfering with mitochondrial and glycolysis enzymes and glucose transporters, respectively (Puzio-Kuter, 2011). It can be activated by diverse mediators like ATM, ATR, JNK, p38 after various stimuli like irradiation, DNA damage, viral infections, hypoxia etc. (Harris & Levine, 2005; Sato & Tsurumi, 2013). A greatly simplified schema of EGFR-pTyr-p53 interactions and p53 functions is shown in (fig.9).   
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  Fig. 9: pTyr driven activation of p53 and some of its tumour suppressor functions. pTyr (red framed) leads via PKCε to an enhanced EGFR phosphorylation and its intranuclear transport, where it activates ATM which activates p53, which enhances the transcription of several activators of anti-cancer mechanisms like cell cycle arrest via p21, p27, p57, DNA repair via BRCA1, GADD45 activation and others. p53 suppresses the glucose intake, the glycolysis and oxidative phosphorylation and is involved in the EGFR intake and transport in coated pits. (For the illustration numerous sources were used, please refer to Chapter 3.2.2 for reference).   Although a direct mutation of p53 is not frequent in Rb, the p53 signalling is found to be inactivated in Rb-cells. The Rbp and p53 pathways are directly coupled, Rbp binds to MDM2 an inactivator of p53, which rescues the apoptotic activity of p53 (Hsieh et al., 1999) additionally the MDMX protein, which is another p53 inactivator, is found to be overexpressed in Rb-/- cells (Laurie et al., 2006; Sherr & McCormick, 2002). p53 signalling was also found to be inactivated by hypermethylation of its promotor region in Rb (Livide et al., 2012) (fig.10).  This various inactivation mechanisms of the p53 pathway led to the hypothesis that pTyr, which was shown to be predominantly radioprotective in cells with active p53, is potentially not radio protective in Rb and is therefore usable for radiotherapy of retinoblastoma.  
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  Fig. 10: p53 inactivation in Rb-/- cells. (Upper panel) In WT cells, the retinoblastoma protein (Rbp) inactivates the inactivator of p53 MDM2 by direct binding and MDM2/MDMX via ARF activation, p53 can be activated by diverse mediators like ATM, ATR, JNK, p38 after various stimuli like irradiation, DNA damage, viral infections, hypoxia etc., which leads to p53 mediated anti-tumour reactions (like cell cycle arrest via p21 activation, metabolic shutdown etc., see fig 9 for reference) (Lower panel) In Rb-/- cells, Rbp cannot suppress the p53-inactivators MDM2 and MDMX, additionally p53 expression and functioning is suppressed by other mechanisms like hypermethylation of the p53 promoter-region. (For the illustration numerous sources were used, please refer to Chapter 3.2.2 for reference).    
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4. Objectives  4. Objectives  The aim of this study was to find a way to increase the effectivity and safety of the radiotherapy of retinoblastoma. In order to develop a strategy to avoid side effects and secondary tumour induction, the radioprotector pTyr was investigated for a possible application before the radiotherapy of retinoblastoma. Three main questions had to be answered: 1. Is there a relevant mouse model, which can be used for radiotherapeutic approaches? 2. Can the application of pTyr protect tissues that are affected by irradiation during radiotherapy and prevent the induction of secondary tumours? 3. Does the application of pTyr interfere with the radiotherapy?  
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5. Results  5. Results  The results of this project are published in the form of two peer-reviewed articles which are presented in this chapter. Furthermore, unpublished additional material and short summaries of the experiments are presented.  5.1 Is there a relevant mouse model, which can be used for radiotherapeutic approaches?  Currently there are two types of retinoblastoma animal models: transgenic- and xenograft models. The advantage of xenograft models is the usage of human cells (Pacal & Bremner, 2006).  The injection of the cells can be performed in various compartments of the eye, in former times the anterior chamber was often preferred because it is more easily accessible for both the implantation and observation (Gallie et al., 1977; Totsuka et al., 1982), (Benedict et al., 1980). However, in patients the tumour starts its growth in the retina and penetrates relatively late into the anterior chamber which is physiologically different to the vitreous body. Thus, a sub-retinal injection of the retinoblastoma cells is a better reflection of the situation in humans (del Cerro et al., 1993; Rowe et al., 1992). Unfortunately, this kind of injection can cause damage to the choroid and retina, which can result in an unnatural spread of the tumour. Another possibility is the intravitreal injection of tumour cells as described by (Chevez-Barrios et al., 2000). After intravitreal injection of Y79 cells in Rag2 KO mice, tumours formed in the eye and gradually spread showing a growth comparable to that in Rb patients. Thus we decided to use the intravitreal route of administration as well. Unfortunately the Rag2 KO model developed by Chevez-Barrioz et al. was never used for radiotherapeutic experiments, but the nude mouse model used by Totsuka (Totsuka et al., 1982) was, therefore we decided to combine the advantages of both models to develop our own model. We established an orthotopic xenograft mouse model by intravitreal injection of human Y79-Rb cells which closely resembles human retinoblastoma tumours and can be used for RT approaches of retinoblastoma treatment (Tschulakow et al., 2016). To see the detailed version, please refer to Chapter 5.1.1.  Briefly: 2x104 human retinoblastoma Y79 cells were intravitreally injected in both eyes of immune-deficient nude mice and the growing tumours were analysed in vivo using scanning laser ophthalmoscopy (SLO) and optical coherence ophthalmoscopy (OCT), as well as  histologically and using electron microscopy (EM). 
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5. Results   Five weeks after the injection, the eyes began to swell in individual animals. This swelling and tumour-growth was similar to that of tumours in untreated human Rb patients.  Xenograft-tumours grew in 29 of 42 investigated eyes. The in vivo as well as the histological and EM analysis showed that the xenograft tumours have similar growth-, cellular- and ultrastructural characteristics to human Rb-tumours (Tschulakow et al., 2016). To see the detailed version, please refer to Chapter 5.1.1. 
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5. Results  5.1.1 Establishment of a novel retinoblastoma (Rb) nude mouse model by intravitreal injection of human Rb Y79 cells – Comparison of in vivo analysis versus histological follow up                                                  
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ABSTRACT
Retinoblastoma (Rb) is the most frequent primary intraocular
tumour in children and, if left untreated, can cause death.
Preclinical animal models that mimic molecular, genetic, and
cellular features of cancers are essential for studying cancer and
searching for promising diagnosis and treatment modalities. There
are several models described for Rb, but none of them fully meet
our requirements. The aim of this study was to create a novel
xenograft-nude mouse-model with broad application possibilities,
which closely resembles the clinical observations of Rb patients
and which could be used to investigate the development and
spread of the tumour by using scanning laser ophthalmoscopy/
optical coherence tomography (SLO/OCT) as well as histology
methods. We injected human retinoblastoma Y79 cells
intravitreally in both eyes of immune-deficient nude mice. The
incidences of retinoblastoma as well as growth velocity were
analysed 3, 6, 9 and 12 weeks after cell injection in vivo by SLO/
OCT as well as ex vivo by electron microscopy (EM) and
hematoxylin/eosin (HE) staining. Moreover, internal organs were
histologically screened for potentially occurring metastases. Three
weeks post-injection, animals developed a retinoblastoma, and
after five weeks tumour growth resulted in swelling of the eyes in
individual animals, showing a similar phenotype to that of untreated
Rb patients at advanced stages of tumour-development. After
12 weeks, 67.5% of all analysed eyes (29 of 42) contained a
retinoblastoma. At early stages of Rb development, the SLO/OCT
analysis correlated with the histology results. If the tumours
were too large, only histological investigations were feasible.
The ultrastructural characteristics of the xenograft-tumours
were very similar to those described for patient’s tumours. In
one mouse, brain metastases were observed. Our retinoblastoma
mouse model closely resembles the human disease. SLO/OCT
can be used for the detection of Rb at early stages of
development and could be used for monitoring the success of
future therapies.
KEY WORDS: Retinoblastoma, Xenograft, Mouse model, SLO, OCT,
Histology
INTRODUCTION
Retinoblastoma (Rb) is the most common primary intraocular
malignancy of infancy with an incidence of 1/15,000 to 1/20,000
births. It is estimated that annually Rb affects 7000-8000 new
patients worldwide (Broaddus et al., 2009; Seregard et al., 2004),
and survival rates vary dramatically. Untreated, mortality is 100%.
In 60% of Rb patients, anunilateral Rb tumour is diagnosed at an
average age of two years, and in most cases these tumours are not
hereditary. In the other 40% of cases, Rb is bilateral and is
diagnosed at an average age of one year. All bilateral and multifocal
unilateral forms belong to a genetic cancer predisposition syndrome
and are hereditary. RB1 gene mutation can be found in all children
with a bilateral or familial form, as well as in 10 to 15% of children
with a unilateral form of Rb (Jehanne et al., 2014).
Knowledge on tumour genesis was increased enormously with the
development of mouse models for retinoblastoma (Villegas et al.,
2013). For example, recently, the chemotherapeutic effect of focal
melphalan was investigated in the transgenic LHBETATAG murine
model. This treatment mediates a significant reduction with respect to
the tumour burden, hypoxia and vasculature (Shah et al., 2014).
Ophthalmic imaging, like wide-field photography and
echography, are reliable tools, not only in diagnosis but also for
detecting regression or progression patterns of Rb (Villegas et al.,
2013; Houston et al., 2011; Shields et al., 2009). Intraocular
calcifications have also been shown to be analysed successfully
using autofluorescence (Ramasubramanian et al., 2011). The role of
optical coherence tomography (OCT) was also investigated in the
evaluation of fundus tumours in children, and the use of OCT scans
during the management of Rb was approved by the clinicians
(Houston et al., 2013; Shields et al., 2004; Mallipatna et al., 2015).
The aim of this study was to generate an animal model for Rb that
closely resembles the human disease for the purpose of developing
new therapeutic options or comparing the efficacy and side-effects
of existing treatments. To this aim, retinoblastoma cells of the
human Rb−/− cell line Y79 were intravitreally injected into the eyes
of immune-deficient nude mice to induce tumour growth.
Development and spread of the tumours were characterized by
scanning laser ophthalmoscopy (SLO), fluorescein angiography
(FA) and OCT, as well as by histology including an analysis at the
ultrastructural level, and the in vivo and ex vivo follow ups were
compared. In addition, ultrastructural analysis of the xenograft Rb
tumours was performed in order to assess the relevance of our Rb
mouse model.
RESULTS
Morphological analysis
Starting at week five after the injection, the eyes began to swell in
individual animals. We determined four stages depending on the
tumour progression as shown in Fig. 1: Stage 0 (S0) wasReceived 6 June 2016; Accepted 20 September 2016
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considered as the morphology of a normal mouse eye. Stage I (SI)
was reached after the eye was swollen up to 2× the normal size
and showed a cloudy appearance, stage II (SII) was reached after
the eye was swollen up to 3× the normal size, stage III (SIII) was
reached when the tumour broke through the cornea. Table 1 shows
the number of eyes and their corresponding stages at the time
points of analysis.
As shown in Fig. 2, there were some intra-individual differences
concerning the time point of the start and the progress of the
swelling of the eyes. The earliest cases of swelling appeared 34 days
after injection, and the latest 70 days after injection. In most cases
the swelling started between week five and seven after injection and
progressed fast from stage I (on average 39 days after injection) to
stage II (on average 43 days after injection) and then to stage III (on
average 48 days after injection) (Fig. 2).
In vivo imaging using SLO/OCT
The SLO/OCT analysis could only be performed in stage 0 eyes
with tumours at very early stages or in eyes without a tumour. In
eyes with tumours at later stages of growth (SI-SIII) no analysis was
possible, because the tumour covered the fundus.
In all cases where SLO/OCT analysis was possible, the results
showed a good correlationwith the results of the histological analysis.
Using OCT, not only could we detect the tumour itself, but could also
get information about its growth characteristics. The tumour shown in
Fig. 3, for example, broke through the retina and began to grow
subretinally, which can be clearly seen on the OCT image (Fig. 3A,
left panel) and could later be found on the corresponding HE-stained
slide Fig. 3B. The results of the angiography analysis with fluorescein
gave a good picture of the tumour’s vessel structure Fig. 3C.
Histological analysis
In the tumour-bearing eyes tumour cells could be observed in the
vitreous, retina and subretinal space. An overview of the exact
number of eyes and areas of tumour growth up to the time points of
analysis is presented in Table 2.
For the initial phase of tumour growth (week 3), eight eyes were
analysed. Tumour cells could be seen in the vitreous and on the retina
in four of them. In two eyes the tumour grew through the retina, in one
of these eyes even subretinal tumour growth could be observed.
In all tumour-bearing eyes which were analysed 6 weeks after
injection, the tumour completely replaced the vitreous and grew into
the anterior chamber, in seven eyes the tumour invaded or damaged
the lens, and in two eyes the tumour did not penetrate the retina
(Fig. 4A). In the other eight tumour-bearing eyes, a subretinal
growth could be detected (Fig. 4B).
In advanced tumours (week 9 and 12) the tumour replaced most
of the eye’s structures, like the vitreous, the lens and retina. Here in
all six tumour-bearing eyes the sclera was the only part of the eye’s
tissue remaining (Fig. 4C).
Histologically, the tumours were composed of typical
undifferentiated hyperchromatic cells with scanty cytoplasm having
a rosette-like growth pattern, as described for the original tumour (Reid
et al., 1974). All tumours showed a high mitotic and necrotic activity.
A tumour was found in 67.5% of the analysed eyes (29 of 42) 12
weeks after the injection of the Y79 cells.
Metastases
We screened tissues near the tumour, like the brain and skull, for
metastases as well as the kidneys, lung, heart, liver, and spleen for the
appearance of distant metastases by analysing HE-stained cross
sections of these tissues. Only in one mouse could metastases in the
brain be found. The metastases were found in the mouse, which after
having reached stage III for one eye was kept for the longest period of
time (35 days) before being killed and analysed (Fig. 2, mouse 16). In
this eye the tumour broke through the sclera in several areas and grew
into the brain (not shown). No distant metastases could be found.
Electron microscopy analysis
The ultrastructural analysis of the xenograft–tumours, shown in
Fig. 5, showed very similar characteristics to those described for
the original tumour (Reid et al., 1974), such as poor differentiation
but still identifiable rosette-like growth, large hyperchromatical
nuclei with multiple nucleoli and elaborate convolutions of the
nuclei (Fig. 5A), and numerous degraded and necrotic cells
(Fig. 5B) (Reid et al., 1974; Green et al., 1979; McFall et al.,
1977). These characteristics are also described as typical for
patient’s Rb tissues (Rodrigues et al., 1986; Allen et al., 1962).
DISCUSSION
Preclinical animal models that mimic molecular, genetic, and
cellular features of retinoblastoma are essential for studying this
type of cancer.
Fig. 1. Results of themorphological analysis. (A-D) the stages S0-SIII of the mouse eyes: (A) stage 0 (S0): eye of a untreatedmouse; (B) stage I (SI): the eye is
swollen up to 2× of the normal size; (C) stage II (SII): the eye is swollen up to 3× of the normal size, the eye is cloudy; (D) stage III (SIII): the tumour breaks through
the cornea.
Table 1. Number and stages of the analysed eyes
Eye, stage
Week 3
(8 eyes)
Week 6
(10 eyes)
Week 9
(10 eyes)
Week 12
(12 eyes)
S0 8 5 3 7
SI - - - -
SII - - 1 1
SIII - 5 6 4
The table shows the number of the investigated eyes and their corresponding
stages at the time points of analysis.
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Currently, two types of retinoblastoma animal models exist:
transgenic models and xenograft models. The transgenic models
have been developed from LH-β-Tag models to conditional gene
knock-out models. There are different types of xenograft models,
for example orthotopic models and subcutaneous transplantation
models. The two types of Rb models present advantages and
disadvantages.
The combination of genetic and xenograft models in
retinoblastoma research has already help to better understand
tumour biology and to find more effective diagnosis and treatments.
Our aim was to create a xenograft mouse model with close
resemblance to human Rb tumours which can be used for broad
application possibilities including radio therapeutic approaches of
Rb treatment.
Literature research indicates that in addition to the use of
transgenic animals as a model system for retinoblastoma, another
possibility is the use of a xenograft model which is based on the
implantation of human retinoblastoma cells into the eye of
immunodeficient animals. Indeed, retinoblastoma xenograft
models are often created using the cell line Y79. This
commercially available human retinoblastoma cell line is derived
from a two-and-a-half-year-old patient, who had a maternal history
of retinoblastoma.
The implantation can be performed in various compartments of
the eye; previously the anterior chamber was often preferred
because it is more accessible for both the implantation and
subsequent observation (Gallie et al., 1977; Totsuka et al., 1982).
However, in patients the tumour starts its growth in the retina and
penetrates relatively late into the anterior chamber which is
physiologically different to the vitreous body, and where the
retinoblastoma first encroaches. Thus, a subretinal injection of the
retinoblastoma cells is a better reflection of the situation in humans
(del Cerro et al., 1993; Rowe et al., 1992). Unfortunately, this kind
of injection can cause damage to the choroid and retina, which can
result in an unnatural spread of the tumour.
Another possibility is the intravitreal injection of tumour cells as
described by (Chevez-Barrios et al., 2000). After the intravitreal
implantation of Y79 cells in Rag2 KO mice, tumours formed in the
Fig. 2. Overview of the results of the
morphological analysis of the mouse
eyes during the experiment. Stages shown
are: the beginning of the swelling (small
circle=SI); the staging of the eye (medium
circle=SII and big circle=SIII); and the time
point of analysis (red X) of each eye. Mouse
16 had brain metastasis, the mouse was
analysed 35 days after the left eye reached
stage III.
Fig. 3. Results of the in vivo and corresponding histological analysis. Panels (A) and (C) show the results from the in vivo analysis of the same tumour-baring
eye. The tumour is at anearly stageof development, and grew in the vitreous directly on the retina 3 weeks after the injection of theY79 cells. Left panel in A is theSLO
image, the tumour (white arrow) can be seen as a dark region in the lower right corner, the right panel in A shows theOCT image of the green-boxed section in the left
panel. (B) The HE-stained sample (×100) of the right panel in A. In both panels A and B, the tumour is shownwith black arrows, and located directly on the retina, the
area of the tumour breaking through the retina and the area of subretinal tumour growth are circled. (C) SLO image fluorescein mode (FA) 5 min after fluorescein
injection (the tumour vessels are circled).
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eye and gradually spread, and later could also be found in the brain.
Thus we decided to use an intravitreal injection as well.
The Rag2KOmodel developed byChevez-Barrioz was never used
for radiotherapeutic experiments, but the nude mouse model used by
Totsuka was (Totsuka and Minoda, 1982), therefore we decided to
combine the advantages of both models to develop another model.
After the injection of Y79 cells, tumour cells proliferated first in
the vitreous and then formed a clearly localised tumour on and
through the retina, not exactly consistent with the retinoblastoma
tumours observed in children that originate in the retina; however
this particularity is common with the retinoblastoma mouse model
developed by Chevez-Barrios et al. (2000). In most cases, the
tumour broke through the retina and began to grow subretinally. In
two cases the tumour did not penetrate the retina at the 6 week time
point of analysis (Fig. 4B).
In contrast to the retinoblastoma mouse model developed by
Chevez-Barrios et al. (2000) in which the authors observe
metastases resulting from migration of tumour cells up the optic
nerve, we observed in our model that the sclera seems to be a strong
barrier for the tumour. The tumour needs to grow very large and
have a long time to break through the sclera. During our experiment
the tumour only penetrated the sclera in one mouse eye and formed
brain metastases. The metastases were found in the brain of a mouse,
which, after having reached stage III for the left eye, was kept alive
for the longest period of time (35 days) before being sacrificed and
analysed (Fig. 2, mouse 16 ). However, in the Rag-2 knockout (KO)
mice used by Chevez-Barrios et al. (2000), the animals were
intravitreally injected with Y79 cells in a similar manner as in our
experiment, but the mice already developed metastases 4 weeks
after the injection (Chevez-Barrios et al., 2000). These results are
consistent with those of other groups, who could show that
metastasization metastasesin Rag-2 KO mouse models are stronger
than in nude mice for several human cancer xenografts like sarcoma
(Nanni et al., 2010), breast cancer (Nanni et al., 2012) or
adenocarcinoma (Ye et al., 2015). This should be considered
when choosing a model. Despite the mentioned differences of the
metastasization process in Rag2 KO and nude mice, Gallie et al.,
described a metastasization of the optic nerve and brain in
cyclophosphamide pre-treated nude mice (Gallie et al., 1977);
unfortunately the authors do not make any statement about the time
point of analysis. In our experiment we had to kill the animals at the
latest 12 weeks after tumour cell injection due to the ethical
requirements of local authorities, and we consider it very likely that
they might develop metastases at a later time point.
A very important aspect of this work was the use of in vivo
approaches like SLO/OCT for the detection and characterisation of
tumours in the mouse eyes and the comparison of the results with
the corresponding results of the histological analysis, which showed
a good correlation as shown in Fig. 3. A similar funduscopy/OCT-
based approach was used for the analysis of the tumours in the eyes
of a TAg-RB mouse model by Wenzel et al. with similar results
(Wenzel et al., 2015).
In ophthalmological research, in vivo analysis like SLO/OCT
allows multiple analysis of dynamic biological processes like
tumourigenesis, tumour growth and angiogenesis at certain time
points in individual animals and can help to reduce the number of
experimental animals used.
In conclusion, we showed that our Rb mouse model mimics the
human disease. The xenograft tumour samples from our model
showed very similar growth characteristics, cellular appearance and
ultrastructural characteristics to those described for Rb patient
tumour tissue samples. This makes our model a promising tool for
the study of retinoblastoma and its potential therapy approaches.
We also show that SLO/OCT can be used for the detection of
tumours at early stages of development and could be used for
monitoring the future therapies.
MATERIALS AND METHODS
Cell culture
The Y79 retinoblastoma cell line originates from a primary tumour of a
two-and-a-half-year-old Caucasian female with a maternal history of
retinoblastoma in 1971 (Reid et al., 1974).
The human retinoblastomaY79 cell line was purchased at American Type
Culture Collection (ATCC, USA). The cells were cultured in RPMI-1640
medium (Gibco®, Darmstadt, Germany) supplemented with 10% fetal
Table 2. Analysis of the HE-stained eyes: the areas of tumour growth
and time-points of analysis are shown
Area of tumour growth Week 3 Week 6 Week 9 Week 12
Vitreous 4/8 10/10 8/10 6/12
Retina 2/8 8/10 8/10 6/12
Subretinal space 1/8 8/10 8/10 6/12
Lens 0/8 7/10 8/10 6/12
Anterior chamber 0/8 10/10 8/10 6/12
The data is expressed as the number of eyes that were positive for tumour at
each site/total number of eyes examined.
Fig. 4. Results of the histological analysis. (A) Y79 xenograft tumour from a nude mouse eye 6 weeks after injection (25× magnification), the tumour (black star)
grows in the vitreous but does not penetrate the retina (black arrow). (B) Y79 xenograft tumour from a nude mouse eye 6 weeks after injection (25× magnification).
Here the tumour, after having grown in the vitreous (smaller black star), penetrated the retina and after strong subretinal growth (bigger black star) pressed the retina
(black arrow) in direction of the lens (L). (C) Y79 xenograft tumour from a nude mouse eye 9 weeks after injection (25× magnification), the tumour (black star) has
replaced all structures of the inner eye, i.e. the vitreous, the retina and the lens and broke through the cornea (out of sight).
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bovine serum and 2 mM L-glutamine. The cells grew as a suspension
culture and were cultured and passaged as recommended by the ATCC. For
the injection, cells from passage 4 were used.
Intravitreal injection
24 BALB/c nude mice [female, 3 months old, purchased at Janvier (Laval,
France)] were used for the study. The animals were kept in individually
ventilated cages (IVC) in our animal facility.
The mice were handled at all times in accordance with the German
Animal Welfare Act and were under the control of the Animal Protection
Agency and under supervision of veterinarians of the University of
Tuebingen. The experiments were approved by the local authorities
(Regierungspräsidium Tuebingen AK 6/12).
Each animal was first anaesthetized with an intraperitoneal injection of a
three component narcosis (0.05 mg fentanyl, 5.00 mg midazolam and
0.5 mg of medetomidine/1 kg body weight, prepared by the Animal
Protection Agency of the University of Tuebingen).
The pupils were dilated with 1 to 2 drops ofMedriaticum drops (Pharmacy of
the University of Tuebingen, Germany) and a drop of topical anesthetic
Novesine (OmniVision, Puchheim, Germany) was applied. Methocel
(OmniVision, Puchheim, Germany) eye drops were used to avoid drying of
the eyes. Injections were performed using a surgical microscope. Two
microlitres of sterile phosphate buffered saline (Gibco®, Darmstadt, Germany)
containing 2×104 Y79 human retinoblastoma cells were injected into the
vitreous of each eye through the sclera using aHamilton syringewith a 26 gauge
cannula. Special care was taken to prevent lens damage or posterior retinal
punctures. After the injection, the eyes were treated with antibiotic eye drops
(Gentamicin-POS®, Ursapharm, Saarbrücken, Germany). Finally themicewere
subcutaneously injected with an antidote (1.2 mg naloxon, 0.5 mg flumazenil,
2.5 mg atipamezol/1 kg body weight, prepared by the Animal Protection
Agency of the University of Tuebingen) which neutralized the anaesthetic.
The animals were examined 2, 12 and 24 h after surgery and then daily.
Clinical findings regarding the presence of tumour were recorded.
In vivo imaging using SLO/OCT
Three, six, nine and twelve weeks after injection, groups of five mice were
formed. Mice which showed tumour-caused phenotypical changes were
primarily analysed. For the analysis a Spectralis™ HRA+OCT SLO/OCT
device was used (Heidelberg Engineering, Heidelberg, Germany). The
whole procedure was performed as described in Huber et al. (2009) and
Fischer et al. (2009). Briefly, the Spectralis® was remodelled to make it
usable for the analysis of small rodents by fixing a 78 dpt double aspheric
lens (Volk Optical, Inc., Mentor, OH 44060, USA) directly to the outlet of
the device, and an additional custom-made 100 dpt contact lens directly on
the eyes of the mice. The mice were anaesthetized by a peritoneal injection
of a three component narcosis (as described above), and the pupils were
dilated with 1 to 2 drops of Medriaticum (Pharmacy of the University of
Tuebingen, Germany). Methocel (OmniVision, Puchheim, Germany) eye
drops were used to avoid drying of the eyes and to ensure the adherence of
100 dpt- lenses on the mice eyes. The mice were put in front of the device on
the XYZ-table and positioned for the analysis. The mice were covered with
cloth to avoid hypothermia.
After positioning, the SLO images were taken. In cases when a tumour
was detected, an angiography analysis was also performed. 25 µl of a 2%
solution of Fluorescein® 10% (Alcon Freiburg, Germany) was given
subcutaneously to the mice to make it possible to visualize the retinal and
tumour vessels using the FA (fluorescein angiography) mode of the SLO
device. After that the OCT-imaging was performed. A detailed protocol for
anaesthesia and imaging is described elsewhere (Huber et al., 2009).
Histological analysis
Directly after the in vivo analysis the mice were killed by cervical dislocation.
One eye, the brain, lungs, heart, kidney, spleen, and liver of each mouse were
immediately fixed in 4.5% formalin containing fixation solution (4.5% Roti
Histofix, Carl Roth, Karlsruhe, Germany). The tissues were processed and
embedded in paraffin using conventional automated systems. The blockswere
cut to obtain serial 4 µm thick sections and stained with conventional
hematoxylin-eosin (HE). The slides were examined by the means of a light
microscope.
Light and electron microscopy (EM)
The other eye of each mouse was fixed in 5% glutaraldehyde for electron
microscopic analysis. After the fixation (min. 3 days) the eyes were screened
under a binocular for areas of interest (aoi), especially tumour-containing
areas. The samples containing these aoi were cut (1 mm×1 mm). These
specimens were post-fixed with 1% OsO4 at room temperature in 0.1 M
cacodylate buffer (pH7.4), en bloc stainedwith uranyl acetate and lead citrate,
and embedded in Epon after dehydration in a graded series of acetones. Semi-
thin sections (0.2 µm)were stainedwith ToluidineBlue and examined by light
microscopy (Zeiss Axioplan2 imaging, Zeiss, Jena, Germany). For electron
microscopy, the sections were cut ultrathin (0.07 µm) and analysed with a
Zeiss 902 A electron microscope (Zeiss, Jena, Germany).
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Fig. 5. EMAnalysis. In both electronmicrographs the tumor cells show typical large hyperchromatical nuclei withmultiple nucleoli (black arrowheads) and elaborate
convolutions of the nuclei (black arrowspoint to cells inwhich this process is very pronounced). (A) A representative electronmicrograph (3000×magnification) froma
tissue sample froma xenograft tumourwhich grew in a nudemouse eye 9 weeks after injection of Y79 cells, here the rosette-like growth of theY79 cells can be clearly
recognized (red circle). (B) A representative electron micrograph (3000× magnification) from the same tissue sample. Here in the centre a necrotic Y79 cell is
surrounded by other tumour cells. Black arrowheads point to multiple nuclei; black arrows point to cells with very pronounced elaborate convolutions of the nuclei.
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5. Results  5.1.1.1 Additional unpublished material  The SLO/OCT results of tumours at early stages of development could be well correlated with the corresponding histological results. However, at stages where the tumour grew too big and covered the fundus, SLO/OCT could not be performed (fig. 11).    Fig. 11: Mouse eye with an advanced tumour 6 weeks after injection of Y79 cells. (Left panel) Photo-image: the eye looks cloudy because of the growing tumour (Right panel) The corresponding SLO-image, as the laser cannot reach the fundus, no imaging is possible.   In one animal a metastasis in the brain was found. It was discovered in the animal which was sacrificed 35 d after the tumour grew so big that it broke through the sclera. In all other cases, due to the suggestions of the veterinarians and the experiments schedule, the animals were sacrificed at an earlier time point. In this animal the tumour had enough time to break through the sclera (fig. 12 A) and to form metastasis in the brain (fig. 12 B).                       Fig. 12: Histological analysis of Y79 xenograft tumour metastases: histological image (x400) of the mouse eye (9 months after Y79 injection). (A) The tumour (T) is breaking (arrow) through the sclera (S). (B) Histological image (x100) of the brain with a metastasis (M). A B TS M S T  
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5. Results  5.2 Can the application of pTyr protect tissues that are affected by irradiation during radiotherapy and prevent radiotherapy-induced secondary tumours?  To analyse the ability of pTyr to protect tissues that are affected during radiotherapy and to avoid the induction of secondary tumours in vivo, B6;129-Rb1tm3Tyj/J Rb+/- mice, which have a mutation in one of the Rb1- gene alleles (Jacks et al., 1992) were irradiated using a radiotherapy simulating irradiation scheme. These mice served as a model for patients with hereditary Rb, who having a genetic defect in the homologue human gene Rb- 1, have a higher risk of secondary malignancies after RT (Abramson & Frank, 1998).  Two pairs of each of a B6;129-Rb1tm3Tyj/J Rb+/- and B6 wild type (WT) mice were purchased at the Jackson laboratory (Bar Harbor, ME, USA). Pairs of each an Rb+/- and WT mouse (Rb+/+) were formed to avoid offspring with a double knockout of the Rb1-gene, because these die in utero. The mice were bred in our animal facility. Twenty-four mice with an Rb+/- genotype were needed for our experiment. Thus, the newborn mice had to be genotyped using a polymerase chain reaction (PCR) according to the instructions given by the Jackson laboratory (tab.1).  Briefly: DNA was isolated using a standard isopropanole extraction method from hairs which were plucked from the mouse. This DNA was used for the PCR analysis. We used 2 sets of primers, the same forward primer and one reverse primer for detection of the wildtype allele (tab.1) of the Rb-gen and another reverse primer for the mutated allele (tab.1) were used. The PCR products were run on a gel. When bands for the PCR products with the reverse primer for both the WT- and mutated allele were detected, the mouse genotype was Rb+/- (fig.13).  
36
5. Results    Table 1. Genotyping protocol (Left panel): Reaction protocol and primers (fig.1), (Right panel): Cycling protocol for the PCR for the genotyping of the newborn B6;129-Rb1tm3Tyj/J Rb+/- mice. (Source https://www.jax.org/strain/008186).    Fig.13: Genotyping of 10 newborn mice of a B6;129-Rb1tm3Tyj/J Rb+/- and B6 WT mouse pair. On the gel under L (1000 bp DNA ladder) bands of 100-1000 bp are presented. In the upper part of the gel, bands from the 423 bp fragment of the WT allele can be seen, which is presented in all animals. In the lower part of the gel bands from the 500 bp fragment of the mutated allele can be seen in the samples of the mice with the numbers 1, 2, 4, 9 and 10 (red circled). These mice have an Rb+/- genotype.   
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5. Results  Twenty four B6; 129-Rb1tm3Tyj/J Rb+/- mice with and without pTyr pretreatment (fig. 14 A) were irradiated in a radiotherapy-simulating way (fig. 14 B) using a linear accelerator Linac-G (fig. 14 C) and a fractionated radiotherapy schedule (fig 14 D).        Fig. 14: Irradiation of Rb+/- mice with and without pTyr. :(A): One group of mice was pre-treated with intraperitoneal injections of pTyr (100 mg/kg body weight) 16 hours before each irradiation. The other group was pre-treated with PBS injections. (B): Diagram of the custom-made system where the mice were anaesthetised and their bodies, except for the area of interest, were covered with a lead shield during the irradiations. (C): Linear accelerator Linac-G (Philips) in the laboratory of the Experimental Radiooncology Department.  
A D B C 
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5. Results  (D): Irradiation schedule: Both groups were irradiated over a period of 3 weeks 3 times a week with a dosage of 5 Gy per exposure. The animals were investigated using SLO/OCT and histologically 1, 3, 6 and 9 months after IR. Radiation-induced tumour induction as well as normal tissue radiation toxicity was evaluated as a function of pTyr-treatment.  The most important results of this part of the project are, briefly, as follows:  Five weeks after the last irradiation, a greying of the fur in the irradiated area began in the pTyr untreated mice. The same change in fur pigmentation started eight weeks after irradiation in the pTyr treated mice and was significantly reduced in the pTyr treated mice six and nine months after RT.  The optical coherence tomography (OCT) analysis results showed a stronger reduction of the retina-thickness in the pTyr untreated animals 3, 6 and 9 months after IR and the corresponding histological analysis showed a greater loss of photoreceptors in the pTyr untreated animals 3, 6 and 9 months after IR. No metastases in the irradiated area or distant metastases were found.  Thus pTyr being radioprotective for normal tissues meets one of the requirements to be considered for the radiotherapy of Rb (Tschulakow et al., 2017). To see the detailed version, please refer to Chapter 5.4. 
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5. Results  5.3 Does the application of pTyr interfere with the radiotherapy of retinoblastoma?  To examine whether pTyr can radioprotect retinoblastoma cells and thus counteracts the effectiveness of the radiotherapy, in vitro irradiation experiments with Y79 cells and in vivo radiotherapeutic experiments using our Y79 xenograft nude mouse model were performed.  5.3.1 In vitro studies    The Y79 retinoblastoma cells grew as a suspension culture and were cultured and passaged as recommended by the American Type Culture Collection (ATTC). The cell cultures were treated and irradiated according to the corresponding protocols (Tschulakow et al., 2017), to see the detailed version please refer to chapter 5.4. and used for western blot and limited dilution assay analysis (fig 15).    Fig. 15: In vitro analysis of irradiated 79 cell cultures with and without pTyr-pretreatment. The Y79 cells were pre-treated with pTyr (10µM) or vehicle (PBS) 16 hours before IR. The irradiations were performed using a linear accelerator Linac-G (Phillips). For the analysis of the ability of pTyr to radioprotect Y79 cells in vitro a “pre- and delayed plating limited dilution assay” was performed after IR with 0 Gy, 
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5. Results  2 Gy and 5 Gy. For the analysis of the p53 protein expression in Y79 cells after the IR with 4 Gy, a western blot analysis was performed. For the analysis of the p53 protein activity, we also measured the amount of its phosphorylated (at Ser-residue-15) form and the amount of p21 (a downstream p53 pathway-member).   5.3.1.1. Western blot  pTyr was shown to radioprotect predominantly p53 WT cells (K. H. Dittmann et al., 2001). Y79 cells have a p53 WT and if pTyr would radioprotect them, it wouldn’t be suitable for a RT of Rb. But for other Rb- and particularly for Y79 cells different mechanisms were described which interfere with the p53-pathway or inactivate p53. To test this hypothesis western-blot analysis was used. We analysed the impact of irradiation with and without pTyr pretreatment on the p53-, phosphorylated p53 and the p53 pathway downstream-member p21 status of Y79 cells (fig.15). As a result, irradiation of Y79 cells resulted in stabilization of p53 and up regulation of the p53 target p21. Moreover, pTyr was capable to stabilize p53 in unirradiated Y79 cells and facilitating radiation-induced p21 up-regulation, confirming a modulation of p53 activity by pTyr (Tschulakow et al., 2017), (Chapter 5.4, supplementary fig. 4). As the p53 inactivation in Y79 could not be shown, we decided to test the capability of pTyr to radioprotect Y79 cells directly in vitro.  5.3.1.2 Pre-plating and delayed plating limited dilution assay- studies with Y79 cells  To test if pTyr (10mM) will radioprotect Y79 cells in vitro, we performed a pre-plating and a delayed plating limited dilution assay after irradiation of Y79 cell cultures with 0 Gy-, 2 Gy- and 5 Gy. No significant radioprotective effect of pTyr could be observed (Chapter 5.4, supplementary fig. 3). Therefore pTyr seemed to fulfill another requirement to be considered for use in radiotherapy of retinoblastoma.  5.3.2 Irradiation studies in our Rb Y79-xenograft nude mouse model  To analyse the possible interference of the application of pTyr with radio therapy in vivo we used our newly established Y79 xenograft nude mouse model. We performed radiotherapies of the xenograft-tumours with and without pTyr pretreatment of the mice. We used the same irradiation-schedule as for the irradiations of the Rb+/- mice (fig. 12 C). 
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5. Results   Twenty seven to 64 days after the radiotherapy, 80% of the eyes of the pTyr pretreated animals started to swell. In the pTyr untreated group only 18% of the eyes were swollen on days 51 to 89. During histological analysis tumours were found in all swollen and unswollen eyes of pTyr pretreated animals (100%) as well as in the swollen eyes of the irradiated but pTyr untreated animals (18%) indicating pTyr-mediated failure of the radiotherapy of the retinoblastoma. These results show that in contrast to the in vitro studies pTyr radioprotected the xenograft-Y79 tumours in vivo (Tschulakow et al., 2017). To see the detailed version please refer to Chapter 5.4.    
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5. Results  5.4 The radioprotector ortho-phospho-L-tyrosine (pTyr) attenuates the side effects of fractionated irradiation in retinoblastoma mouse models but also decreases the local tumour control                                                  
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a b s t r a c t
Background: Radiotherapy (RT) is used to treat retinoblastoma (Rb), the most frequent ocular tumour in
children. Besides eradicating the tumour, RT can cause severe side effects including secondary malignan-
cies. This study aimed to define whether the radioprotector ortho-phospho-L-tyrosine (pTyr) prevents RT-
induced side effects and affects local tumour control in a xenograft and a genetic orthotopic Rb mouse
model.
Methods: B6;129-Rb1tm3Tyj/J (Rb+/) and Y79-Rb cell-xenografted nude mice were fractionated external
beam irradiated (15 fractions of 5 Gy 6 MV photons during 3 weeks) with or without pTyr pre-treatment
(100 mg/kg BW, 16 h prior to each irradiation). One, three, six and nine months after RT, tumour control
and RT toxicity were evaluated using in vivo imaging and histology. We also analysed pTyr dependant
post irradiation cell survival and p53 activity in vitro.
Results: In vitro pTyr pre-treatment showed no radioprotection on Y79 cells, but led to p53 stabilisation
in unirradiated Y79 cells and to a facilitation of radiation-induced p21 up-regulation, confirming a mod-
ulation of p53 activity by pTyr. In both mouse models, secondary tumours were undetectable. In Rb+/
mice, pTyr significantly lowered RT-induced greying of the fur, retinal thickness reduction and photore-
ceptor loss. However, in the xenografted Rb model, pTyr considerably decreased RT-mediated tumour
control, which was observed in 16 out of 22 control eyes but in none of the 24 pTyr treated eyes.
Conclusions: In Rb+/ mice pTyr significantly prevents RT-induced greying of the fur as well as retinal
degeneration. However, since non-irradiated control mice were not used in our study, a formal possibility
exists that the effect shown in the retina of Rb+/mice may be due to ageing of the animals and/or actions
of pTyr alone. Unfortunately, as tested in a xenograft model, pTyr treatment reduced the control of Rb
tumours.
 2017 Elsevier B.V. All rights reserved. Radiotherapy and Oncology 124 (2017) 462–467
Retinoblastoma (Rb) is the most common intraocular neoplasm
of childhood originating in progenitor cells of the developing retina
with an estimated incidence of 1/20,000 births [1]. Untreated Rb
always leads to death. Rb is closely linked to the inactivation of
the retinoblastoma tumour suppressor gene Rb1. According to
the two-hit hypothesis, both alleles of the Rb1 tumour suppressor
gene must be inactivated to initiate Rb [2].
Deciphering the molecular mechanisms of tumourigenesis
allowed the development of genetic Rb mouse models [3–5]. In
addition, a BALB nude mouse Rb xenograft model has been estab-
lished by our group [6].
New imaging techniques have improved diagnosis, understand-
ing and management of Rb [7–9]. Moreover, the introduction of
optical coherence tomography (OCT) in diagnosis and monitoring
of the therapy of Rb patients allows a detailed monitoring of
tumour-growth in all tissues of the eye [10]. In vivo methods like
scanning laser ophthalmoscopy combined with OCT (SLO/OCT)
have been successfully adapted for detection and characterisation
of tumours in mouse models by our group [6] and others [11].
For advanced Rb with high risk of metastasis and low probabil-
ity of vision preservation, enucleation is still the only treatment
[12]. Rb responds very well to radiotherapy (RT) and external beam
RT was the first established Rb therapy preserving globe and vision.
However, it enhances the risk of secondary malignancies, in partic-
ular in patients with hereditary Rb [13]. The incidence of secondary
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tumours 50 years after Rb radiotherapy is 38% [14]. Therefore,
other therapy approaches like cryo-, thermo-, chemotherapy and
chemosurgery meanwhile have been established as first line treat-
ments [15,16]. Nevertheless, RT is considered as the last option
prior to enucleation for patients with large tumours or as second
line treatment for patients with recurrent Rb. Approximately 80%
of the Rb patients are diagnosed at a locally advanced stage, and
local control by chemotherapy fails in more than two-thirds of
advanced Rb [17].
Strategies which could reduce the side effects of RT are cur-
rently the focus of extensive scientific investigations. High-tech
RT like proton beam RT [18], intensity-modulated and fractionated
stereotactic RT [19] enable precise radiation delivery to the tumour
and spare the healthy tissue, thereby improving the efficacy/toxic-
ity ratio. The use of radioprotectors before and mitigators after RT
is a further approach to reduce side effects of the RT [20]. The
specificity for the non-tumoural tissues is a prerequisite for the
use of such drugs during RT of Rb.
In vitro and in vivo studies on the radioprotective effect of ortho-
phospho-L-tyrosine (pTyr) showed significant differences between
non-tumoural and tumoural cells with p 53 dysfunction [21–23].
The present study aimed by using a genetic knock out- and a
xenograft Rb mouse model to analyse the potency of pTyr to pre-
vent normal tissue damage and to define whether pTyr interferes
with the local Rb control mediated by fractionated RT.
Materials and methods
For our in vitro studies Y79 cells were cultured as recommended
by the American Type Culture Collection (ATCC), where the cells
were purchased. 16 h before IR pTyr (10 mM) or vehicle was added
to the culture medium.
Limited dilution assays
For the preplating assay the cells were put directly in 96 wells
plates for IR, incubation and readout for the delayed plating assay
the cells were irradiated in the culture-flasks and put in 96 wells
plates for incubation and readout after IR. The cells were irradiated
with 0 Gy, 2 Gy and 5 Gy. The readout was performed after two
weeks of incubation using a microplate spectrophotometer.
Western blot
A sample of unirradiated cells was analysed immediately after
16 h of pTyr treatment (co). The other samples were irradiated
with 4 Gy. 1, 6, 24 h after IR cells were lysed, and proteins were
resolved by SDS–PAGE. Western blotting was performed according
to standard procedures. All primary antibodies were diluted
1:1000 and purchased from the following sources: anti-TP53 (Cell
Signaling, clone 7F5), anti-phospho-TP53 (Ser15) (Cell Signaling,
clone 16G8), anti-p21 Waf1/Cip1 (Cell Signaling, clone 12D1) and
anti-Actin (Sigma, A2066). Quantification was performed with
the LI-COR detection system (LI-COR, Odyssey Fc).
Mouse models
B6;129-Rb1tm3Tyj/J Rb+/ mice (n = 24, 5–6 weeks old, Jack-
son’s lab, Bar Harbor, USA, having a mutation in one of the Rb1-
gene alleles [24] were used as a model for patients with hereditary
Rb, who having a genetic defect in the homologue human gene Rb-
1 have a higher risk of secondary malignancies after RT [13]. In
addition, BALB nude mice (n = 24, 6 weeks old, Janvier Labs, Le
Genest-Saint-Isle, France) were xenotransplanted intravitreally
with human Y79 Rb tumour cells as described in [6]. All animal
experiments were performed in accordance with the German Ani-
mal Protection Law and approved by the local authorities
(Regierungspraesidium Tuebingen AK 6/12).
Radiation protocol
Fractionated external beam radiation (IR) of the eyes was per-
formed under isoflurane anaesthesia applying 9 fractions of 5 Gy
within 3 weeks (Fig. 1) by the use of a linear accelerator (LINAC
SL25, Phillips, dose rate of 4 Gy/min). The IR- and the pTyr admin-
istration schedule were chosen in consideration of the results of
our group [21]. In particular, both eyes were irradiated simultane-
ously with a single field technique by the use of 6 MV photons that
were directed from lateral to an area of about 4  4 mm (50% iso-
dose) [25] supplementary appendix Fig. 1A, B). The dose distribu-
tion as determined in a mouse phantom by film dosimetry is
shown in (supplementary appendix Fig. 1C). Prior to each radiation
fraction (16 h) mice received i.p injections of vehicle or pTyr (0 or
100 mg/kg BW in PBS).
The animals were examined at 2, 12 and 24 h after RT and then
daily. Clinical findings regarding the presence of secondary
tumours or other side effects were recorded.
In vivo and ex vivo analysis of the mice after IR
The eyes of each 3 of pTyr pre-treated and 3 pTyr untreated
mice of the immune-compromised mice carrying retinoblastoma
xenografts and of the Rb+/ mice were assessed in dependence of
pTyr treatment 1, 3, 6 and 9 months after irradiation for radiation
toxicity and tumour development by SLO/OCT and histology
(Fig. 1).
Analysis of the fur of Rb+/ mice
Directly after SLO/OCT analysis and similar to the method
described in [26], hairs were plucked from the area between the
eyes/forehead (supplementary appendix Fig. 2A). Using a binocular
microscope (EXACTA+OPTECH, Muenchen, Germany), the hairs
were manually sorted into three categories: black, white, and grey.
A total of 100 to 150 hairs were counted for each mouse.
In vivo analysis using SLO/OCT
One, three, six and nine months after irradiation, groups of
three pTyr pre-treated and -untreated mice were analysed using
a SpectralisTM HRA+OCT (Heidelberg Engineering, Heidelberg, Ger-
many) SLO/OCT device. The whole procedure was performed as
described in [27] and the mice were anaesthetized and prepared
as described in [6].
For a detailed analysis of the changes of the retinal thickness a
custom-made program (multimodalmapper) was used which auto-
matically measures the retina thickness on the OCT images (sup-
plementary appendix Fig. 2B).
Histological analysis
Upon sacrification of the mice by cervical dislocation, eyes,
brain, lungs, heart, kidney, spleen, and liver were resected and his-
tologically analysed as described in [6]. As a measure of photore-
ceptor damage, photoreceptor nuclei were counted at 15 distinct
areas near to the optical nerve in each eye (supplementary appen-
dix Fig. 2C).
Statistics
Data are mean ± SD. Statistical analysis was performed using
Student’s t-test or log rank test where appropriate.
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Results
Post irradiation cell survival and p53 activity in vitro
Under in vitro conditions pTyr treated and irradiated Y79 cells
showed no significant radioprotection when tested in pre- and
delayed plating limited dilution assays (supplementary appendix
Fig. 3). However, when compared to vehicle-treated cells, in non-
irradiated and irradiated Y79 cells, pre-treatment with pTyr
resulted in an increased stabilisation of the p53 protein (TP53)
and its phosphorylation at Ser-residue-15. As a consequence of
p53 activity in irradiated cells, the expression of p21 as down-
stream target of p53 was substantially stimulated by pTyr treat-
ment (supplementary appendix Fig. 4).
Rb+/ mice
Five weeks after the last irradiation, a greying of the fur in the
irradiated area began in the pTyr untreated mice. The same change
in fur-pigmentation started eight weeks after irradiation in the
pTyr treated mice and was significantly reduced in the pTyr treated
mice six and nine months after RT (Fig. 2A).
Nine months after the end of the irradiation procedure, all mice
developed a cataract but the opacity of the lenses was still slight
enough to allow an OCT-analysis. As a result, 3, 6 and 9 months
after irradiation retinal thickness was significantly reduced in the
pTyr untreated group compared to the pTyr treated one (p < 0.05
3 months, p < 0.001 6 months and p < 0.0001 9 months after irradi-
ation) (Fig. 2B).
Histological analysis of the retina showed a significantly
increased photoreceptor loss in the pTyr untreated group vs. the
pTyr treated one (p < 0.001, 3 months and p < 0.0001 6 and
9 months after irradiation) (Fig. 2C). Furthermore, we screened tis-
sues in and near the irradiated area, like skull, skin, brain for
induced tumours and metastasis. In kidneys, lung, heart, liver
and spleen the appearance of distant metastasis was evaluated
by analysing haematoxylin and eosin stained cross sections of
these tissues. No RT-induced tumours or metastasis were found
in any of the analysed organs.
Xenografted mice
Three weeks after intravitreal Y79 tumour challenge, 38 of 42
analysed eyes developed tumours at an early stage as detected
by SLO/OCT. Four tumour-developing eyes were swollen. These
eyes could not be analysed in vivo (Table 1). Initial swelling of
the four eyes disappeared during the first two weeks of RT sugges-
tive of a RT-mediated tumour down-sizing. Importantly, in the
pTyr treated group swelling of 12 eyes newly occurred on days
27 to 64 after RT while in the pTyr untreated group only three mice
developed a swollen eye on days 51 to 89 (Table 2) strongly sug-
gesting radioprotection of the Y79 Rb tumour cells by pTyr
(Table 2). Three months after RT, all other eyes developed a severe
cataract making further in vivo analysis impossible.
During histological analysis tumours were found in all swollen
and unswollen eyes of pTyr treated animals as well as in the three
swollen eyes but in non of the unswollen eyes of the irradiated
control animals (Table 2 and Fig. 3) indicating pTyr-mediated fail-
ure of Rb tumour eradication by RT. In all investigated animals, no
distant metastases were found.
Discussion
Most radioprotectors are reactive oxygen species scavengers
reducing the cellular damage caused by irradiation [28–31]. pTyr,
in contrast, induces in irradiated cells [21] accumulation of EGFR
in the nucleus [32] which has been proposed to enhance DNA
repair and chromatin remodelling [33] and to induce a metabolic
switch from oxidative respiration to lactatic acid fermentation
[34].
Importantly, pTyr has been shown to radioprotect predomi-
nantly normal cells with wild type p53 genotype [21]. Mutations
in the p53 gene are infrequent in Rb and Y79 cells have been
demonstrated to express p53 protein [35,36]. On the other hand
Y79 cells do not express functional RB1 protein, which reportedly
prevents E3 ubiquitin-protein ligase MDM2 from targeting p53
[37] which, e.g., rescues the apoptotic activity of p53. However,
Y79 cells have been shown to overexpress the p53 inhibitors
MDMX [38] and MDM2 [39]. Additionally in Rb/ cells a downreg-
Fig. 1. Time schedule of the irradiation and pTyr treatment protocol and the in vivo and ex vivo analysis. All eyes of the immune-compromised mice carrying retinoblastoma
xenografts and of the Rb+/ mice were irradiated over a period of 3 weeks 3 times a week with a dose of 5 Gy per fraction with (+) or without () pTyr pre-treatment (16 h
before IR 0 or 100 mg/kg BW in PBS). Radiation toxicity and tumour development were assessed in dependence of pTyr treatment 1, 3, 6 and 9 months after irradiation in 3
mice per group by SLO/OCT and histology.
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ulation of the MDM2 inactivator p14 ARF [40] and hypermethyla-
tions in the p53 promotor-region [41] were found, suggesting that
Rb and particularly Y79 cells might have an impaired p53 function
[42].
Despite functional Rb1 deficiency and MDM2/MDMX overex-
pression and downregulated p14 ARF expression, irradiation of
Y79 cells resulted in the present study in stabilization of p53 and
upregulation of the p53 target p21 as demonstrated by Western
blotting (supplementary appendix Fig. 3A). Moreover, pTyr was
capable to stabilize p53 in unirradiated Y79 cells and to facilitate
radiation-induced p21 up-regulation confirming a modulation of
p53 activity by pTyr (supplementary appendix Fig. 3A). Since in
some p53 wild type cells, such as FSAII sarcoma, pTyr has been
demonstrated, not to act radioprotective [21–23] we tested the
effect of pTyr (10 mM) in 0 Gy-, 2 Gy- and 5 Gy-irradiated Y79 cells
in vitro by pre-plating and delayed plating limited dilution assays.
No radioprotective effect by pTyr could be observed (supplemen-
tary appendix Fig. 3).
In the present study, the radiosensitivity of the eyes differed
between the two mouse models. Cataract formation started much
earlier in the xenograft nude mice as compared to the Rb+/ mice.
Three months after RT, all nude mice already have developed sev-
ere cataract, which made in vivo OCT analysis impossible. In the
Rb+/ mice, in contrast, the cataract formation did not start earlier
than six months after IR and the opacity of the lenses, even nine
months after IR, was still slight enough to allow an OCT analysis.
Fig. 2. pTyr effect on the radiation-associated toxicity in normal tissue. (A) Mean percentage (±SD, n = 24) of black, grey and white hairs of the irradiated skin of pTyr or
vehicle-treated Rb+/ mice before (control), 1, 3, and 9 month after irradiation. *and **indicate p  0.05 and p  0.001, respectively (Student’s t-test). For the classification of
hair colours hairs were plucked from the area between the eyes/forehead directly after the SLO/OCT analysis and were manually sorted into three categories: black, white, and
grey. A total of 100 to 150 hairs were counted per mouse. (B) Mean (±SD, n = 24) retinal thickness as analysed by OCT applying 30 automatised measurements using
multimodalmapper-software. Retinal thickness was determined 1, 3, and 9 months after irradiation in pTyr- or vehicle treated Rb+/ mice. *, **, and ***indicate p  0.05,
p  0.001, and p  0.0001, respectively (Student’s t-test). (C) Mean (±SD, n = 24) number of nuclei outer nuclear layer of the retina. For this histological analysis, photoreceptor
nuclei rows of pTyr- or vehicle-treated Rb1+/mice were manually counted 1, 3, and 9 months after irradiation. ** and ***indicate p  0.001 and c001, respectively (Student’s t-
test).
Table 1
Shows the number of swollen eyes, eyes with tumours at an early stage of
development and eyes where no tumour was detected three weeks after the injection
of the human Y79 Rb cells. The table shows as well how the eyes were split into the
groups, which were irradiated with pTyr pre-treatment (group 1: +pTyr-group, n = 12
mice (24 eyes)) and without pTyr pre-treatment (group 2: pTyr, n = 11 mice (22
eyes)).
Eyes No tumour
detected
Tumour at early stage of
development
Swollen
eye
+pTyr
group 1
2/24 20/24 2/24
pTyr
group 2
2/22 18/22 2/22
Table 2
shows the results of the histological analysis of the Rb xenograft nude mouse eyes after RT (group 1: +pTyr-group; n = 12 mice (24 eyes)) and without pTyr pre-treatment (group
2: pTyr, n = 11 mice (22 eyes)).
Eyes Not analysable No tumour detected Tumour at early stage of development Tumour in swollen eye
+pTyr 5/24 0 3/24 16/24
pTyr 2/22 16/22 1/22 3/22
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Radiation irreversibly impairs the self-renewal capacity of fol-
licular melanocyte stem cells resulting in hair greying of black
mice [26,43]. In our study, pTyr reduced the greying of the fur in
Rb+/ mice after IR. Moreover, in the rodent retina, photoreceptors
are the most radiosensitive cells [44]. The inverted heterochro-
matin organization, containing a single large chromocentre in the
middle of the nucleus, impairs double-strand break repair in the
photoreceptors [45]. In our Rb+/ mouse model, pTyr significantly
reduced the photoreceptor loss observed after IR. pTyr, in contrast,
failed to protect in both mouse models the lenses which are
assumed to be the most radiosensitive tissue of the eye [46]. How-
ever, there was a clear difference between the two mouse models
used. The cataract formation started much earlier in the nude xeno-
graft mice. Indeed, three months after RT all mice already had sev-
ere cataracts. In the Rb+/ mice, the cataract formation started not
earlier than six months after RT and the opacity of the lenses, even
nine months after IR, was still slight enough to allow an OCT
analysis.
Combined, our data indicate a radioprotective function of pTyr
in vivo in follicular melanocyte stem cells of the hair follicles and
photoreceptors of the retina.
Unexpectedly, pTyr in vivo also radioprotected the Rb Y79 xeno-
graft contraindicating its use for radioprotection of the eyes during
RT of Rb patients, although in our in vitro studies pTyr did not show
a significant radioprotection of Y79 cells based on the results of the
limited dilution assay. The reason for the different outcome for the
in vitro/vivo studies might be of technical nature. For the limited
dilution assays, a single cell solution is needed, but normally the
Y79 cells in solution grow in clusters and even show some differ-
entiation. Therefore, the behaviour of Y79 cells might be different
concerning micromilieu and grow conditions in single cell solution,
in clusters or as a solid tumour-mass, causing the different
outcome.
In neither mouse model, radiation-associated secondary
tumours were observed in pTyr treated as well as pTyr untreated
animals. RT-induced secondary tumours in Rb patients are
reported in most cases not to appear earlier than 30 years after
treatment [47]. In the present study, the maximum life-span of
the used mouse models is about 18 months; therefore, we cannot
exclude that this life-span is too short for analyses of RT-induced
secondary tumours. In addition, Rb+/ mice did not develop Rb,
suggesting that further knockouts of other genes of the Rb gene
family like p107 or p130 or an additional knockout of p53 are
required to establish a genetic Rb model [3–5]. Moreover, to our
knowledge, studies investigating the occurrence of second cancers
were not performed in this mouse model yet. Since non-irradiated
control mice were not used in our study, a formal possibility exists
that the effect shown in the retina of Rb+/mice may be due to age-
ing of the animals and/or actions of pTyr alone.
To conclude, pTyr acts as a potent radioprotector preventing
radiation-induced normal tissue toxicity/alterations in Rb+/ mice.
However, based on the tumour control data presented here for Y79
Rb tumour xenografts, pTyr treatment seems to be contraindicated
for RT, at least of Rb p53 wt tumours, but it could be interesting for
RT of other tumour types presenting a p53 dysfunction.
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SUPPLEMENTARY APPENDIX  
 
FIGURES  
Figure 1:(A) mouse in the mouse fixation unit (B) scheme of the mouse holder with the lead 
shield s, (C) IR dose distribution as determined in a mouse phantom by film dosimetry [25]. 
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Figure 2: (A) For the classification of hair colors, the hairs were plucked from the area 
between the eyes/forehead (circle) after the SLO/OCT analysis and were manually sorted 
into three categories: black, white, and gray. A total of 100 to 150 hairs were counted in each 
tested mouse. Representative images of pTyr pretreated and not pTyr pretreated mice for 
each time point of analysis are presented. (B) principle of the analysis of the OCT images of 
the retina with the MultiModalMapper-software: the retina thickness was automatically 
measured at each of the 30 points shown on the scale at the bottom of the image, here 
shown on an image of a not irradiated Rb+/- mouse. Representative OCT scans of the retina 
of pTyr pretreated and not pTyr pretreated mice for each time point of analysis are 
presented. (C) principle of the analysis of the histological slices of the retina: the outer nuclei-
layers (ONL) were manually counted on representative slides, here shown on an image of a 
not irradiated Rb+/- mouse. The mean/standard deviation of 45 counts for each time point 
and condition were used for statistical analysis. Representative images of histological slides 
of the retina of pTyr pretreated and not pTyr pretreated mice for each time point of analysis 
are presented. 
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Figure 3: Results of a preplating (A) and delayed plating (B) limited dilution assay of 
pTyr pre-treated (16 hours before IR, 10µM) (▲) and untreated (ο) Y79 cells after 
irradiation with 0 Gy, 2 Gy and 5 Gy. No significant differences between pTyr treated 
and untreated cells were found. 
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Figure 4: Western blot analysis: Y79 cells were pretreated with pTyr (10µM) or vehicle 16 
hours before IR (4 Gy). Unirradiated cells in absence of pTyr express TP53 and it is 
phosphorylated, p21 is not expressed. After pTyr administration and after IR TP53 was 
stabilised, phosphorylated and p21 was expressed. pTyr treatment led to TP53 stabilization 
and p21 expression in unirradiated cells and increased p21 expression after IR compared to 
untreated cells, confirming a modulation of TP53 activity by pTyr. 
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6. Discussion  6. Discussion  6.1 Is there a relevant mouse model, which can be used for radiotherapeutic approaches?  For the development of effective and safe radiotherapy of retinoblastoma studies with suitable models are needed. A good model should have as many characteristics of the original tumour as possible. To implement this, we used cultured human Y79 Rb cells and injected them into the vitreous of nude mouse eyes, the area the tumour grows into in most cases (orthotopic). Indeed, the growth characteristics of the xenograft-tumours of our model were similar to those of Rb-tumours in patients. The histological and ultrastructural analysis of the xenograft–tumours showed very similar characteristics to those described for the tumour the Y79 cells originate from (Reid et al., 1974) and Rb-tumours of other patients in general such as multiple degraded and necrotic cells, poor differentiation but still identifiable rosette-like growth, large hyperchromatical nuclei with multiple nucleoli and elaborate convolutions of the nuclei (Green et al., 1979; McFall et al., 1977; Reid et al., 1974), (Allen et al., 1962; Rodrigues et al., 1986).  Interestingly, typical metastasation via the optic nerve, ciliary body or blood vessels of the eye (Rodriguez-Galindo et al., 2003) was not observed in our model and the sclera forms a strong barrier for the growing xenograft-tumour, thus the tumour needs to grow very large and to have long time to break through the sclera. During our experiment, a tumour only penetrated the sclera in one mouse eye and formed brain metastases. The metastases were found in the brain of the animal (fig. 12), which after its tumour broke through the cornea, was kept alive for the longest period of time (35 days) of all analysed mice before sacrifice. However, in the Rag-2 knockout mice, which were used by Chevez-Barrios et al., the animals were intravitreally injected with Y79 cells in a similar manner as in our experiment, the mice already developed metastasis 4 weeks after the injection (Chevez-Barrios et al., 2000). These results are consistent with that of other groups, who showed, that metastasising in Rag-2 knockout based mouse models is superior to that in nude mice for several human cancer xenografts like sarcoma (Nanni et al., 2010), breast cancer (Nanni et al., 2012) or adenocarcinoma (Ye et al., 2015). This different metastasising behaviour should be taken into account when choosing a model.  In conclusion, we showed that our retinoblastoma mouse model mimics the symptoms observed in Rb patients. The xenograft tumours from our model showed very similar growth characteristics, cellular appearance and ultrastructural 
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6. Discussion  characteristics to that of retinoblastoma tumour tissue samples of Rb patients. This makes our model a promising tool for the study of retinoblastoma and its potential therapeutic approaches.   A very important aspect of this thesis was the use of SLO/OCT for the detection and characterization of tumours in the mouse eyes and the comparison of these results with those of the corresponding histological analysis. SLO/OCT can be used for the detection of tumours at early stages of development and might be used for monitoring of the success of the potential therapy approaches. Unfortunately the method is limited to tumours at early stages of development. If the tumour covers most of the fundus no analysis is possible (fig. 11).  A similar fundoscopy/OCT based approach was used for the analysis of the tumours in the eyes of a TAg-RB mouse model by Wenzel et al. Using OCT the group was able to characterise developing retinoblastomas in mice two weeks after birth. Their results showed, similar to our findings, that their OCT-data could also be correlated with the fundoscopy- and corresponding histology-results (Wenzel et al., 2015). In ophthalmological research, in vivo analysis like SLO/OCT allows multiple analysis of dynamic biological processes like tumourigenesis, tumour growth and - angiogenesis at certain time points in individual animals and can help to reduce the number of experimental animals used according to the 3 rules in animal welfare (replace, reduce, refine).  6.2 Can the application of pTyr protect tissues that are affected by irradiation during radiotherapy and prevent the induction of secondary tumours?  In the rodent retina the photoreceptors are the most radiosensitive cells (Amoaku et al., 1992). It was shown that the double-strand break repair in the photoreceptors is weaker than in all other cells of the retina because of their inverted heterochromatin organization, containing a single large chromocentre in the middle of the nucleus (Frohns et al., 2014). The fractionated, therapy simulating irradiations of 5 Gy used for each single irradiation were administered at such low rates to avoid cell damage and to give the tissues enough time to regenerate with the help of cellular repair mechanisms. It was shown, that radiation-effects on a mouse retina are characterized by a non-linear dose-response curve. After irradiation with intensities up to 14 Gy, no morphological destruction was observed after a period of 30 days, indicating that retinal repair mechanisms took place (Tronov et al., 2015; Vinogradova Iu et al., 2014). We were interested in long-term side effects of RT. We 
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6. Discussion  analysed the animals 3, 6 and 9 months after nine irradiations with 5 Gy. In the non- pTyr pretreated animals the reduction of the retina thickness and photoreceptor loss did not differ from the pTyr pretreated animals one month after IR. However, 3, 6 and 9 months after IR the retina thickness reduction and photoreceptor loss we measured in the non-pTyr pretreated mice was about 10% compared to the corresponding pretreated groups and results one month after IR, and thus comparatively low but statistically significant. The retinal thickness and photoreceptor number 1, 3, 6 and 9 months after IR did not significantly differ in the pTyr pretreated animals, indicating pTyr effectivity.  Radiation-induced hair greying in black mice is a known IR-induced side effect. It is caused by irreversible defects in the self-renewal of melanocyte stem cells in the hair follicles (Aoki et al., 2011; Boyland & Sargent, 1951). Thus during our experiment in the Rb+/- mice this effect could also be observed in the irradiated area. Our results showed that pTyr-administration can reduce this side effect, which was a clear indication for radioprotection by pTyr.  The question as to whether pTyr can prevent the induction of secondary tumours after IR unfortunately could not be answered. During the period of investigation no induced tumours were detected. Actually, in Rb patients, radiotherapy-induced secondary tumours in most cases were not diagnosed any earlier than 30 years after treatment (Marees et al., 2009). In our study we used mouse models which unfortunately are not able to live longer than one and a half years. Thus the period of investigation seems to be too short for the tumours to appear, which probably explains the absence of IR-induced tumours in the mice.  6.3. Does the application of pTyr interfere with the radiotherapy of retinoblastoma?  The results of former experiments suggested that pTyr is predominantly radioprotective in cells with a p53 wild type (WT) (K. H. Dittmann et al., 2001). The results of our western blot analysis showed that Y79 cells express p53. Irradiation of the cells resulted in the stabilization of p53 and upregulation of the p53 target p21. Moreover, pTyr was capable of stabilsing p53 in unirradiated Y79 cells and facilitating radiation-induced p21 up-regulation confirming a modulation of p53 activity by pTyr.  However, because of the mentioned inactivation mechanisms of the p53 pathway in Y79 cells like MDM2-activity increase (Hsieh et al., 1999), overexpression of MDMX (Laurie et al., 2006; Sherr & McCormick, 2002) and hypermethylation of the p53 promotor region (Livide et al., 2012), we decided to test the ability of pTyr to radio-
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7. Final conclusions  protect Y79 cell cultures directly in in vitro irradiation experiments. We discovered that pTyr did indeed fail to protect the cell cultures after irradiation.  Unexpectedly and in contrast to our in vitro irradiation studies, pTyr showed radioprotection in vivo of Rb Y79 xenografts in the nude mouse eyes. The reason for the different outcome of the in vitro/vivo studies might be of a technical nature. For the limited dilution assays, a single cell solution was prepared, but normally the Y79 cells in solution grow in clusters and even show some differentiation (Reid et al., 1974). Therefore, the behaviour of Y79 cells might be different with regard to the micromilieu and growing conditions in a single cell solution, in clusters or as a solid tumour-mass, causing the different outcome. A similar effect was, for example, shown for the variation of the radioprotection of WR-2721 on tumours which depended on the tumour size (Milas et al., 1984).  Additionally in FSAII sarcoma cells, which have a p53 WT, pTyr has been demonstrated not to act radioprotectively due to possible additional mutations which interfere with the p53 function (K. Dittmann, Toulany, et al., 2005). Thus, the p53 status does not seem to be an exclusive criterion for pTyr to be radioprotective in a certain cell type.  6.4 Additional finding  The lens is the most radiosensitive tissue of the whole rodent eye (Brown, 1997). In our study we did not detect a radioprotective effect of pTyr on the lens, but there was a clear difference between the two mouse models used. The cataract formation started much earlier in the nude mice, as three months after RT all the mice already had severe cataracts. In the Rb+/- mice the cataract formation did not start earlier than 6 months after IR and even 9 months after IR the opacity of the lenses was slight enough to enable an OCT analysis. The nude mice we used are historically on a BALB/c mouse genetic background. Thus the finding that BALB/c mice are more sensitive to radiation-induced cataractogenesis than pigmented mice (Sayama et al., 1991) is consistent with our results. Of course the mutation in the FOXN1 gene in the nude mice can also have an influence on their cataractogenesis.  7. Final conclusions  The application of pTyr before irradiation significantly reduced the negative effects of radiation on the retina and hair coat of Rb+/- mice 3, 6 and 9 months after irradiation. 
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8. Perspectives  A fractionated radiotherapy can eliminate Y79-retinoblastoma-tumours in nude mice eyes if the treatment is started at an early time point of tumour growth, and the mice can remain tumour-free up to 9 months after radiotherapy. pTyr is a potent radioprotector for human Y79 xenograft tumours and is consequently contraindicated for the radiotherapy of retinoblastoma. The appearance of secondary tumours which is an often seen side effect of radiotherapy in patients was not observed in our mouse-models at the investigated time points. The development of irradiation-induced tumours might take a longer period of time.  Although pTyr is contraindicated for the radiotherapy for retinoblastoma, its radioprotective abilities might make it interesting for the radiotherapy of other cancers, which are not protected by pTyr, especially those with p53 mutations. The radioprotective effects on the retina might also make pTyr interesting for the reduction of occupational risks in areas where humans are exposed to irradiation, for example in space and aviation sectors (Cucinotta et al., 2014; Moreno-Villanueva et al., 2017).  8. Perspectives  It can be assumed that radiotherapy will continue to play a role in the therapy of retinoblastoma, and a search for possibilities, which could help to make the radiotherapy of retinoblastoma more efficient and safe, will also continue.  Currently chemotherapies with vincristine, etoposide, carboplatin, melphalan, or combined chemotherapies are the state of the art treatment of retinoblastoma (Yanik et al., 2015). Depending on the size and location of the tumour, the chemotherapeutic agents are administrated via the intra-arterial, intra-venous or intra-vitreal route. Although being successful in over 90% of the cases for tumours at an early stage of development, if they are confined to the retina with no seeding, (Fabian et al., 2018), the therapy is far from being optimal, especially for tumours at advanced stages, with seeds or metastasis. Here the treatment success is only 48% (Mendoza & Grossniklaus, 2016).  To conclude, my vision about future retinoblastoma treatment could be the use of a very promising method of therapeutics administration to the eye via a catheter in the retrobulbar space that I am currently developing. This approach will help to reduce the number of traumatic operative interventions in young children and prevent systemic side effects. Moreover, it will allow a better local bioavailability and 
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8. Perspectives  importantly the fast supply of a therapeutic dose in case of tumour recurrence ensuring a better tumour control.   
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ABSTRACT
Objective. In the foveola of the eye, photoreceptors and Müller cells with a unique
morphology have been described, but little is known about their 3D structure and
orientation. Considering that there is an angle-dependent change in the foveolar
photoreceptor response for the same light beam, known as the Stiles Crawford Effect
of the first kind (SCE I), which is still not fully understood, a detailed analysis of the
anatomy of the foveolar cells might help to clarify this phenomenon.
Methods. Serial semithin and ultrathin sections, and focused ion beam (FIB) tomogra-
phy were prepared from 32 foveolae from monkeys (Macaca fascicularis) and humans.
Foveolae were also analyzed under the electron microscope. Serial sections and FIB
analysis were then used to construct 3D models of central Müller and photoreceptor
cells. In addition, we measured the transmission of collimated light under the light
microscope at different angles after it had passed through human foveae from flat
mounted isolated retinae.
Results. In monkeys, outer segments of central foveolar cones are twice as long as those
from parafoveal cones and do not run completely parallel to the incident light. Unique
Müller cells are present in the central foveolae (area of 200 µm in diameter) of humans
and monkeys. Light entering the fovea center, which is composed only of cones and
Müller cells, at an angle of 0◦ causes a very bright spot after passing through this area.
However, when the angle of the light beam is changed to 10◦, less light is measured after
transpasssing through the retina, the foveolar center becomes darker and the SCE-like
phenomenon is directly visible. Measurements of the intensities of light transmission
through the central foveola for the incident angles 0 and 10◦ resemble the relative
luminance efficiency for narrow light bundles as a function of the location where the
beam enters the pupil as reported by Stiles and Crawford. The effect persisted after
carefully brushing away the outer segments.
Conclusion.We show that unique cones andMüller cells with light fibre-like properties
are present in the center of the fovea. These unique Müller cells cause an angle
dependent, SCE-like drop in the intensity of light guided through the foveola. Outer
segments from the foveolar cones of monkeys are not straight.
Subjects Biophysics, Cell Biology, Anatomy and Physiology, Ophthalmology, Histology
Keywords Foveola, Fovea, Müller glial cells, Cone receptors, 3D model, Stiles–Crawford effect
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INTRODUCTION
The primate retina contains two types of photoreceptors, rods for night vision and cones for
daylight vision. Cones are predominately located in the macula lutea. This has a diameter of
around 5.5 mm in humans and is subdivided into the fovea and parafovea with diameters
of 1.8 mm and 2.3 mm, respectively (Hogan, Alvarado & Weddell, 1971).
The fovea is a small pit in the retina which contains the largest concentration of cones
and is responsible for sharp central vision. The central part of the fovea is called the
foveola (Hogan, Alvarado & Weddell, 1971) and has been regarded as being 350 µm in
diameter since 1941 (Polyak, 1941). Only in the foveola does visual acuity reach 100
percent (Trauzettel-Klosinski, 2010).
The original discovery by Stiles and Crawford described that the apparent brightness of
an object is not proportional to the pupil area because light rays entering the pupil distant
from the axis are not so visually effective as rays entering along or near to the central axis
(Stiles & Crawford, 1933).
Stiles also showed that monochromatic light will differ in hue between on- and off-
axis even after the light beams are equated for brightness. This was described as the
Stiles–Crawford effect of the second kind (SCE 2).
The Stiles Crawford Effect of the first kind (SCE I) was regarded as one of the most
important discoveries in visual science of the last century (Westheimer, 2008). The
explanation of the SCE has so far been handled in abstract models involving specific
photoreceptor orientation, subtle morphological differences in rods and cones, anchoring
of photo-pigment molecules in membranes or possible phototropism of retinal cells
(Laties, 1969). But none of these models could be proven and a full explanation of the SCE
continues to provide challenges (Westheimer, 2008).
Since the first report of Stiles and Crawford, a large body of histological and
psychophysical evidence has accumulated (for review see Westheimer, 2008) showing
that cones in different retinal regions are directionally sensitive.
It was speculated that a change in the shape or the orientation of foveal cones was
probably responsible for the SCE (Westheimer, 1967). But until now, no morphologic
evidence for this assumption has been found, and in contrast a different orientation
of foveal and parafoveal cones in monkeys and humans (Hogan, Alvarado & Weddell,
1971) was ruled out by histologic examinations more than four decades ago (Laties, 1969;
Westheimer, 2008). To study the SCE I, monkey eyes are suitable because human and
monkey foveae are very similar (Krebs & Krebs, 1991) and the existence of the SCE I has
also been demonstrated for monkeys (Matsumoto et al., 2012).
The most renowned publication about the histology of the human eye (Hogan, Alvarado
& Weddell, 1971) states that in meridional sections of the foveolar region, the cones are
perfectly straight and oriented vertically with respect to the retinal surface, and their axes
are parallel to each other. Thus, the view that foveal cones lack directional morphology has
remained valid right up to the present day.
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Clinically the SCE I is used for diagnosis of macular telangiectasia type 2 (Charbel Issa et
al., 2016) which is a poorly understood condition of the retina that may result in blindness
(Charbel Issa et al., 2013).
The SCE is absent in rod photoreceptors (Lu et al., 2013) leading to the speculation that
differences in photo-pigment structure and anchoring of cones and rods may be involved
in SCE (Enoch & Stiles, 1961; Walraven & Bouman, 1960; Westheimer, 2008). Despite its
pivotal role for sharp central vision the definite anatomy of the fovea at high resolution is
not known (Yamada, 1969).
The aim of our study was to investigate the 3D anatomy of foveolar cells (Fig. 1) and
whether it can help to explain the SCE I.
MATERIALS AND METHODS
Light and electron microscopy from monkey eyes
Twenty-four monkey eyes (Macaca fascicularis, 14 males, 10 females) were collected
after sacrificing the animals under general anesthesia, i.e., intramuscular injection of
ketamine hydrochloride followed by an intravenous sodium pentobarbitone (Lethabarb R©,
Virbac, Australia) overdose. Monkeys were kept at Covance Laboratories GmbH
(Münster, Germany study numbers 0382055, 8260977, 8274007) or SILABE-ADUEIS
(Niederhausbergen, France). The Covance Laboratories GmbH test facility is fully
accredited by the Association for Assessment and Accreditation of Laboratory Animal
Care (AAALAC). This study was approved by the local Institutional Animal Care and Use
Committee (IACUC), headed by Dr. Jörg Luft and the work was carried out in accordance
with the Code of Ethics of the World Medical Association (Declaration of Helsinki). The
monkeys from SILABE-ADUEIS were euthanized due to veterinarian reasons. Since they
had not been included in a study before, they do not have a study number. The age of the
monkeys varied between four to eight years. The eyes were enucleated 5 min post-mortem,
cleaned of orbital tissue, and were slit carefully at the limbus without damaging the ora
serata. Then, 200 µl of the fixative (5% glutaraldehyde) were carefully injected into the
center of the vitreous. The intraocular pressure was balanced because vitreous could leak
out from the opening thereby compensating the volume of the fixative. This protocol has
been shown to minimize fixation artefacts according to our own experience. The eyes were
then fixed at 4 ◦C by immersion into 5% glutaraldehyde in 0.1 M cacodylate buffer (pH
7.4; Sigma, St. Louis, MO, USA) overnight for electron microscopy. Glutaraldehyde fixed
specimens were post-fixed with 1% OsO4 at room temperature in 0.1 M cacodylate buffer
(pH 7.4), stained with uranyl acetate, and the maculae were excised and embedded in Epon
after dehydration in a graded series of ethanol and propylene oxide. Semi-thin sections
were stained with toluidine blue and examined by light microscopy (Zeiss Axioplan 2
imaging; Zeiss, Jena, Germany). For electron microscopy, ultrathin sections were made
and analyzed with a Zeiss 900 electron microscope (Zeiss, Jena, Germany). The foveae
from 24 eyes were sectioned in a sagittal plane until the center of 21 foveolae was found.
In three eyes, the foveal centers were missed. The center of the foveola was defined as the
site where the cell fiber layers at the bottom of the foveal pit were free of nuclei and were
10 µm thin or less.
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Figure 1 Anatomical findings in monkey foveae and cones. (A) In an electron micrograph, an extra
foveal cone contains irregularly ordered stacks of photoreceptor disc membranes (black arrowheads) and
spaces free of photoreceptor membranes (arrow). In contrast, the disk membranes in rods are highly or-
dered (white arrowhead). (B) In a semi-thin transverse section of the central fovea, the prominent Müller
cells are present (arrow). Inner segments are curved and are (continued on next page. . . )
Full-size DOI: 10.7717/peerj.4482/fig-1
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Figure 1 (. . .continued)
cut transversely in the plane of section. Spaces between the curved inner segments form symmetrical pat-
terns (white arrowhead) (see also C and the model in D). Also in the middle of the subretinal space the
outer segments are cut transversely (black arrowhead). (C) In an electron micrograph sectioned parallel
to the optical axis through the central fovea, the inner segments of the cones are cut longitudinally (aster-
isk), diagonally (black arrow) and transversely (black arrowhead) in the same plane of section indicating
their curved nature. The spaces between the curved inner segments shown in (B) are marked (white ar-
rowhead). The white arrow marks the outer limiting membrane. (D) Different shapes of cones are pre-
sented schematically from the central fovea to the parafovea. (E + F) Central cones (E) and parafoveal
cones (F) are shown in different views integrated into the retinal environment (top), from the front (mid-
dle) or from the RPE towards the vitreous (bottom). Parafoveal rods are marked in red, inner segments in
green, outer segments in yellow and the outer limiting membrane in blue.
Light and electron microscopy from human eyes
Three human eyes from a 57 and 81-year-old male, and a 68-year-old female were fixed 8
and 12 h postmortem at 4 ◦C by immersion into 5% glutaraldehyde in 0.1 M cacodylate
buffer (pH 7.4; Sigma, St. Louis, MO, USA) for half an hour. Then the cornea was removed
and fixation continued overnight for electron microscopy. The human eyes were gifts
from the Clinical Anatomy of the University of Tuebingen (ethical number for scientific
issues 237/2007B01), and taken from full body donors, who had previously given informed
consent. Embedding and sectioning was done as described for the monkey eyes.
Evaluation of serial sections through the fovea of monkey and
humans
For 3D model reconstruction, semi-thin (700 nm) serial sections were performed from 6
monkey foveae.
Series 1 and 2 comprised 21 sections which correspond after mounting to a foveal tissue
piece with a thickness of 14.7 µm. Unexpectedly, due to their curved shape, a foveal cone
did not completely fit into such a tissue block. Therefore series 3 and 4 were sectioned in
sagittal planes with 41 and 160 sections respectively. Additionally, series 5 and 6 were cut
as transverse sections with 450 and 195 sections respectively. Sagittal sections run within
or parallel to the optical axis, while transverse sections were made perpendicular to it.
Serial transverse sections were performed from two human foveae. Series 7 from a
68-year-old female and series 8 from an 81-year-old male contained 250 and 460 sections,
respectively. From each section, the fovea was photographed at a 600-fold magnification.
3D modelling
The 3D reconstructions of the presented figures and measurements were performed with
Amira R© software (version 5.6; FEI, Hillsboro, OR, USA). Using previous embedded
fixed marker, the images of the sections were aligned manually following digitization by
comparing superimposed slices, translating, and rotating adjacent slides with respect to
one another. Additionally, the border of each slide and the regular structures and patterns
were used as markers for alignment.
Once the aligned sections were imported into Amira, the structures of interest were
labeled using the software segmentation tools. The structures of interest were cone nuclei,
inner and outer segments, the outer limiting membrane, andMüller cells. The length of the
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Figure 2 Unique central foveolar Müller cells frommonkeys. In the fovea there are only two types
of cells. Müller cells appear white or electron-lucent and cone photoreceptors appear blue or electron-
opaque. Thus they can be easily distinguished. (A) In a semi-thin section perpendicular to the optical
axis the central Müller cells are translucent (arrow). (B) The Müller cells (arrow) are shown in the same
orientation as in (A) at high magnification. They do not contain cell organelles at this topographic site and
appear white or electron-lucent. The arrowhead marks a Henle fibre. (C) The plateau zone of a Müller
cell is indicated by a white arrowhead in a section parallel to the optic axis. Henle fibers are indicated by a
black arrowhead and cone nuclei by (N). (D) A 3D model shows the main part of the central Müller cells
of a monkey.
Full-size DOI: 10.7717/peerj.4482/fig-2
inner and outer segments of cones from the parafovea and the central fovea were measured
using the ‘‘Amira-3D length—measurement-tool’’. For Fig. 2D and Video S1, areas of
interest were selected by visually adjusting the grey value threshold of the volumetric
dataset.
Focused ion beam/scanning electron microscopy
Focused ion beam/scanning electron microscopy (FIB/ SEM) tomography data were
acquired using a Zeiss Auriga CrossBeam instrument at the Natural and Medical Sciences
Institute at the University of Tuebingen (NMI, Reutlingen, Germany) as described
(Steinmann et al., 2013). For FIB/SEM analysis, the block of the embedded sample was
sputter coated with gold palladium and mounted on an appropriate SEM sample holder.
A semi-thin section of the embedded sample was imaged with the light microscope and
correlated with the SEM image of the ultramicrotome block face to define the region of
interest for three-dimensional analysis. Using a Crossbeam instrument (Zeiss) equipped
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with a gallium FIB and a low voltage SEM, FIB/SEM serial sectioning tomography was
accomplished. The gallium FIB produces thereby a series of cross-sections containing the
region of interest. Each of these cross-sections is imaged by the low keV SEM using the
energy-selected backscattered (EsB) electron detector for image acquisition. The following
parameters were used for SEM: Primary energy of 1.8 keV with the aperture 60 µm:
for image acquisition the EsB detector was used with a grid voltage of −1,500 V, i.e.,
only backscattered electrons with a maximum energy loss of 300 V were used for image
acquisition. The resolution was 2,048 × 1,535 pixels with a pixel size of 42.41 nm.
For FIB, the following parameters were used: Primary energy of 30 keV, slicing was
performed with a probe current of 2 nA, the slice thickness was 42 nm. In this way
cubic voxels were obtained, i.e., the same resolution in x,y , and z , which is good for the
reconstruction. The resulting stack of two-dimensional images was utilized for three-
dimensional reconstruction using appropriate software.
Wholemount preparations from human retinae
The maculae of five eyes from three donors were excised using a trephine with 1 cm
diameter. The donors were two females of 74 and 90 years old, and one male of age 18.
Three maculae were fixed in formalin transferred into phosphate buffered saline and
mounted on slides covered with a cover glass on wax feet to prevent squeezing of the
retinae. Another two eyes were treated identically but fixation was omitted. Finally, the
maculae were observed under the light microscope having the condenser replaced by a
modification with adjustable mirror (Fig. 3C).
Illumination optics for measuring angle dependent light transmission
through Müller cells
The optical fiber homogenizes the light of the light-emitting diode (LED). The light cone
at the end of the fibre is collimated with an aspherical lens. With the focal length fcol, the
core diameter Dfiber defines the divergence angle θdiv and the opening angle θNA defines the
diameter Dspot of the light spot on the sample. The mirror can be tilted and slid. The angle
of incidence of light on the sample is αslide.
To homogenize the intensity distribution of the light spot to be projected, the light
from a light emitting diode (high power white LED, type: OSLON SSL, LCW CP7P.PC) is
coupled to an optical fibre with the core diameter Dcore = 200 µm (Fig. 3C). Through the
principle of total reflection, the incident light in this optical conductor is reflected on the
wall several times. In this way, the light is mixed and emerges homogeneously from the
conductor. The light cone emitted in the opening angle θNA is collimated by an aspheric lens
of focal length fcol = 35 mm. Since the light is not a point source, the rays diverge slightly.
The divergence angle is in paraxial approximation θdiv =Dcore/fcol = 0.2 mm/35 mm= 5.7
mrad (0,3◦). The diameter Dspot of the projected light spots is given as NA = 0.16 through
the focal length fcol of the lens and the numerical aperture of the optical fibre. With NA
= θNA/2, Dspot = 2 · fcol ·NA= 2 ·35 mm · 0,16=11,2 mm. The light striking the slide at an
angle αslides ispartially reflected according to the Fresnel equations and should be taken into
account when measuring the intensity on the microscope. In normal incidence, αslide = 0
◦,
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Figure 3 Measurement of light intensity after transpassing human foveolae. (A) The central Müller cell
(arrowheads) is shown integrated into a stack mounted from serial sections. (B) A human foveolar Müller
cell 3D model is shown and its plateau zone marked by an arrow. (C) Schematic drawing of the measure-
ment equipment is shown. Illumination optics for angle measurement at the Müller cells. The optical fiber
homogenizes the emitted light of the light-emitting diode (LED). The light cone at the fiber end is colli-
mated with an aspherical lens. With the focal length fcol, the core diameter Dcore defines the divergence an-
gle θdiv and the aperture angle θNA defines the diameter Dspot of the light spot on the sample. The mirror
is rotatable and movable. The angle of light incidence on the sample is αslide. (For more details, see Meth-
ods.) (D) Measurements of light intensities of translucent light in the foveolar centre entering at different
angles are shown. The mean loss of intensity + standard deviation at an angle of 5 and 10◦ was calculated
as a percentage of the 0◦’s value and was 15,3% + 9,6% and 67,8% + 11,3% respectively. (E) A human
foveolar center is shown in translucent light entering at 0, 5 and 10◦ respectively. These images correspond
to the measurements in (D). (F) Hypothetical explanation of the SCE-like drop of light intensity: light hit-
ting the Müller cell at an angle is partly reflected (black dashed line) at the surface when entering the wa-
tery cytoplasm and reduces the transmission of light into the cones. Light not entering at an angle is fully
transmitted into the cones (red line).
Full-size DOI: 10.7717/peerj.4482/fig-3
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the transmitted light intensity is about 96% of the incident intensity, depending on the
refractive index of the slide when nslide = 1.5255 (λ = 546 nm, borosilicate glass/Schott).
The intensity declines by about 4% when light incidence is under αslide = 20
◦. The angle
αmüller of a light beam to a Müller cell can be distinguished from the angle of incidence on
the slide through the multiple refractions of previous optical layers (glass material etc.).
This angle is determined by the refractive index nfront of the substrate before the Müller
cell and the angle of incidence αmüller = αslide/nfront.
The maximum acceptance angle (half angle) under which a light beam can penetrate
the cell is
2max = sin
−1
(
1
nfront
√
n2core−n
2
gladding
)
, (1)
with the refractive indices ncore of the substrate within the cell and ngladding < ncore of the
cell edge.
The acceptance angle of the Müller cells in vivo is estimated with the refractive indices
according to Franze et al. (2007) whereby nfront = 1.358 (neuron), when the light coupling
of a cell does not connect to the vitreous body of the eye, and ncore = 1.359 (end foot). The
refractive index of the cell edge is not known and is set as ngladding = nfront. According to
Eq. (1), the acceptance angle in vivo is θmax = 2,2
◦. When fixing the sample with phosphate
buffered saline (PBS—buffer, nPBS = 1.33) it can be assumed that the substrate surrounding
the Müller cells has the index value ngladding = nPBS. The acceptance angle is then θmax =
12,0◦ and is measured in the experiment with αslide = nfront ·θmax = 16
◦.
Quantification of angle dependent foveal light transmission
Light micrographs with 100-fold magnification from the foveae and parafoveae of the three
donors were taken under equal conditions with collimated light hitting the sample at a 0◦ ,
5◦ , and 10◦ angle. The photos were processed using ImageJ 1.48v. The mean pixel intensity
of the fovea or parafovea area was measured. The value of the image taken at the angle of
0◦ was set as 100% for each fovea. The mean loss of intensity ± standard deviation at an
angle of 5◦ and 10◦ was calculated as a percentage of the 0◦’s value.
RESULTS
The first interesting finding was that the arrangement of disk membranes is more regular
in rods compared to cones (Fig. 1A).
In semi- and ultrathin cross sections of fixed monkey foveolae, inner and outer segments
of the cone photoreceptors were arranged in a highly ordered pattern (Fig. 1B). In the same
plane of section, the inner segments were hit longitudinally, diagonally, and transversely in
subsequent underlying rows (Figs. 1C and 4). These results indicate that the inner segments
of the cones in the central foveola area are curved. We detected curved inner segments in
18 out of 21 monkey foveae. There were substantial differences in the shape of individual
foveae, which corresponds to the variance among individuals observed in psychophysical
measurements (He, Marcos & Burns, 1999). The diameter of the area containing curved
inner segments was 267 µm ± 132 µm A calculation of cone numbers in the central part
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Figure 4 Distribution of central cone orientation in serial sections of the monkey fovea. (A) At the
level of the outer limiting membrane (arrow) inner segments are hit in different directions (arrowheads)
in the same plane of section. (B) Cones are thin and separated. (C) The foveolar center is kept open (ar-
row). (D) Cone outer segments run perpendicularly (arrowhead) within the open center (arrow). (E) The
tips of central cones (white arrowhead) reach the RPE (black arrowhead). Close to the RPE, cone outer
segments run parallel (white arrow). The black arrow points to melanosomes of the RPE. (F) Arrowheads
show the planes of section in (A–E). The arrow indicates central Müller cells.
Full-size DOI: 10.7717/peerj.4482/fig-4
of the foveola with a diameter of 200 µm results in approximately 6,500 cells. Of these
cones, 75% of the inner segments are curved. These cones are located in the ring—like area
between the central part of the foveola with a diameter of 100 µm. The remaining 25%
of cone inner segments within the area of the central 100 µm diameter are straight. The
pattern formed by the outer segments was of an even higher complexity but they were not
straight in the central foveola (diameter of 200 µm).
The precise form of foveal fundus cells, however, can only be judged by three-
dimensional (3D) reconstruction. To unravel the form and shape of foveal cells (Fig. 1D),
we performed serial horizontal and vertical semi-thin sections through monkey foveae and
constructed 3D models of foveal cones. The outer segments of cones within the central
foveolae were indeed curved or even spiraly twisted (Fig. 1E and Video S2). In addition,
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the central foveolar cone outer segments (52 µm ± 5.8 µm) were twice as long as the cone
outer segments in the parafovea (26 µm ± 1,6 µm) (Fig. 1F).
To understand the three-dimensional shape of the central Müller cells, we formed 3D
models of human and monkey retinae (Fig. 2D, Videos S3 and S4) from light and electron
microscopic serial sections. The cross-section of individualMüller cells was often triangular
(Video S5, bottom left). Focused ion beam (FIB) analysis shows that the Müller cells adapt
to the shape of the cone nuclei and cross the retina in a wavy manner (Video S4). We
found that individual foveolar Müller cells have a plateau zone at the site where their
processes bend horizontally (Figs. 2C and 3B). Our model resembled the one described
earlier (Bringmann et al., 2006).
We found that when the light enters the fovea of human retinae at an angle of 0◦ ,
the transmitted light forms a very bright spot in the center of the foveola (approximately
200 µm in diameter) (Fig. 3C). This area corresponds exactly to the area composed only
of cones and Müller cells (Bodis-Wollner, Glazman & Yerram, 2013). However, when the
angle of the transmitted light was changed to 10◦ , the bright spot in the foveolar center
became dark (Fig. 3D, bottom right) and the SCE-like drop in light intensity became
directly visible (Video S6). Measurements of the intensities of light transmission in the
central foveola for incident angles of 0, 5, and 10◦ (Fig. 3F) resemble the relative luminance
efficiency for narrow light bundles as a function of the location where the beam enters the
pupil as reported by Stiles & Crawford (1933). The effect was observed in all human foveae
and persisted after carefully brushing away the outer segments. The 3D structure of human
fovelolar Müller cells is shown in Video S7.
DISCUSSION
Already in 1907 the unique central cones were described and called the ‘‘bouquet of central
cones’’ (Rochon-Duvigneaud, 1907). The fact that the form and outer segment lengths of
the central cones differ from that of the peripheral ones also was described in Greeff &
Graefe, (1900) but their spatial organization remained unclear. In the present study we
performed 3D modeling of central- and para-foveolar cones to investigate their exact
anatomical shape, orientation and spatial arrangement.
The lengths of inner and outer segments and numbers of cones in our study correspond
to reported measurements from monkey and human cones (Borwein et al., 1980; Packer,
Hendrickson & Curcio, 1989; Yuodelis & Hendrickson, 1986). The 3D model of the central
foveolar cones shows that outer segments do not run parallel to the incident light as
reported earlier (Hogan, Alvarado & Weddell, 1971; Laties, 1969) but are curved or even
coiled (Video S2) and proceed collaterally to the retinal pigment epithelium (RPE) (Fig. 1E).
Our serial sections through the inner and outer segment layer of foveal cones clearly show
that in the foveal center (100 µm) cones have unique shapes, directionalities, and distances
from each other (Fig. 4). However, using these findings no convincing hypothesis for the
origin of the SCE I could be proposed.
Thus, we searched for the origin of the SCE within the neural retina and performed
sagittal and transverse serial sections through the foveolae of humans and monkeys to
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construct 3D models and investigate its three-dimensional structure. Unexpectedly, we
found extremely large Müller cells in the central foveola of monkeys (Fig. 2A and Video S1)
and humans (Fig. 3A, Videos S7 and S4) in which cell organelles are rarely present
(Figs. 2B, 2C andVideo S5). TheseMüller cells were already described 47 years ago (Yamada,
1969) in human eyes as having an unusual watery cytoplasm but have been neglected
(Gass, 1999).
As light propagation by Müller cells through the retina (Franze et al., 2007) has been
shown to be important and increases photon absorption specifically by cones (Labin et
al., 2014), we hypothesize that light hitting the Müller cell plateau at an angle of 0◦ is
effectively transmitted into the photoreceptors whereas light hitting the Müller cell plateau
at a different angle is partly reflected accordingly, which reduces the amount of light guided
through the Müller cells (Fig. 3F). This is in accordance with the finding that retinal foveal
structures reflect light entering at an angle different from 0◦ (Gao et al., 2008;Van de Kraats
& Van Norren, 2008).
To test this hypothesis, we used human foveae from flat mounted isolated retinae and
measured the transmission of collimated light under the light microscope at different
angles. We could indeed measure a SCE-like decrease in the transmitted light intensity
when the angle of the lightbeam was deflected from 0◦ . We do not completely exclude
that the Henle fibres and the shape of the foveal pit are also involved in light reflection. It
is also not ruled out that the specific shape of the cone outer segments plays an additional
role in causing the SCE by possible angle dependent sensitivity of conopsins for photons.
The spatial resolution of human vision decreases by 50% when a subject in the view is
deviated 2.3◦ from the foveation point (Zhang et al., 2010). The present findings may be
physiologically involved in foveation, which is a process of bringing eccentric targets to the
direct sight line by saccadic eye movements. This process may be accelerated by reflection
of photons entering at an angle different from the direct sight line.
This study might also add a new piece to the puzzle of the pathogenesis of macular
telangiectasia type 2 which is characterized by a loss of Müller cells and a reduction of SCE
(Powner et al., 2013; Zhao et al., 2015).
CONCLUSIONS
This paper shows the 3D anatomy of primate foveolar Müller cells and cones for the first
time. Outer and inner segments of foveolar cones in monkey eyes have directionality and
are not arranged in a perfectly straight manner in the axis of the straight entering light.
UniqueMüller cells with optical fibre characteristics are present in the center of the foveola.
These findings may be involved in the foveation process.
In addition, our findings could be of interest for the understanding of the pathogenesis
of macular telangiectasia type 2. Finally a new hypothesis for foveal Müller cells, causing
the SCE by angle-dependent light reflection, is presented.
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Abstract 
Purpose: Anti-VEGF drugs are used to treat neovascular eye diseases. Some of 
these drugs contain Fc fragments (Fc), but it is unknown how their mode of action is 
influenced by Fc. Therefore, Fc effects were investigated on rat eyes after intravitreal 
injection.  
Methods: 18 Long Evans rats were intravitreally injected with sterile, biotin-labelled 
rat Fc (9.1 μg in 5 µl PBS). For control, 5 μl PBS were injected in another nine rats. 
Animals were sacrificed between 1-3 days (group 1), 7 (group 2) and 14 days (group 
3) after injection. Right eyes were examined by electron microscopy (EM). Left eyes 
were stained for distribution of Fc and presence of macrophages by 
immunohistochemistry. 
Results: After one day, Fc had penetrated into the anterior chamber and the retina up 
to the inner nuclear layer and was located especially in retinal vessels. High amounts 
of infiltrating cells within the vitreous, around the ciliary body, anterior chamber and 
inside the retina were present 1-3 days after Fc injection (p<0.02 group 1 vs. control). 
Immunohistochemistry and EM showed that they were macrophages or granulocytes 
in close association with Fc. Ultrastructurally, there were effects on the blood vessels 
such as thrombocyte activation and fibrin formation.  
Conclusions: Biotin-labelling is ideal for investigating the distribution of intravitreally 
injected proteins in ocular tissue. Fc fragments at a dose corresponding to their 
concentration in standard AMD treatments induced inflammation, particularly the 
attraction of immune competent cells. This might be associated with the risk of 
inflammation or endophthalmitis after anti-VEGF treatment and needs further 
investigation. 
 
Keywords: Fc fragment, anti-VEGF therapy, intravitreal injection, endophthalmitis 
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Introduction 
 
The eye is an immune-privileged organ, which means that immune responses are 
usually suppressed [1, 2]. Nevertheless, side effects including inflammation or sterile 
endophthalmitis were observed after intravitreal application of full length antibodies 
[3, 4]. 
Fc receptors (Fc stands for fragment crystallisable) are present in more or less all 
parts of the eye, e.g. the outer nuclear layer, Müller cells, nerve fiber and 
photoreceptor layer and the pigment epithelium (RPE) of the retina, but also in the 
ciliary body, cornea, trabecular meshwork, choroid and iris [5]. In humans, age-
related decrease in Fcγ receptor expression was shown [5] and could play a role in 
the pathogenesis of age-related macular degeneration (AMD) and its treatment. 
Indeed, Fc-containing anti-VEGF therapeutics (bevacizumab (Avastin®, 
Genentech/Roche), aflibercept (Eylea®, Regeneron/Bayer)) are used as a standard 
therapy in AMD and could affect treatment outcome [6-11].  
Bevacizumab is a humanized monoclonal antibody that inhibits all isoforms of VEGF-
A [12, 13], while aflibercept is a recombinant fusion protein containing VEGF receptor 
sequences (VEGFR1 and VEGFR2) fused to an IgG backbone [14]. Aflibercept binds 
to all VEGF-A isoforms, VEGF-B and placental growth factor [13]. Both drugs contain 
the human Fc fragment. A third anti-VEGF drug is ranibizumab (Lucentis®, 
Genentech/Novartis), a humanized monoclonal antibody fragment (Fab) [15]. 
Ranibizumab inhibits all VEGF-A isoforms [13], but in contrast to bevacizumab, lacks 
the Fc fragment. 
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Fc-containing anti-VEGF therapeutics have been reported to induce protein 
complexes [6] and platelet activation [16] in vitro, while ranibizumab did not [6, 16]. 
Additionally, it was found that bevacizumab can induce platelet aggregation, 
degranulation and thrombosis via complex formation with VEGF, heparin and 
activation of the platelet FcγRIIa receptor [17]. Bevacizumab accumulates in vitro in 
RPE cells, whereas ranibizumab does not [18]. It was shown that this difference in 
pharmacokinetics is due to bevacizumab being recognized by the neonatal Fc 
receptor and thus transported into the RPE cells [19, 20]. Whether intravitreally 
administered anti-VEGF therapeutics with an Fc fragment really cause more ocular 
and/or systemic adverse effects is still under debate since study results are divergent 
[21-24]. 
Therefore, the present study was performed to investigate the effects of intravitreally 
administered isolated Fc fragment on rat eyes. Since, in the therapeutic context, 
injection of human Fc fragment containing anti-VEGF drugs is of interest for patient 
treatment, we performed our study in rats with their respective rat Fc fragment.  
   
97
                                                                                                                                5 
Methods 
 
Animals 
6 week-old Long Evans rats (n=27) were purchased from Janvier Labs, Le Genest-
Saint-Isle, France. Animals were kept under 12-h on-off cyclic lighting and provided 
with water and food ad libitum. All procedures involving animals were in accordance 
with the German laws governing the use of experimental animals and were 
previously approved by the local authorities (Regierungspraesidium Tuebingen; 
AK02/14). All efforts were made to minimize suffering. 
 
Biotinylation of Fc fragment 
Fc fragment from rat IgG (ChromPure Rat IgG, Fc Fragment, Jackson 
ImmunoResearch, Baltimore, PA, USA) was obtained as a 2.4 mg/ml solution in a 
0.25M saline solution buffered with 0.01M sodium phosphate (pH 7.6). The solution 
was concentrated to approximately 100 µl by ultrafiltration using a Pierce® 
Concentrator 9k MWCO (Thermo Scientific, Waltham, MA, USA). Biotinylation was 
done with the BiotinTag™ Micro Biotinylation Kit (Sigma-Aldrich, St. Louis, MO, USA) 
according to the manufacturer's instructions. Briefly, the biotinylation reagent (BAC-
SulfoNHS) was reconstituted with sodium phosphate buffer, pH 7.2 and 10µl of the 
biotinylation reagent solution was added to the Fc fragment and incubated for 30 
minutes at room temperature. Excess biotinylation reagent was removed by loading 
the reaction mixture onto micro-spin G-50 columns and eluting the labeled protein 
with PBS. The concentration of the labeled protein was determined with the 
Bicinchoninic Acid Protein Assay Kit (Sigma-Aldrich, St. Louis, MO, USA) according 
to the manufacturer's instructions. In brief, the biotinylated Fc Fragment and a diluted 
series of BSA as a standard were mixed with freshly prepared working solution 
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containing copper sulfate and bicinchoninic acid and incubated in a 96-well plate at 
room temperature for 2 hours. Absorption was measured at 562 nm with a microplate 
reader (Synergy HT, Biotek). Before injection into the eyes the Fc fragment solution 
was sterile-filtered. 
 
Intravitreal injection 
18 rats were anaesthetized using a mixture of ketamine and xylazine (WDT, 
Garbsen, Germany). They were intravitreally injected in both eyes with sterile, 9.1 μg 
biotin-labelled Fc from rats in 5 μl PBS using an UltraMicroPump III microsyringe 
injector with Micro4 controller. The pump was equipped with a NanoFil 100µL syringe 
loaded with the labeled Fc fragment. A 34 gauge beveled needle was connected to 
the syringe with a SilFlex tubing and a needle holder. All instruments were obtained 
from World Precision Instruments, Berlin, Germany. The advantage of this system is 
accurate and repetitive injection. Injection volume was 5 µl per eye and injection rate 
was 2 µl per second. For control, 5 μl sterile PBS was injected in another 9 rats. 
Eleven Fc fragment and six PBS treated animals were sacrificed 1-3 days (group 1) 
after injection and another five / three animals 7 days (group 2) after injection, 
respectively. Two rats were killed 14 days after Fc fragment injection (group 3). 
 
Tissue preparation  
On days 1-3 (group 1), 7 (group 2) and 14 (group 3) after intravitreal injection, the 
animals were sacrificed by cervical dislocation under general anesthesia using a 
mixture of ketamine and xylazine (WDT, Garbsen, Germany). The eyes were 
enucleated immediately post-mortem and cleaned of orbital tissue. Right eyes were 
fixed for electron microscopy in 5 % glutaraldehyde in 0.1 M cacodylate buffer (pH 
98
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7.4, Sigma, St. Louis, MO, USA). Left eyes were fixed for immunohistochemistry in 
4.5 % formalin (Carl Roth, Karlsruhe, Germany).  
 
Immunohistochemistry 
Eyes were fixed in formalin, embedded in paraffin wax, cut into 5-μm sections and 
deparaffinized according to standard procedures.  
Biotinylated Fc fragments were detected using a streptavidin alkaline – phosphatase 
detection kit (RED Rabbit/Mouse K5005 Dako, Glostrup, Denmark) or a Cy3-
conjugated AffiniPure Goat Anti-Rat IgG (H+L) antibody (112-165-143, Jackson 
ImmunoResearch, Baltimore, PA, USA, 1:250) according to the manufacturer's 
protocol. Sections were counterstained with hematoxylin solution modified according 
to Gill III for microscopy (Merck, Darmstadt, Germany). 
For detection of macrophages, sections were incubated for 1 hour with mouse anti- 
rat CD-68 antibodies (SeroTec MCA 341R, Kidlington, Oxford, UK) 1:100 and stained 
with Goat Anti-Mouse IgG (H+L) Cy3 Conjugate (Invitrogen 81-6515, Carlsbad, CA, 
USA) 1:100 diluted 30 min at room temperature. Dilution was performed with 
antibody diluent with background reducing components (Dako S3022) at room 
temperature.  
Sections were mounted on SuperFrost Plus slides (Langenbrinck, Emmendingen, 
Germany) using FluoroSave (Calbiochem, La Jolla, CA, USA) and inspected with a 
fluorescence microscope (Axioplan2; Carl Zeiss, Oberkochen, Germany). 
 
Light and electron microscopy  
After fixation in glutaraldehyde for 30 minutes, the corneas were carefully removed 
from the bulbi and the fixation was continued overnight. Specimens were post-fixed 
with 1% OsO4 at room temperature in 0.1 M cacodylate buffer (pH 7.4), stained with 
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uranyl acetate, and embedded in Epon after dehydration in a graded series of 
ethanol and propylene oxide. Semi-thin sections were stained with toluidine blue and 
examined by light microscopy (Zeiss Axioplan2 imaging, Zeiss, Jena, Germany). For 
electron microscopy, the sections were cut ultrathin and analyzed with a Zeiss 900 
electron microscope (Zeiss, Jena, Germany). 
 
Quantification of infiltrating cells in the vitreous-retinal interface 
Cells that were present within the vitreous close to the retina were counted in semi-
thin sections. 
 
Quantification of macrophages in the vitreous and retina  
CD68 positive cells that were present within the vitreous close to the retina were 
counted in paraffin sections.   
 
Statistical analysis 
Statistical significance for the evaluation of the occurrence of macrophages in the 
vitreous was determined by using the Dunnett’s test and the JMP11.0 statistical 
program (SAS, Heidelberg, Germany). The null hypothesis was that the treated 
samples were histologically not different from the PBS controls. All p-values < 0.05 
were stated significantly different (error probability 5%).   
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Results 
 
Detection of Fc fragments and macrophages by immunohistochemistry 
Between one and three days after injection, Fc fragments were detected within the 
vitreous, often associated with fibrous material (Fig. 1 a). Fc fragments were also 
present in infiltrating cells within the vitreous (Fig. 1 b, e), around the ciliary body 
(Fig. 1 c) and the anterior chamber (Fig. 1 c). One day after injection, the Fc 
fragments were localized in infiltrating cells (Fig. 1 e) and the inner retina (Fig. 1b). 
However, two and three days after injection, Fc fragments permeated into the retina 
and were taken up by ganglion cells and cells of the inner nuclear layer (Fig. 1 a). 
Also within retinal vessels Fc fragments were clearly detectable (Fig. 1 a). Infiltrating 
cells were very prominent between one and three days after injection of Fc fragments 
(Fig. 1 a, b, c, e). By CD68 labelling many of them were identified as macrophages 
(Fig. 1 f). These macrophages also infiltrated the retina (Fig. 1 f). After 7 and 14 days 
of injection, the Fc fragments disappeared from the vitreous (not shown) but were still 
detectable in the RPE (Fig. 1 d). In PBS injected rats, staining for biotin was 
completely negative in sections from all eyes (Supplementary Figure 1). 
 
Light microscopy of semi-thin sections  
After Fc fragment injection, all three groups showed infiltrating cells within the 
vitreous and thrombocyte activation in the retinal vessels (Fig. 2). Infiltrating cells 
were most frequent in treated group 1.  
 
Electron microscopy  
At electron microscopical level, the loosely aggregating thrombocytes (Fig. 3 a, c), 
unknown fibrous material, fibrin (Fig. 3 b) and granulocytes fixed in the state of 
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degranulation (Fig. 3 c) were regularly seen in retinal veins of all groups after Fc 
fragment treatment. After the injection of PBS, these findings were only infrequently 
observed. Also microparticles were observed after Fc injection in all groups (Fig. 3b), 
but also in the respective PBS injected controls in retinal and choroidal vessels (not 
significant). In untreated LE rats we never noticed such an accumulation of 
microparticles (not shown). 
In a few cases of groups 2 and 3, unusual electron-dense material accumulated 
within the subretinal space and the vitreous, as shown in an examples from group 3 
(Fig. 4). This electron-dense material penetrated the retina and was localized close to 
the retinal veins (Fig. 4 b). At higher magnification vesicular transport (transcytosis) 
of this material through smooth muscle cells and endothelium into the lumen of the 
veins was clearly seen (not shown). As this phenomenon was only infrequently 
observed, it was not further investigated. 
 
The most prominent finding after Fc fragment treatment was cellular infiltration of the 
vitreous and retina (Fig. 5). The cells were frequently seen within damaged retinal 
cells close to the inner limiting membrane (Fig. 5 a, c). Some of them were clearly 
identified as granulocytes by the morphology of their nuclei (Fig. 5 a). Also eosinophil 
granulocytes were detected infiltrating the retina. These cells can be clearly 
recognized by the typical morphology of their granules, as shown in Fig. 3 c. Others 
resembled macrophages judged by the U-shape of their nuclei (Fig. 5 c, d). 
Macrophages within the vitreous were highly activated which was indicated by the 
formation of microvilli (Fig. 5 b, d). Infiltrating cells were only infrequently seen after 
PBS injection. The number of these cells is quantified in figure 6.  
14 days after Fc treatment, cells attached to the inner limiting membrane and 
collagen fibers were seen within the vitreous (Fig. 5 e). 
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Quantification of infiltrating cells in the vitreous-retinal interface   
Cells that were present within the vitreous close to the retina were counted in semi-
thin sections. Fc fragment injection significantly (p<0.02) enhanced the number of 
infiltrating cells in group 1 (Fig. 6). The type of infiltrating cell was not distinguished  
(n = 6 eyes/group). 
 
Quantification of macrophages in the vitreous   
To identify the number of CD68 positive macrophages within the group of infiltrating 
cells observed in the Fc-treated rats, all CD68 positive and negative cells were 
counted along the vitreo-retinal interface in central paraffin sections of whole eyes of 
each two to three rats per group. Both, CD68 positive and negative infiltrating cells 
were most prominent in the Fc treated group1 (both p<0.05 as compared to PBS 
control in group 1, Fig. 7). Note, that the majority of infiltrating cells were found to be 
CD68 positive (ratio 2.88 in group1; 7.67 in group 2).  
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Discussion 
To our knowledge this is the first study that has investigated the role of isolated Fc 
fragments after intravitreal injection. There is clear evidence that Fc fragments have 
multiple effects on eye tissues that are not yet understood in detail. It is, however, 
well known that Fc receptors are involved in pharmacokinetics of therapeutic IgG in 
eye tissues and play an important role in eliminating intravitreally administered full-
length IgGs across the blood-retinal barrier into the systemic blood system [19].  
Previous work showed that Fc-containing anti-VEGF drugs preferentially accumulate 
in endothelial and RPE cells with prolonged treatment time. This implies potential 
side effects in the treatment of AMD and diabetic retinopathy which both are to be 
applied over several years [10, 11]. Indeed, Fc fragments induce platelet 
aggregation, degranulation and thrombosis through complex formation with VEGF 
and activation of the platelet FcγRIIa receptor, and this can provide an explanation 
for the thrombotic events observed in vivo after bevacizumab [8, 9, 17, 25] and 
aflibercept [7] treatment of AMD patients.  
Also endothelial cells in mammals express the endocytic Fcγ receptor IIb2 [26] and 
the neonatal Fc receptor [27]. Fc fragment binding stimulates phagocytosis of waste 
material [26]. In this manner, endothelial cells can directly communicate with Fc 
fragments yielding the clearance of the drugs from the eye [19]. Additionally, the RPE 
has been shown to express Fc receptors and to take up Fc-containing drugs like 
bevacizumab and aflibercept via membrane-standing Fcγ and the intracellular 
neonatal Fc receptors [20]. 
The present findings are in accordance with the common knowledge about the 
interaction of Fc fragments and Fc receptors. Stimulation and modulation of cellular 
immune reactivity is the natural function of Fc fragments and phagocytes, including 
epithelial cells, are also known to express Fcγ receptors [28]. Thus, it is not 
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surprising that Fc fragments induced cellular activation of macrophages and 
granulocytes in the vitreous and retina. 
This study demonstrates uptake of Fc fragments into the retina and the blood stream 
of retinal vessels within the first 3 days after injection. Alteration of the serum 
composition in general and by Fc fragments in particular can activate platelets and 
induce fibrin formation and were frequently observed in this study. Microparticles are 
also strongly correlated to thrombotic events, but whether they are risk factors or 
results of thrombosis is under discussion [29]. Thus, the alterations in the retinal 
veins i.e. activation of platelets, fibrin formation and degranulation of granulocytes is 
not surprising. These observations are also in accordance with our previous findings 
in monkey studies [7-9]. 
Exclusively after Fc fragment injection, immune cells infiltrated the retina and vitreous 
and were found associated to damaged retinal cells (Fig. 5 a, c). At least two thirds of 
the infiltrating cells in the vitreous were CD68 positive monocytes/macrophages. The 
remnant CD68 negative infiltrating cells are supposed to be lymphocytes or 
granulocytes, as shown in Figure 5a and d. Infiltrating cells, both CD68 positive and 
negative, were most prominent on day 1, and diminished over time. 
The present study also shows that biotinylation is a suitable method to investigate the 
transport and turnover of intravitreal injected proteins and excludes cross reactions 
with endogenous immune globulins in the eye. 
In conclusion, intravitreal injection of Fc fragments at a dose corresponding to Fc 
fragment portion in standard treatments in AMD patients induced multiple reactions in 
rats within the first days particularly the attraction of immune competent cells which 
might be associated with the risk of inflammation or endophthalmitis and needs 
further investigation.  
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Figure legends 
Fig. 1 Distribution of Fc fragments and infiltrating cells by light and 
fluorescence microscopy 
(a) Three days after injection, biotinylated Fc fragments (red) can be detected within 
the vitreous often associated with fibrous material as visualized with streptavidin 
alkaline-phosphatase stain. Fc fragments are present in infiltrating cells within the 
vitreous (black arrowhead). Fc fragment penetrated through the retina up to the inner 
nuclear layer (white arrowhead). The photoreceptor nuclei (asterisk) are not reached 
by permeating Fc fragments. The lumen of a retinal vessel (arrow) contains Fc 
fragments. The same is true for ganglion cells to the left and right of this vessel. (b) 
One day after injection, the Fc fragments were localized to the inner limiting 
membrane (white arrowhead) and cells infiltrating the vitreous (black arrowhead). (c) 
One day after injection, red labelled Fc fragments are seen within the space between 
lens (L) and ciliary body (C) in the anterior chamber (asterisk). Around the ciliary 
body and attached to the iris (I) many infiltrating cells (arrowheads) can be seen. (d) 
After 7 days of injection, the Fc fragments disappeared from the vitreous (not shown), 
but were still detectable in the retinal pigment epithelium (white arrowhead). (e) A 
fluorescent light micrograph one day after injection shows cells infiltrating the vitreous 
(arrow) that have taken up anti-rat IgG-labeled Fc fragments and are associated with 
fibers. Fc fragments are also seen in the central vitreous (asterisk). The inner limiting 
membrane is marked by an arrowhead. (f) By CD68 labelling, these infiltrating cells 
(1 day after infection) were identified as macrophages. The macrophages also 
infiltrated the retina (arrows). The inner limiting membrane (ILM) is marked by 
arrowheads and macrophages are seen on both sides of the ILM within the retina 
and within the vitreous  
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Fig. 2 Light microscopy of the distribution of infiltrating cells and 
thrombocytes in the inner retina 
(a) Infiltrating cells within the vitreous are shown one day after Fc fragment injection 
(black arrowheads). Loosely aggregating thrombocytes are marked by an arrow 
within the central vein (higher magnification in b). The central artery is marked by a 
white arrowhead. For more details see EM image in Fig. 3 a. (c) One day after 
injection, fibrin fibers (arrowheads) can already be detected by light microscopy 
within the central vein. The diameter of the central vein appears enlarged 
 
Fig. 3 Electron microscopy of thrombotic events and inflammation within 
retinal vessels 
(a) Loosely aggregating thrombocytes are marked by an arrow within the central 
vein, one day after Fc fragment injection. (b) Unknown fibrous material (arrow), 
thrombocytes (white T) and microparticles (black arrow heads), 14 days after 
injection. The endothelium has unusual projections (white arrowhead) towards the 
vessel lumen. (c) An eosinophil granulocyte has been fixed in the state of 
degranulation in a retinal vein, 14 days after Fc fragment injection. The plasma 
membrane is partly missing (black arrowhead). Eosinophilic granules are seen free in 
the cytoplasm (arrow) but also within the cell (white arrow head). Activated 
thrombocytes (T) are also present  
 
Fig. 4 Electron microscopy of electron-dense material in the vitreous and retina 
14 days after intravitreal injection of Fc fragment 
(a) An electron micrograph shows unusual electron-dense material which 
accumulated within the vitreous (black asterisk) from an Fc treated rat. This material 
is probably transported into the vessel lumen (white asterisk) but cannot be 
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recognized at this magnification. The ILM (black arrow) is well preserved but a 
damaged cell (white arrow) is attached to it. (b) Electron-dense particles are localized 
in the vitreous (black asterisk) and in the space around the central retinal vein (white 
asterisk). The ILM (black arrow) is well preserved. (c) Very unusual electron-dense 
particles of unknown origin are shown in the subretinal space between outer 
segments (ROS) and attached to the microvilli of the RPE (black arrowheads). The 
nucleus of this RPE cell is marked by an N and a melanosome by a white arrowhead. 
The outer segments appear healthy 
  
Fig. 5 Electron microscopy of infiltrating cells 
(a) The most prominent finding one day after Fc fragment treatment is cellular 
infiltration of the vitreous and retina as shown here in an electron micrograph. The 
cell in the ganglion cell layer can be clearly identified as a granulocyte (G) by the 
morphology of the nucleus. Microvilli (arrow) of this granulocyte are within a 
damaged retinal cell close to the inner limiting membrane (arrowhead). (b) A 
macrophage within the vitreous is highly activated which is indicated by the formation 
of microvilli (arrow), one day after injection. (c) This micrograph reveals a cell with 
microvillar (arrow) projections within a retinal cell one day after Fc treatment. The cell 
probably is a macrophage (M) infiltrating the retina close to the inner limiting 
membrane (arrowhead). (d)  An activated macrophage (M) with a U-shaped nucleus 
and a granulocyte (G) and a third cell (arrow) are infiltrating the vitreous close to the 
ILM (arrowhead), two days after injection. (e) 14 days after Fc treatment, cells 
(arrow) are attached to the inner limiting membrane (black arrowhead) and newly 
formed collagen fibers (white arrowhead) are seen within the vitreous 
 
Fig. 6 Quantification of infiltrating cells in the vitreous-retinal interface  
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Cells that were present within the vitreous close to the retina were counted in 
semithin sections and their number is given per mm inner limiting membrane length. 
The type of cell was not distinguished. Fc fragment injection significantly (p<0.02) 
enhanced the number of infiltrating cells in group 1 (n = 6 eyes/group) 
 
Fig. 7 Quantification of macrophages in the vitreous  
CD68 positive and CD68 negative infiltrating cells were counted along the vitreo-
retinal interface in paraffin sections. In group 1, Fc treatment yielded accumulation of 
CD68 positive macrophages as compared to PBS treatment (* p<0.05). The ratio 
between stained and unstained infiltrating cells was 2.88 for Fc group1, and 7.67 for 
Fc group 2, respectively  
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Abstract Purpose:  To investigate the effects of intravitreal ranibizumab (Lucentis®) and aflibercept (Eylea®) on the ciliary body and the iris of 12 cynomolgus monkeys regarding the fenestrations of its blood vessels. Materials and Methods: Structural changes in the ciliary body and in the iris were investigated with light, fluorescent and transmission electron microscopy (TEM). The latter was used to specifically quantify fenestrations of the endothelium of blood vessels after treatment with aflibercept and ranibizumab. Each of the two ciliary bodies treated with aflibercept and the two treated with ranibizumab and their controls were examined after 1 and 7 days, respectively. Ophthalmological investigations including funduscopy and intraocular pressure measurements were also applied.  Results: Ophthalmological investigations did not reveal any changes within the groups. Both drugs reduced the VEGF concentration in the ciliary body pigmented epithelium. The structure of the ciliary body was not influenced, while the posterior pigmented epithelium of the iris showed vacuoles after aflibercept treatment. Ranibizumab was mainly concentrated on the surface layer of the ciliary epithelium, in the blood vessel walls, the lumen of some of the blood vessels and in the cells of the epithelium of the ciliary body. Aflibercept was more concentrated in the stroma and not in the cells of the epithelium, but as with ranibizumab, also in the blood vessel walls and some of their lumina, and again on the surface layer of the epithelium. Both aflibercept and ranibizumab treated eyes showed a decreased number of fenestrations of the capillaries in the ciliary body compared to the untreated controls. On day 1 and day 7, aflibercept had fewer fenestrations than the ranibizumab samples of the same day.  Conclusions: Both aflibercept and ranibizumab were found to reach the blood vessel walls of the ciliary body and effectively reduced their fenestrations. Aflibercept might eliminate VEGF to a greater extent, possibly due to a higher elimination of fenestrations in a shorter time. Moreover, the vacuoles found in the iris need further research, in order to evaluate whether 
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they carry a possible pathological potential.    Keywords: aflibercept, ranibizumab, anti-VEGF therapy, ciliary body, iris, fenestration, blood vessels, electron microscopy  
4 
Introduction: Anti-vascular endothelial growth factor (VEGF) therapy is currently used to treat uncontrolled neovascularisation in the eye, e.g. with age-related macular degeneration (AMD), diabetic macular oedema or retinal vein occlusion [1], glaucoma [2], iris rubosis [3] and others [4, 5]. Especially for the treatment of wet AMD, four different VEGF inhibitors are available and delivered by intravitreal injections: ranibizumab (Lucentis®), aflibercept (Eylea®), pegaptanib (Macugen®) and for off-label use, bevacizumab (Avastin®) [6]. The effects of these therapies on the retina have meanwhile been studied quite thoroughly. Remarkable was the decrease of fenestrations in the choriocapillaris [7-9] of monkeys treated with ranibizumab, bevacizumab or aflibercept, respectively. However, the effects of intravitreal ranibizumab and aflibercept on other ocular tissues like the ciliary body have not yet been studied, and will be presented in this work. The ciliary body is located right behind the iris and is nourished by the same blood vessels which also nourish the iris. It consists of smooth muscle fibers and the ciliary processes, which are connected by zonular fibers to the crystalline lens, and are thus able to change the latter’s shape for the purpose of focusing, a process known as accommodation [10]. The ciliary processes epithelium consists of a pigmented outside layer and a non-pigmented inside layer connected by gap-junctions. It is this structure which releases a transparent liquid into the eye called the aqueous humour, whose in and outflow maintains the intraocular eye pressure (IOP). In the ciliary processes there are lots of fenestrated capillaries whose fenestrations are permeable for water and smaller hydrophilic structures [11]. It already has been shown that VEGF blockade can also reduce the number of fenestrations in the ciliary body [12]. The VEGF-family is important for lymphangiogenesis, vasculogenesis and angiogenesis [13]. The mammalian VEGF-family presently contains five members: VEGF-A, placenta growth factor (PlGF), VEGF-B, VEGF-C, and VEGF-D (reviewed by [14]). VEGF-A plays an important role in vascular development and in diseases involving abnormal growth of blood vessels. Clinical studies have shown the significance of VEGF-A in ocular neovascularization, such as diabetic retinopathy and age-related macular degeneration, with the use of VEGF-A neutralizing antibodies [15]. VEGF is a glycosylated, multifunctional cytokine which consists of dimeric polypeptides and executes its effects through receptors 
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mainly expressed on the vascular endothelium. It also stimulates lymphocyte activation, chemotaxis and increases microvascular permeability [16].  In previous studies, our group investigated the effects of bevacizumab [17], ranibizumab and aflibercept [8] on the retina-choroid interface of cynomolgus monkeys. Systemical effects of aflibercept and ranibizumab were studied by analysing the kidneys of these animals in addition [18]. The same monkeys were used in this work to investigate the effects of aflibercept and ranibizumab on the ciliary body and in particular on the fenestrations of the capillaries of the same individuals. 
6 
Materials and Methods: 1. Animals and study protocol In this study, we used new tissue samples taken from the same monkeys we had used in a previous study to investigate the effects of intravitreal ranibizumab and aflibercept on the retina-choroid complex [8]. The materials and methods applied in vivo are thus repeated here as follows. Twelve Cynomolgus monkeys (Macaca fascicularis, aged 3 to 10 years) were raised at the Covance Laboratories (Muenster, Germany) under standard conditions. The monkeys in this study were an average of 5.5 years old for the aflibercept group and an average of 6.5 years old for the ranibizumab group. Animals were housed and handled in strict accordance with good animal practice under supervision of veterinarians and were monitored for evidence of disease and changes in attitude, appetite or behaviour suggestive of illness. Handling and housing of the animals at Covance Laboratories GmbH was done in accordance with the German Animal Welfare Act. For the notice of approval by the appropriate institutional animal care and use committee, please see Covance Studies 8260977 and 8274007.  2. Intravitreal injection of ranibizumab, aflibercept and aflibercept’s vehicle The animals were sedated by intramuscular injection of medetomidine (Domitor) and ketamine hydrochloride. Before injection, the eyes were examined for any signs of inflammation. Pupils were dilated (Mydriasis with 1% tropicamide) and anesthetized (proxymetacaine; Proparakain-pos 0.5 %; Ursapharm). The conjunctival and corneal surface was disinfected (povidone iodine 10%). After sterile coating and insertion of a lid speculum,  50 µl of ranibizumab (10 mg/mL), aflibercept (40 mg/mL) and aflibercept’s vehicle (10mM sodium phosphate, 40mM sodium chloride, 0.03% polysorbate 20, and 5% sucrose, pH 6.2) were intravitreally injected using a 27-gauge canula. When removing the syringe, the injection site was compressed with forceps to prevent reflux. A topical antibiotic (gentamicin) was administered. Animals were monitored for signs of inflammation until sacrificed.   
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3. Ophthalmic examinations For all ophthalmic examinations, a mydriatic agent (tropicamide) and a local ophthalmic anaesthetic (proxymetacaine) were instilled in the eyes of the sedated animals before examination.  3.1 Funduscopy and fluorescein angiography (FA) Fundus photographs and FA were obtained for all animals once during the pre-dose phase and on the day of necropsy. For FA, an indwelling catheter was inserted and fluorescein was injected intravenously. A series of images immediately after injection and 10 min thereafter was performed. The equipment used was a digital stationary fundus camera (TRC-50 ex; Topcon, Tokyo, Japan).  3.2 Spectral-domain-optical coherence tomography (SD-OCT) SD-OCT was obtained for all animals once during the pre-dose phase, directly after injection (only for aflibercept and its vehicle) and on the day of necropsy. The equipment used was Spectralis™ HRA+OCT (Heidelberg Engineering, Heidelberg, Germany).   3.3 Intraocular pressure (IOP) Measurement of IOP was performed in all animals once during the pre-dose phase, before administration of the drugs, directly after administration, 10 min after administration and on the day of necropsy by using TonoVet® (Kruuse, Langeskov Denmark). Two readings were obtained per eye for each time point, and the mean IOP value was calculated and reported in millimetre of mercury (mm Hg).  4. Enucleation and post mortem analyses On days 1 and 7 after intravitreal injection, the animals were sacrificed under general anaesthesia, i.e., intramuscular injection of ketamine hydrochloride followed by an intravenous sodium pentobarbitone (Lethabarb®, Virbac, Australia) overdose. The eyes were 8 
enucleated five minutes post-mortem and cleaned of orbital tissue, and were slit carefully at the limbus without damaging the ora serrata. Then 25 μl of the fixative were carefully injected into the vitreous before the eyes were fixed at 4 °C by immersion into 5 % glutaraldehyde in 0.1 M cacodylate buffer (pH 7.4, Sigma, St. Louis, MO, USA) overnight for electron microscopy or into 4% formalin  in PBS (Carl Roth, Karlsruhe, Germany) for immunohistochemistry. The eyes of three healthy monkeys without treatment, or with aflibercept’s vehicle injection, were handled in the same manner.  5. Immunohistochemistry with paraffin embedded sections Enucleated eyes were fixed in formalin, embedded in paraffin wax, cut into 4-μm sections and deparaffinised according to standard procedures. a) Localisation of drug in the ciliary body (fluorescence microscopy) Ranibizumab and aflibercept were detected respectively using a goat antiserum to human Fab of IgG (GAHu/Fab/7S, dilution 1:250; Nordic Immunological Laboratories, Tilburg, The Netherlands) and a goat anti-human IgG-Fc antibody (NB7446, dilution 1:200, Novus Biologicals Europe, Cambridge, UK), each with a cy3-rabbit anti-goat antibody as a secondary antibody (305-167-003, dilution 1:400, Jackson ImmunoResearch Europe, Suffolk, UK). Stained sections were embedded (FluorSave; Calbiochem, La Jolla, CA, USA) and inspected with a fluorescence microscope (Axioplan2; Carl Zeiss, Oberkochen, Germany).  b) Localisation of VEGF in the ciliary body (light microscopy) Monoclonal Mouse Anti-Human Vascular Growth Factor, Clone VG1, which labels the VEGF-165, VEGF-121 and VEGF-189 isoforms of vascular endothelial growth factor (DakoCytomation Denmark, Code No.M7273), dilution 1:150, was used as a first antibody and detected with REAL™ Detection System, Alkaline Phosphatase/RED, Rabbit/Mouse(Code k5005,Dako), dilution 1:25 and inspected with a light microscope (Axioskop; Carl Zeiss, Oberkochen, Germany).  6. Light and electron microscopy (LM and EM) of plastic sections from the ciliary body Glutaraldehyde fixed specimens were post-fixed with 1% OsO4 at room temperature in 0.1 M 
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cacodylate buffer (pH 7.4), stained with uranyl acetate, and embedded in Epon after dehydration in a graded series of ethanol and propylene oxide. Semi-thin sections were stained with toluidine blue and examined by light microscopy (Zeiss Axioplan2 imaging, Zeiss, Jena, Germany). For electron microscopy, the sections were cut ultrathin and analysed with a Zeiss 900 electron microscope (Zeiss, Jena, Germany). For every eye at each time point (days 1 to 7 and control), two different regions of interest were chosen. One piece of tissue was taken in which both ciliary body and iris were visible.  7. Quantification of the endothelial fenestration in the ciliary body A transmission electron microscope was used for counting the fenestrations per µm of endothelium in the ciliary body. The ciliary bodies were investigated for blood vessels, which were photographed. Depending on the size of the blood vessels, lower magnifications from 1100x up to 7000x were used so that the whole blood vessel could be seen on the image and the length of its endothelium could be measured (Fig. 1). For counting the fenestrations, images of the fenestrated parts of the endothelium were taken at 20000 x magnification (Fig. 2). For quantification of the length of endothelium and of fenestrae, image analysis software (iTEM, Olympus Soft Imaging Solutions, Muenster, Germany) was used.  8.Semi-quantification of VEGF staining in the ciliary body From each specimen, one eye was investigated for VEGF analysis (2 samples per time point). One section was analysed for each eye. Each section was photographed at 630-fold magnification, using a Zeiss Axioscope light microsope with AxioVision software.  For each section, 4 photos were taken, that almost covered the whole pigmented epithelium of the ciliary body. So for every sample, 8 photos were  analysed.   9.Statistical analysis Whole blood vessels were investigated for endothelial length and number fenestrations. As vessels always show a fenestrated area and a non-fenestrated area, fenestrations were normalized to fenestrations/10 µm of fenestrated endothelium. Statistical significance for the comparison of aflibercept and ranibizumab to the controls was determined by using the 10 
Dunnett’s test and the JMP10 statistical program (SAS, Heidelberg, Germany). P<0.05 was considered statistically significant.  To quantify the staining in the pigmented epithelium of the ciliary body we used the “colour cube based” function in the Image-Pro Plus software. Statistical testing was performed using JMP10 software as described above. 
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Results: Ophthalmic examinations (FA, SD-OCT, IOP) The results from the in vivo ophthalmological examinations have already been published [8]. In brief, FA and SD-OCT analyses did not show any drug-related changes. The intraocular pressure (IOP), baseline 10 -20 mm Hg, was raised immediately after intravitreal injection up to 31 ± 14 mm Hg in the ranibizumab treated group, and up to 50 ± 12 mm Hg in the aflibercept treated group. Both regained normal levels after 10 minutes (ranibizumab 19 ± 6 mm Hg, aflibercept 14 ± 3 mm Hg) and further stabilized after day 1 (ranibizumab 10 ±1 mm Hg, aflibercept 11 ± 7 mm Hg) and day 7 (ranibizumab 19 ± 4 mm Hg, aflibercept 10 ± 3mm Hg).  Localisation of drug in the ciliary body (fluorescence immunohistochemistry) The distribution of aflibercept and ranibizumab within the different structures of the ciliary body were not different, however the staining of aflibercept was a bit stronger (data not shown). The aflibercept treated ciliary bodies were intensively stained in the walls of blood vessels also including the lumen of some, but not all, of these blood vessels. Further staining was detectable on the surface layer of the epithelium and in the connective tissues surrounding the vascular plexus. The ciliary muscle tissue was more weakly stained, as was the cytoplasm of the epithelium, but not their nuclei. The ranibizumab treated ciliary bodies showed a staining similar to the aflibercept ciliary bodies, on the surface layer of the epithelium and the walls of blood vessels including some of their lumina. The ciliary muscle and the vascular layer were also stained more weakly. We did also not find any significant changes in the distribution of staining between day 1 and day 7 samples.   Localisation of VEGF in the ciliary body (light microscopical immunohistochemistry) In the paraffin embedded samples, no histological changes were detected in the ciliary body after intravitreal aflibercept and ranibizumab as compared to the controls.  Within the pigmented epithelium of the ciliary body, all samples were checked for their amount of VEGF using immunohistochemistry. The pigmented epithelium of the ciliary body of untreated monkeys was intensely stained, while both aflibercept and ranibizumab treated groups showed less VEGF immunoreactivity at all time points (Fig. 3; all p values <0.0001). 12 
VEGF levels of samples treated with ranibizumab or aflibercept did not change after day 1 or 7, respectively.  Structural changes in ciliary body and iris (LM and EM of plastic sections) Investigating the semi-thin sections of whole eye preparations in the light microscope did not show any significant changes in the ciliary body. However, since the iris was shown in the same sections and did show differences between aflibercept and ranibizumab treated samples, it was analysed as well using both light and electron microscopy (Fig. 4). In all aflibercept treated samples, clearly visible vacuoles showed up throughout the posterior pigmented epithelium of the iris as shown in Figs. 4b and 4c. Neither the controls, nor the ranibizumab treated samples showed these vacuoles in either light or electron microscopical evaluations. The vacuoles in the iris in the aflibercept group showed up on day 1 and did not appear to change in the samples taken at day 7.  The transition zone between the pigmented iris epithelium and the unpigmented ciliary epithelium was evaluated as well and didn´t show pathological changes in any of the samples. We also couldn't find any other ultrastructural alterations in the area covering the iris and ciliary body.  Quantification of fenestrations in blood vessels of the ciliary body (EM) The fenestrations of the endothelium decreased in all aflibercept as well as in all ranibizumab treated samples compared to controls. On day 1, the aflibercept samples had an average fenestration rate of 2.7 per 10µm of endothelium and on day 7 lower 2.5 fenestrations per 10µm. The ranibizumab treated samples had an average of 2.9 fenestrations per 10µm on day 1 and an average of 2.6 fenestrations per 10µm on day 7. Both ranibizumab values are higher than the aflibercept values of the same day. Compared to the control’s average of 3.8 fenestrations per 10µm, the samples with VEGF-inhibitors showed a significant decrease of fenestrations in aflibercept on day 1 and 7 and in ranibizumab on day 7. Exemplary images of the clear differences in fenestrations before and after treatment can be seen in Fig 5. The box plot shows the statistical analysis. The ranibizumab-treated group of day 1 is not significantly different as compared to the controls (p=0.1), whereas the other groups (ranibizumab day 7, p= 0.0003; aflibercept day 1, p=0.007: aflibercept day 7, p=0.053) had a lower p-value than 0.05, thus showed significant changes.  
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Discussion: It has been shown before that VEGF-A inhibition leads to a degeneration of blood vessels [19, 20], and since an unusual growth of new blood vessels is characteristic for neovascular age-related macular degeneration (wet AMD) [21], this effect was identified as being an adequate way to treat this disease [22]. Apart from wet AMD, VEGF-dependant ischemic retinopathies going along with pathological neovascularization of the anterior segment of the eye have been described. This is for example the case in rubeosis iridis, which is characterized by a neovascularization of the iris and represents a complication of diabetic retinopathy or central vein occlusion. In the following, neovascular glaucoma may occur. In a previous study, our group has shown that intravitreally injected bevacizumab penetrates quickly not only into the posterior segment of the eye but also into the iris, anterior chamber angle and ciliary body and accumulates particularly in blood-vessel walls [23]. Bevacizumab has already been used intracamerally and intravitreally for the adjuvant treatment of rubeosis iridis and neovascular glaucoma with promising results [3][24, 25][26]. Recently, also ranibizumab injections for the treatment of these diseases have been published [27, 28], but to our knowledge, no trials have yet been performed with aflibercept. Our results show that the VEGF-A inhibitors ranibizumab and aflibercept both reduce the amount of VEGF in the ciliary pigmented epithelium and also reduce the number of fenestrations in the blood vessels of the ciliary body without significant changes in the ultrastructure. We further demonstrate that aflibercept administration resulted in a lower number of fenestrations both after day 1 and day 7 compared to ranibizumab. Since fenestrations can be induced by VEGF-A in vitro and in vivo [29, 30], and an inhibition of VEGF eliminates fenestrations in the choriocapillaris, the ciliary body and even in endothelial cells of the glomeruli of the kidney [7, 9, 12, 18, 31], the loss of them here can be seen as a proof of activity of the drugs in the ciliary body.  All morphological changes observed in the eye and other tissues always have been related to not only the physiological situation but also the age of the subject. For example in the retina it is known that physiological aging processes include steady loss of photoreceptors, thickening of Bruch´s membrane, thinning of the choroid and forming of hard drusen in the periphery[32]. For the iris and ciliary body increased pigmentation of the trabecular meshwork, an increase in the resistance to the outflow of aqueous humour with an increased risk of glaucoma are described. Moreover, the iris tends to become less reactive with age and 14 
loses pigment and also the shape and tone of ciliary body changes with age [33]. Taken into account that the average life expectancy of humans in the developed countries is about 77 years [34] and that the average life span of Macaca fascicularis is 31 years [35], then the human equivalent age of the study subjects with an average of 5.5 years for aflibercept- and an average of 6.5 years for ranibizumab-treated monkeys is 13.8 and 16 years, respectively. Thus, none of the described aging changes have been observed in our study and the vacuoles found in the iris of aflibercept samples cannot be related to the age of the monkeys. However, the loss of fenestrations in the ciliary body can have negative effects on the function of the ciliary body, e.g. defects of the pigmented epithelial layer, as observed by others after VEGF-A neutralization [12]. A greater loss of fenestrations, as we saw it in the aflibercept treated ciliary bodies, might thus not be desirable, as irreversible damage of the ciliary body can cause prolonged ocular hypotony and phthisis bulbi [36]. By contrast, we did not find a significant amount of microthrombi in the blood vessels after VEGF-A inhibition, as our group previously observed in the choriocapillaris and choroidal vessels after intravitreal bevacizumab injection [37]. Another clinical complication has been documented before, when a 65-year-old patient with unilateral exudative age-related macular degeneration showed a focal atrophic area in the ciliary body corresponding to the site of the intravitreal bevacizumab injection [38]. Another group found a decrease in retrobulbar blood flow after intravitreal bevacizumab injections [39]. VEGF inhibitors also lead to several other defects in various other cell types, for example signs of thrombotic microangiopathy in the glomerular endothelium [40], a decreased vascular perfusion in the choroid plexus of the brain [41], and an increased apoptosis in the neuronal retina of the eye [42]. However, in the retina-choroid complex, there were indications that the fenestrations in the choriocapillaris recovered from the VEGF blockade after day 14 [7]. In a different study, where VEGF-A inhibition led to blood vessel degeneration in pancreas, thyroid, adrenal cortex, pituitary, choroid plexus, small-intestinal villi and epididymal adipose tissue, the vessels also recovered 14 days after the inhibition was stopped [43]. On the other hand- as described above- a higher effectivity in eliminating fenestrations in the ciliary body can be a desirable effect in the treatment of iris neovascularization and neovascular glaucoma and in lowering IOP.  Furthermore, we found vacuoles in the posterior pigmented epithelium of the iris in the aflibercept treated samples, but not in the ranibizumab treated ones. To our knowledge, this is 
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the first time this has been found in the iris after intravitreal injection with aflibercept or other VEGF-A inhibitors. Vacuolization of the iris pigmented epithelium has been found before in 40% of enucleated eyes of patients with diabetic diseases, and it was also discovered that the material in the vacuoles was glycogen [44]. The vacuoles can also be called microcysts of the iris pigmented epithelium (MIPE) and have been found in enucleated eyes of patients with several different diseases, not necessarily associated with the eye, like alveolar cell carcinoma of the lung, prostatic adenocarcinoma or acute lymphocytic leukemia [45]. The material inside the vacuoles was not identified in this study, but microcysts were found in other compartments of the eye, like the non-pigmented epithelium of the ciliary body [45], which was not the case in our samples of the ciliary body. Microcysts have been identified as a common pathological feature associated with many disorders and in patients who have been on high dosage corticosteroids and the speculative conclusion was drawn that neoplasms might alter the body's metabolism and lead to fluid accumulation in the pigmented epithelium of the iris [45]. Oedema have been found in the macula as a result of branch retinal vein occlusion, which is the second most common major retinal vascular disease, causing decreased visual acuity [46]. Interestingly, the VEGF-A inhibitor bevacizumab showed beneficial effects on macular oedema caused by branch retinal vein occlusion [47] as well as ranibizumab, which can also be used for macular oedema caused by diabetes [48]. In contrast, in our study, the VEGF-A inhibitor aflibercept might cause oedema in the iris. Macular oedema have also been found as a result of retinitis pigmentosa, where changes in the retinal pigmented epithelium take place, endangering the blood-retinal-barrier, causing a subretinal leakage and therefore macular oedema [49]. However, new research in this area might be indicated to get more insight into the influence of the vacuoles in the iris after intravitreal aflibercept injection.  Our immunohistochemical localisation of aflibercept and ranibizumab showed no histological changes compared to the controls, which is in agreement with other studies with bevacizumab where this also did not occur [50]. However, we already saw an intense staining after the first day, showing that both intravitreally injected drugs penetrate the ciliary body well and fast. In all our samples, ranibizumab and aflibercept could be mostly located in the walls of blood vessels, being the place of secretion and binding of VEGF to its receptors on the vascular endothelial cells. This seems to be the optimal place for the best effect of the VEGF-inhibitors 16 
[51]. Despite this, we found staining in other compartments of the ciliary body, where their impact remains theoretical. For example, the immunoreactivity of aflibercept and ranibizumab in the lumen of the blood vessels could lead to the conclusion, that there is a quick distribution, but also a quick elimination of the intravascular drugs. But since there are aggregations of this type only in some, but not all, blood vessels, circulation might not be disturbed in these vessels. The same effect in the ciliary body has been shown before, with intravitreal bevacizumab injection [23]. The effects and distribution of the intravascular drugs throughout the whole body, especially on other structures with fenestrations like the glomerular endothelium of the kidney is an interesting topic for further research. Our group recently published a study in which the kidneys of the animals studied in this work were analysed. Interestingly, both drugs could be detected within the capillaries of the glomeruli and fenestration changes in the glomerular endothelium differed from those observed in the walls of blood vessels in the ciliary body as described above [18]. The drug staining on the surface of the epithelium might indicate the penetration through these tissues and even the stroma, as seen after intravitreal injections with bevacizumab [23].  In conclusion, aflibercept might eliminate more fenestrations than ranibizumab. Whether this is desirable or not remains subject to discussion and will depend on the treated ocular disease and its desired effect. Moreover, the role of the vacuoles in the iris should be clarified, as well as some other effects, where VEGF-A plays some other important roles, such as in photoreceptors and Müller cells. There, increased apoptosis was noticed after VEGF-A inhibition, which in an experiment with mice led to a degraded retinal function [42]. Another experiment where VEGF-A inhibition was paired with ischemia led to retinal ganglion cell death [52]. Furthermore VEGF improved the survival of retinal pigmented epithelium cells under oxidative stress [53] and provided neuroprotection [54]. A more effective VEGF neutralization, as provided by aflibercept, might be beneficial for treating the wet form of AMD or rubeosis iridis/neovascular glaucoma, but regarding all of the preceding aspects, further research is needed to rule out any unexpected side effects.    
117
 
17 
Funding: Novartis provided financial support in the form of a honorary for author US. The sponsor had no role in the design or conduct of this research.  Conflict of Interest: All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers' bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements) other then stated below, or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript. STZ OcuTox Preclinical Drug Assessment provided support in the form of an honorarium for author US, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.   Animal Experiments: Ethical approval: All applicable international, national, and/or institutional guidelines for the care and use of animals were followed. All procedures performed in studies involving animals were in accordance with the ethical standards of the institution at which the studies were conducted (Covance Studies 8260977 and 8274007).  18 
Figure Legends: Fig. 1 Overview of a blood vessel (black arrow indicates vessel wall) in the ciliary body treated with aflibercept on day 1; TEM, magnification x3000; CPE ciliary pigmented epithelium  Fig. 2 Detail of endothelium with fenestrations (black arrows), aflibercept day 1 TEM, magnification x20000; e erythrocyte, en endothelium, l lumen  Fig. 3 Reduction of VEGF staining (red) after treatment with ranibizumab and aflibercept. Light micrographs of (a) untreated control eye (b) eye treated with ranibizumab on day 1 (c) eye treated with aflibercept on day 1; CE ciliary unpigmented epithelium, CPE ciliary pigmented epithelium  Fig. 4 Effect of ranibizumab (a) and aflibercept (b, c) on the iris pigmented epithelium. (a) Ranibizumab treated iris day 7 without vacuoles. Semi-thin section, light microscope, magnification x100. (b) Aflibercept treated iris day 1 showing vacuoles between the pigment cells (black arrows); Semi-thin section, light microscope, magnification x100. (c) Aflibercept treated iris day 1 with vacuoles (black arrows); TEM, magnification x7000; IPEa anterior iris pigment epithelium, IPEi interior iris pigment epithelium  Fig. 5 Fenestration in ciliary blood vessels (a) Endothelium with a lot of fenestrations (black arrows) in an untreated blood vessel of the ciliary body. (b) Endothelium with significantly less fenestrations (black arrow) in a ranibizumab treated sample after day 7; TEM, magnification x12000. (c) Box-plot of average fenestrations per 10 µm. Lines extending vertically from the boxes (whiskers) indicate the variability outside the upper and lower quartiles and individual points marking outliers. * statistically significant to control group (p < 0.05). CPE ciliary pigmented epithelium, en endothelium, l lumen 
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Abstract
Purpose: It is known that endothelial cells in the kidney are also strongly VEGF-
dependent. Whether intravitreal drugs can be detected within the glomeruli or affect
VEGF in glomerular podocytes is not known. Therefore, the aim of this pilot study
was to investigate the effects of a single intravitreal injection of aflibercept and
ranibizumab on glomeruli of monkeys.
Methods: The kidneys of eight cynomolgus monkeys, which were intravitreally
injected either with 2 mg of aflibercept or with 0.5 mg of ranibizumab, were
investigated one and seven days after injection. Two animals served as controls.
The distribution of aflibercept, ranibizumab and VEGF was evaluated using anti-Fc-
or anti-F(ab)-fragment and anti-VEGF antibodies respectively. The ratio of stained
area/nuclei was calculated using a semi-quantitative computer assisted method.
Glomerular endothelial cell fenestration was quantified in electron microscopy using
a systematic uniform random sampling protocol and estimating the ratio of
fenestrae per mm.
Results: Compared to the controls, the anti-VEGF stained area/nuclei ratio of the
ranibizumab-treated animals showed no significant changes whereas the stained
areas of the aflibercept-treated monkeys showed a significant decrease post-
treatment. Immune reactivity (IR) against aflibercept or ranibizumab was detected
in aflibercept- or ranibizumab treated animals respectively. The number of
fenestrations of the glomerular endothelial cells has shown no significant
differences except one day after aflibercept injection in which the number was
increased.
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Conclusion: Surprisingly, both drugs could be detected within the capillaries of the
glomeruli. After a single intravitreal injection of aflibercept, VEGF IR in the
podocytes was significantly reduced compared to controls. Ranibizumab injection
had no significant effect on the glomeruli’s VEGF level. Whether this is caused by
aflibercept’s higher affinity to VEGF or because it is used in a higher stoichiometric
concentration compared to ranibizumab remains to be investigated.
Introduction
Vascular endothelial growth factor (VEGF) is a 43- to 46-kd glycoprotein and a
major regulator of physiological and pathological angiogenesis [1]. It increases
vascular permeability and plays a vital role in endothelial cell migration,
proliferation and survival. In the kidney, VEGF is highly expressed in presumptive
as well as in mature podocytes and plays a critical role in glomerular development
and function i.e. to establish the glomerular filtration barrier [2].
Anti-VEGF-agents were first used in cancer treatment with some severe side
effects in consequence of systemic administration. Concerning the kidneys,
proteinuria and hypertension have been reported [3–5]. In addition, thrombotic
microangiopathy, nephrotic syndrome, bowel perforation, haemorrhages, stroke,
myocardial infarction, decreased pulmonary surfactant and delayed wound
healing may occur [6–9].
Also in ophthalmology, excessive angiogenesis is a pathogenic factor in many
diseases. These include diabetic proliferative retinopathy and age-related macular
degeneration (AMD) in adults and retinopathy of prematurity in infants. In the
pathogenesis of wet AMD, VEGF plays an outstanding role as it appears to be
sufficient and essential in both physiological and pathological angiogenesis
[10, 11]. Bevacizumab (Avastin, Genentech/Roche), used in an off-label manner in
ophthalmology, is a full length antibody, as such carries the Fc-fragment and is
therefore kept in circulation by the binding to the neonatal Fc receptor (FcR) [12].
The importance of the FcR for pharmacokinetics of agents containing the Fc
domain was also shown in animal models [13]. Besides good clinical results in
ophthalmologic treatment, adverse effects like arterial thromboembolic events,
hypertension and renal thrombotic microangiopathy were observed [14–17]. Our
group has extensively described the effects of intravitreally injected bevacizumab
on monkey eyes [18–21]. Local ocular effects like reductions in choriocapillaris
fenestrations, alteration of choroidal blood flow [19], formation of immune
complexes and thrombotic microangiopathy [20, 21] have been reported.
Ranibizumab (Lucentis, Genentech/Novartis) was approved in 2006 by the food
and drug administration (FDA) for the treatment of wet AMD after the first off-
label uses of bevacizumab. As a cleavage product of bevacizumab, it only consists
of a Fab fragment and similarly to bevacizumab it blocks the receptor binding
domain of all isoforms of VEGF-A. In contrast to the latter, its modified
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molecular structure aims to avoid immunological reactions. Aflibercept (VEGF
Trap-Eye/Eylea, Regeneron/Bayer) is the latest FDA approved agent for
ophthalmic use. It possesses binding sequences for VEGFR-1 and VEGFR-2 that
were fused to the Fc segment of human IgG1 antibody with a binding affinity that
was 140 times greater than that of ranibizumab and binds to all VEGF-A isoforms,
VEGF-B and PIGF [22].
After intravitreal injection of anti-angiogenic agents, Csaky et al., detected these
substances in the systemic circulation [16] and there is evidence that anti-VEGF
drugs reach the systemic circulation sufficiently to decrease serum VEGF
concentrations [10, 23, 24]. Heiduschka et al. have shown in monkeys that some
2% to 5% of bevacizumab is already in the blood stream one and four days after
intravitreal injection [18]. Bevacizumab with its long serum half-life of 20 days
can lower blood VEGF levels even when intravitreally administrated in an amount
comparable to that achieved with intravenous therapy [10, 25, 26]. This finding
raises the possibility that intravitreally administered bevacizumab may suppress
baseline physiologic VEGF activity. Ranibizumab, in contrast, has a much shorter
serum half-life of 6 hours and its serum levels remain low. Although renal
complications have been reported in only rare cases after intravitreal injections of
ranibizumab or bevacizumab [14, 17, 27–29], the possibility of systemic
complications after intravitreal injections of anti-VEGF agents has to be
considered. Regarding aflibercept, little data concerning systemic effects after
intravitreal injection is available although a clearance from the eye into the
systemic circulation has been shown [30]. Therefore, it is vital to investigate the
effects of anti-VEGF agents in nonhuman primates to establish biologic activity
and adverse effects relevant to humans. This in vivo study was performed in
monkeys as antibody molecules and their interaction with Fc receptors in
monkeys mimic those present in humans [31]. To this aim, we investigated the
effects of a single intravitreal injection of ranibizumab and aflibercept on the
kidneys of eight monkeys on days one and seven after injection. The distribution
of aflibercept and ranibizumab in renal glomeruli was analysed, VEGF levels in
glomeruli and the glomerular endothelial cell fenestrations were quantified.
Note that due to the high costs of experiments, this pilot study only consists of
a small number of animals and the study design does not allow the evaluation of a
great variety of time points.
Materials and Methods
1. Animals and study protocol
Ten cynomolgus monkeys (Macaca fascicularis, aged 3 to 8 years) were raised at
the Covance Laboratories (Muenster, Germany) under standard conditions. All
animals were housed and handled in strict accordance with good animal practice
under supervision of veterinarians in accordance with the German Animal
Welfare Act and were monitored for evidence of disease and changes in attitude,
appetite or behaviour suggestive of illness. Full details are shown in Table 1.
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The naive Cynomolgus fascicularis monkeys are from a closed breeding colony
(Noveprim Mauritius). Tests for TB, B-Virus, SIV, SRV, STLV, are carried out
during export and import quarantine. Additionally tests for TB, B-Virus, SIV,
SRV, STLV are carried out regularly for all animals on site regardless if they are in
studies or not.
Cynomogus monkeys are housed in social groups before and during studies.
The space requirements are according to the EU directive (DIRECTIVE 2010/63/
EU OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 22
September 2010 on the protection of animals used for scientific purposes).
The animal live under a 12 hour dark light cycle, have ad libidum access to
water and food provided twice daily, lab diet plus fresh fruit. The foremost
enrichment is social housing. Additionally mirrors, wooden trunks, balls are
supplied as a standard. Further enrichment devices are available and made
available on a rotating scheme.
The animal welfare officer on site regularly checks the housing and handling
conditions.
Since animals are housed in groups during the study the individuals are not
randomised to the dose group, but rather a stable group of animals created a long
time before the study.
Both eyes of four animals were intravitreally injected with ranibizumab and
another four animals with aflibercept. The doses of anti-VEGF agents were the
same as clinically used in humans and as provided and recommended by the
manufacturers: 2 mg of aflibercept and 0,5 mg of ranibizumab, respectively.
All injections were carried out in the morning, following slight sedation with
ketamin and diazepam. One and seven days after intravitreal injection, the
animals were sacrificed under general anaesthesia and the kidneys were removed
(except the left kidney of a monkey that was sacrificed on day seven after injection
of aflibercept showing aplasia). The left kidney of each animal was prepared for
immunohistochemistry, specimens of the right kidneys served for electron
microscopy as described below. One untreated monkey sacrificed on day seven
and one monkey injected with aflibercept’s vehicle and sacrificed one day after
injection served as controls. Blood samples were taken before injection (predose)
and on days one and seven after injection. Platelet-poor plasma was prepared by
centrifugation. For injection specifications, ophthalmic examinations as well as
Table 1. Details of the animals used in this study.
Covance Study 8260977 Covance Study 8274007
Species: Cynomolgus monkeys (Macaca fasicularis) Sprecies: Cynomolgus monkey (Macaca fasicularis)
Origin: Mauritius Origin: Mauritius
Age at predose start: 3 to 8 years Age at predose start: 3 to 8 years
Predose body weight: 4 to 12 kg Predose body weight: 4 to 12 kg
Number and sex: 5 healthy male animals Number and sex: 5 healthy male animals
Animal housing: Pair and single, due to the single
control animal
Animal housing: Pair and single, due to the single
control animal
doi:10.1371/journal.pone.0113701.t001
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fixation methods and histological procedures, please see our previous publications
[21, 32].
Ethical Statement
Handling and housing of the animals were only done at Covance Laboratories
GmbH. All animals were housed and handled in strict accordance with good
animal practice under supervision of veterinarians in accordance with the German
Animal Welfare Act and were monitored for evidence of disease and changes in
attitude, appetite or behaviour suggestive of illness. The animals were sacrificed,
and their kidneys were fixed at Covance Laboratories GmbH. The animals were
sacrificed under general anaesthesia, i.e., intramuscular injection of ketamine
hydrochloride followed by an intravenous sodium pentobarbitone (Lethabarb,
Virbac, Australia) overdose. Only the further investigations: electron microscopy
and immunohistochemistry were performed in our lab in Tuebingen. These
investigations did not necessitate approval by an institutional review board.
Covance Laboratories GmbH test facility is fully accredited by the AAALAC. This
study was approved by the local IACUC, headed by Dr. Jörg Luft, and performed
in consideration of the following recommendation:
Commission Recommendation 2007/526/EC on guidelines for the accommo-
dation and care of animals used for experimental and other scientific purposes
(Appendix A of Convention ETS 123).
2. Kidneys samples and fixation
On days one and seven after intravitreal injection, the animals were sacrificed
under general anaesthesia, i.e., intramuscular injection of ketamine hydrochloride
followed by an intravenous sodium pentobarbitone (Lethabarb, Virbac, Australia)
overdose. The kidneys were extracted five minutes post-mortem. The left kidney
of each animal was fixed in paraformaldehyde uncut for immunohistochemistry, a
specimen of the right kidneys was dissected into small cube-like pieces with a
length of 2–3 mm and then fixed in glutaraldehyde (ice cooled) for electron
microscopy (the only available kidney of the monkey described above was
prepared for electron microscopy). The kidneys of the monkey without treatment,
or with aflibercept’s vehicle injection, were handled in the same manner.
3. Immunohistochemistry
Sections (4 mm) were cut from formalin-fixed, paraffin embedded tissue and
mounted on superfrost Plus microscope slides (R. Langenbrinck Labor- u.
Medizintechnik).
The slides were deparaffinised and rehydrated, and heat induced epitope
retrieval in TRIS EDTA (pH 9) using a pressure cooker was performed. After two
washing steps in TBS (0.5% TWEEN) immunohistochemical staining of VEGF
was performed according to the instructions provided by the manufacturer in a
humid chamber. The slides were incubated for 60 min with the primary mouse
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anti-VEGF antibody (1:50, DAKO, Denmark) at 37 C̊ and then processed using
the DAKO REAL Detection System Alkaline Phosphatase/RED kit rabbit/mouse,
then counterstained with hematoxylin and covered. The same procedure was
performed for immune reactivity analysis against ranibizumab and aflibercept
using respectively a primary mouse antibody against the human IgG-Fab-
fragment (Dianova, 1:100) and a primary mouse antibody against the human IgG-
Fc-fragment (Dianova, 1/150). These samples were used for the quantification and
normalisation of VEGF or ranibizumab/aflibercept stainings.
Additionally an immune reactivity analysis using fluorescent antibodies was
performed. A mouse antibody against the human IgG-Fab-fragment of IgG
(dilution 1:400, Jackson ImmunoResearch) and a goat anti-mouse alexa488
labelled secondary antibody (dilution 1:400, Invitrogen) were used for
ranibizumab staining. Goat anti-human IgG-Fc antibody (dilution 1:200, Novus
Biologicals) and a donkey anti-goat alexa488 labelled secondary antibody
(dilution 1:500, molecular probes) were used for aflibercept staining.
4. Quantification and normalisation of VEGF and ranibizumab/
aflibercept stainings
From each tissue sample, photos from 10 randomly chosen glomeruli-containing
regions were taken using a Zeiss Axioscop microscope with AxioVision image
capture software at a magnification of 400x. On these photos the glomeruli were
defined as the area of interest (aoi). These aoi were isolated using the image j
software. In the next step the nuclei in the aoi were counted using a semi-
quantitative computer assisted method (image j). Then the stained area of each
aoi was determined (Fig. 1). Briefly, the image j program offers a colour
deconvolution plug which splits images into three color-channels and is widely
used for immunohistochemistry analysis [33]. The number of nuclei could be
calculated after the hematoxilin stained areas were isolated using the ‘‘H&E’’ filter
of the color deconvolution plug in. After that ‘‘watershed’’ and ‘‘particle counter’’
algorithms were run for the nuclei count as described by others [34, 35]. This
method was compared with manual counting and was found to be as accurate as
the manual method. For the determination of the stained area we used the colour
deconvolution plug in with the RGB (red, green, blue) filter. The red image was
used for the calculation of the stained area.
For the determination of the background for the stained area determination the
red dye intensity from a control which was treated only with the secondary
antibody and the red dye was set as threshold for the filter settings for the image j
analysis. The ratio of stained area/nuclei was calculated and the statistical analysis
was performed as further described.
5. VEGF-A plasma levels
Blood samples of all monkeys were collected in tubes containing EDTA before
intravitreal injection (predose) and on day one and seven after injection of anti-
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VEGF agents, and plasma was prepared by centrifugation, transferred to new
tubes and stored at 270 C. Plasma samples were analyzed using commercially
available ELISA kits for human VEGF-A (DVE00) (R&D Systems, Minneapolis,
Minnesota). Briefly, the microtitration plates were coated with monoclonal
antibodies specific for VEGF-A, standards and probes were added, incubated and
washed. Then, an enzyme-linked polyclonal antibody specific for VEGF-A was
added and its substrate solution followed after a second incubation and wash step.
After stopping the colour development, the intensity of colour (Optical Density)
was measured by photospectrometry with the lower detection limit of VEGF-A set
at 30 pg/ml. Calculation of VEGF concentration was performed according to the
manufacturer’s recommendations.
6. Light and electron microscopy
Specimens were postfixed with 1% OsO4 at room temperature in 0.1 M
cacodylate buffer (pH 7.4), en bloc stained with uranyl acetate and lead citrate,
and embedded in Epon after dehydration in a graded series of acetones. Semithin
sections were stained with Toluidine Blue and examined by light microscopy
Figure 1. Semi-quantitative computer assisted method used for the quantification and normalisation
of the VEGF staining. Glomeruli were defined as the area of interest (AOI), and then the AOI were isolated
using the image j software. The nuclei in the AOI were then counted and finally the stained area of each AOI
was determined.
doi:10.1371/journal.pone.0113701.g001
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(Zeiss Axioplan2 imaging, Zeiss, Jena, Germany). For electron microscopy, the
sections were cut ultrathin and analyzed with a Zeiss 902 A electron microscope
(Zeiss, Jena, Germany).
7. Quantification of the glomerular endothelial fenestrations
Under the light microscope at a low magnification (x10) glomeruli were identified
in semi-thin sections and checked on mechanical or fixation artifacts and
pathological features at a higher magnification. Three glomeruli per kidney (six
per time point for ranibizumab and aflibercept, three for controls) with middle to
large diameter and intact bowman’s capsules were chosen and cut ultrathin for
electron microscopy. After examination of the probes at a magnification of 3000
fold, montages of transmission electron micrographs were performed by using the
multiple image arrangements 5 MIAs in order to provide montages of the entire
glomeruli (Fig. 2). The montages consist of overlapping images that were taken
using an image analysis software (iTEM, Olympus Soft Imaging Solutions,
Muenster, Germany). Similarly to a previously described method [36], high-
magnification images were taken from the chosen glomeruli according to a
systematic uniform random sampling protocol (SURS). Starting at the top-most
portion of the glomerular tuft,620000 images were taken moving the position of
the thin section grid with the help of the X and Y grid position control keys. For
this purpose, the grid was moved ten units horizontally taking a picture at each
stop point until the opposite portion of the capsule was reached. Then the
position of the grid was moved 10 units vertically and 5 units to the right or left,
respectively. This procedure was continued until the entire glomerular profile was
scanned through (Fig. S1). After pictures were scanned through for artefacts by a
blinded observer, high- magnification images were used for quantification of
glomerular fenestration using a counting tool of the iTEM software. Only pictures
on which glomerular endothelium was undoubtedly identifiable were analyzed. A
line was drawn and measured along the lamina rara interna of the endothelial
basement membrane adjacent to the fenestrated endothelium and fenestrations
were counted by a single observer under standardised conditions. As capillary
walls can be divided into peripheral and mesangial regions [36], only peripheral
portions where glomerular basement membranes and capillary walls show
parallelism were considered. We found that the quantification in the mesangial
portions is not comparable to the peripheral parts as the predominant amount of
mesangial endothelium is not fenestrated whereas on the other hand there are
parts with increased fenestration (as described as ‘‘alveolus fenestratus
endothelialis’’ by Kondo et al., [37]. Thus, this endothelium is morphologically
not comparable to the single layered endothelium in the peripheral portions so
that applying the same quantification method would not be admissible
(Fig.3A–B). Therefore, the mesangial portions were excluded from the
quantification of the fenestrations.
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8. Statistical analysis
The ratio of fenestrae per mm was calculated using Microsoft-Office-Excel for each
image considered. Statistical significances for the evaluation of the fenestrae per
mm of the glomerular capillaries and for the quantification of VEGF as well as
ranibizumab/aflibercept were determined by using the Student’s t test from the
JMP10 statistical program (SAS, Heidelberg, Germany). P,0.05 was considered
statistically significant.
Results
1. Immunohistochemistry
1.1. Ranibizumab/aflibercept fluorescence staining.
Kidney sections from the control animal did not show any specific staining in the
glomeruli after staining either with an antibody against the anti-human IgG-Fc
fragment (Fig. 4A) or against the anti-human Fab fragment of IgG (not shown).
Only the erythrocytes within the capillaries showed a weak autofluorescence
(Fig. 4A). After omitting the first antibodies, the same staining pattern as in
Fig. 4A was observed (not shown). One day after aflibercept injection, the
endothelium cell layer and material within the capillaries of many glomeruli were
highly fluorescent (Fig. 4B–C). Occasionally, glomeruli in which only the
endothelium was stained were localised close to others that contained high
amounts of IgG-Fc reactive material within the capillaries (Fig. 4B). Erythrocytes
within the glomeruli were highly fluorescent (Fig. 4C). Seven days after aflibercept
injection, the fluorescent material within the capillaries was fewer and the
fluorescence intensity became weaker (Fig. 4D). One day after ranibizumab
injection, the endothelium cell layer and erythrocytes of most glomeruli became
Figure 2. Example of a montage of transmission electron micrographs by using multiple image
arrangements (MIAs) in order to provide the entire renal glomerulus. These images were taken using the
image analysis software iTEM at the magnification of 63000. Here one day after aflibercept injection.
doi:10.1371/journal.pone.0113701.g002
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fluorescent after labelling with an antibody against the human Fab fragment of
IgG (Fig. 4E). However, the specific fluorescence was nearly lost seven days after
injection of ranibizumab (Fig. 4F).
Figure 3. Examples of representative transmission electron micrographs of (A) a fenestrated
glomerular endothelium and of (B) peripheral versus mesangial portions of the glomerular
endothelium (both one day after aflibercept injection). (A) Blood lumen on the upper part, urinary space
on the lower part of the image. The healthy glomerular filtration barrier consists of three layers [6]: the
fenestrated glomerular endothelial cells, the intervening glomerular basement membrane and the podocyte
processes and slit diaphragm. GBM5 glomerular basement membrane, CL5 capillary lumen, POD5
podocyte. Arrows mark glomerular endothelial cells fenestrae (note the absence of diaphragm), asterisks
mark podocyte foot processes, arrowheads mark podocyte slit diaphragm. (B) At this magnification, podocyte
foot processes (asterisks) allow the clear identification of the capillary lumen (CL). In accordance with our
definition, the peripheral portion begins where the endothelium and the glomerular endothelial basement
membrane (GBM) run approximately parallel (marked by arrows). Arrows mark direction into which peripheral
endothelium begins. In between the arrows the mesangium (Mes) and the mesangial portion of the capillary
endothelium (MesE) is located. Note that in the mesangial portion there is no GBM adjacent to the fenestrated
endothelium so that the described counting method is not applicable and the endothelium does not show the
typical single- layered configuration. Magnification 620000.
doi:10.1371/journal.pone.0113701.g003
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1.2 Quantification and normalisation of ranibizumab/aflibercept stainings.
Immune reactivity against aflibercept or ranibizumab was only detected in
aflibercept- or ranibizumab-treated animals respectively and did not show any
significant differences between days one and seven (Fig. 5A–B).
1.3 Quantification and normalisation of VEGF staining.
The anti-VEGF stained area to cells ratio in the aoi of the samples (representing
the mean VEGF level/cell ratio) from the tissue of the ranibizumab-treated
animals showed no significant changes at any of the analysed time points
(486¡55 (day 1) and 451¡66 (day 7)) compared to the untreated control-animal
samples (456¡99). However, the stained area to cells ratio of the tissue-samples
of the aflibercept-treated animals showed a significant decrease one day (383¡85)
after treatment (p,0.05) and an even stronger decrease seven days (233¡41)
after treatment (p,0.0001) compared to the untreated control-animal samples
(456¡99). The levels of VEGF were found to be significantly lower in the
Figure 4. Immune fluorescent photomicrographs of glomeruli from control (A), aflibercept-treated
(B–D) and ranibizumab-treated (E–F) monkeys eyes. In all figures, the asterisks label the spaces of the
Bowman capsule. A) Kidney sections from the control animal did not show any specific staining with anti-
human IgG-Fc antibody in the glomeruli. Only the erythrocytes (arrow) within the capillaries showed a weak
fluorescence. B) One day after aflibercept injection, the endothelium cell layer and material within the
capillaries of a glomerulus were highly fluorescent (white arrow) after labelling with an antibody against the Fc
region of IgG. In an adjacent glomerulus, only the endothelium was stained (white arrowhead) whereas the
lumina of the vessels did not contain IgG-Fc positive material (black arrow). C) Erythrocytes within the
glomeruli (arrowhead) as well as the endothelium (arrow) were highly fluorescent. D) Seven days after
aflibercept injection, the fluorescent material within the capillaries (arrowhead) and the fluorescence intensity
of the endothelium became weaker. E) One day after ranibizumab injection, the endothelium cell layer (white
arrow) and erythrocytes (arrowhead and black arrow in the inset) were fluorescent after staining with an
antibody against human Fab of IgG. F) The specific fluorescence of the endothelium (arrow) and erythrocytes
(arrowhead) was nearly lost seven days after injection of ranibizumab.
doi:10.1371/journal.pone.0113701.g004
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aflibercept-treated animals on days one (383¡85 vs. 486¡55; p,0.05) and seven
(233¡41 vs. 451¡66; p,0.0001) after treatment as compared to the
corresponding ranibizumab-treated ones. The decrease of the VEGF level from
day one to day seven after treatment was also found to be significant (383¡85 vs.
233¡41; p,0.0001) (Fig. 6).
2. Measurement of VEGF-A
165
plasma levels
All doses were below the detectable limit of the assay meaning under 30 pg/ml
(not shown).
3. General examinations by light and transmission electron
microscopy
The biopsies of all the kidneys were first studied by light microscopy and also by
TEM with increasing magnification in order to scan the specimens on artefacts
and pathologic features. None of the glomeruli was sclerotic. The podocyte foot
processes were well-formed and did not show effacement, and a continuous slit
diaphragma could be observed. The glomerular basement membrane (GBM) was
of normal thickness and did not show duplication in all specimens without
widening of the subendothelial space or cellular interposition. The well-defined
glomerular endothelium was flattened though there were slight variations in
thickness without endotheliosis. In all samples, it was mostly adjacent to the
GBM.
The capillary loops were filled with more or less electron-dense serum. The
density difference could be observed in glomeruli of all of the kidneys (Fig. 7).
Figure 5. Quantification and normalisation of aflibercept/ranibizumab staining. Results of the analysis of aoi of glomeruli from kidneys of monkeys one
and seven days after aflibercept (A) or ranibizumab (B) treatment and the corresponding controls, respectively after staining with the anti-Fc-fragment
antibody for aflibercept and the anti-Fab fragment antibody for ranibizumab immune reactivity analysis; t-test against the corresponding control was
performed: ** for p,0.001,*** for p,0.0001.
doi:10.1371/journal.pone.0113701.g005
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4. Quantification of the glomerular endothelial cells fenestrations
In total, 30 glomeruli e.g. three glomeruli per monkey fulfilling the criteria
described above were investigated. The total amount of pictures taken was 4855 of
which 1327 (27.3%) were evaluated. After the ratio of fenestrae per mm was
calculated for each image, the values obtained for the two monkeys of aflibercept
and ranibizumab for each time point were pooled. Student’s test was performed
with values of the untreated monkey as control values and it showed a statistically
significant increase (p,0.05) in the number of fenestrae per mm one day after
aflibercept injection (median: 2.05) compared to all other groups (medians: 1.27
for aflibercept day 7, 1.46 for ranibizumab day 1, 1.29 for ranibizumab day 7 and
1.25 for the untreated group) (Fig. 8). The other conditions did not show any
statistical significance compared to the controls (Fig. 8).
Discussion
In the normal kidney, VEGF is expressed on podocytes. Dysregulation of VEGF
expression within the glomeruli has been associated with a wide range of renal
diseases that may occur within weeks to months after intravitreal administration
of VEGF inhibitors [14, 27]. The dose of anti-VEGF agents used in ophthalmology
is minute compared with that used intravenously, but there is evidence of systemic
absorption and diffuse inhibition of VEGF [14, 17, 38, 39]. Pelle et al., reported a
non diabetic patient with normal kidney function who developed kidney toxicity
after four injections of ranibizumab for the treatment of age-related macular
degeneration [14]. Several studies evaluating the safety and efficacy of intravitreal
Figure 6. Quantification and normalisation of the VEGF staining. Results of the analysis of aoi of
glomeruli from kidneys of monkeys one and seven days after ranibizumab and aflibercept treatment and the
corresponding controls after anti-VEGF staining; t-test against control: * for p,0.05, *** for p,0.0001; t-test
ranibizumab day 1 versus aflibercept day 1 and ranibizumab day 7 versus aflibercept day 7: # for p,0.05,
### for p,0,0001; t-test aflibercept day 1 versus aflibercept day7: +++ for p,0.0001.
doi:10.1371/journal.pone.0113701.g006
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anti-VEGF in diabetic patients have reported renal adverse effects [17, 39, 40].
Georgalas et al., postulated that plasma levels of anti-VEGF could possibly cause
deregulation of VEGF expression in the kidney and cause renal damage. Of course
the fact that the patients were diabetic should be taken into consideration since
such patients are prone to develop renal failure [17]. Previous studies [41] have
shown that intravitreally injected ranibizumab is cleared from the eye into the
circulation with a half-life of approximately three days in monkeys [42] and that
ranibizumab can be found in the serum but the concentrations detected were
considered below the necessary threshold for a sufficient VEGF inhibition [43].
Since ranibizumab is not protected from serum elimination by an Fc-fragment, it
has been suggested that it is rapidly cleared from the circulation via renal
elimination. Our data is in accordance with these studies since indeed
ranibizumab was indeed localised in the glomeruli one and seven days after
intravitreal injection and it did not affect the VEGF level in the glomeruli nor the
number of glomerular endothelial fenestrations. We were unable to measure
plasma VEGF levels since the concentrations were always below the detectable
limit (30 pg/ml) of the assay. Larsson et al., have determined in 80 plasma samples
of healthy humans that the mean value ¡ SD of VEGF was 32¡21 pg/ml [44].
Moreover, the use of serum instead of plasma would be preferable since serum
Figure 7. Examples of transmission electron micrographs used for the quantification of the glomerular
endothelial cells fenestrations. The red line drawn a long lamina rara interna, the length of line is in mm, the
red crosses point out fenestrations. (A) after injection of the vehicle; (B) in the untreated control; (C) one day
after injection of ranibizumab; (D) seven days after injection of ranibizumab; (E) one day after injection of
aflibercept; (F) seven days after injection of aflibercept. Magnification 620000.
doi:10.1371/journal.pone.0113701.g007
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VEGF levels are several fold higher than plasma levels, because platelets express
VEGF and secrete it during blood clotting [45].
Unfortunately we have no data concerning the urinary sediments. It would be
of great interest to analyse them, especially as there are indications that anti VEGF
therapies have influence on the kidneys, and can cause proteinuria and
hypertension [3–5]. The analysis of the urinary sediments will also be an aim of
our further studies.
It has been published that aflibercept, in contrast to bevacizumab, binds VEGF-
A in a 1:1 stoichiometry which remains stable in the circulation [46]. The authors
speculated that because of this stoichiometry and the inert nature of the
complexes, aflibercept is not expected to accumulate in renal glomeruli as has
been found for bevacizumab [46]. The present study shows for the first time that
in reality aflibercept is found in the glomeruli after intravitreal injection and
moreover that it significantly decreases their VEGF level. Whether pathological
alterations were caused by ranibizumab or aflibercept in a different manner or not
is out of the focus of this pilot study. Surprisingly one day after injection,
aflibercept was able to increase the number of glomerular endothelial cells
Figure 8. Box plot representation of the quantification of the fenestrations per mm depending on the
treatment and its duration. Application of the Student’s test showed no significant differences in the number
of fenestrations per mm except one day after aflibercept’s injection where the number was increased
compared to all other groups (*, p,0.05).
doi:10.1371/journal.pone.0113701.g008
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fenestrations compared to the controls or ranibizumab-treated monkeys. Since
the glomerular VEGF level was reduced, we rather expected a reduction or a
stabilisation of the number of fenestrations, as apparent in the choriocapillaris
after intravitreal injection of an anti-VEGF agent [19]. This result suggests a
complex regulation of glomerular endothelial cell fenestrations which is not
completely elucidated. Indeed in contrast to the choriocapillaris, it has been
shown that the fenestration of glomerular capillaries requires the action of TGF-
b1 [47]. Moreover, in systemic endothelial fenestrations, the intracellular
pathways through which VEGF acts to induce fenestrations include a key role for
the fenestral diaphragm protein plasmalemmal vesicle-associated protein-1 (PV-
1). However, the role of PV-1 in glomerular endothelial cell fenestrations is less
clear, not least because of controversy over the existence of glomerular endothelial
cell fenestral diaphragms [48]. Satchell and Braet thought that the glomerular
endothelial cell fenestrations generally do not express PV-1 and, it is generally
asserted, do not possess diaphragms. However, they should note that a number of
observations challenge this position. To some extent, appearance of this feature
may be dependent on the fixation and labelling techniques used, since a
diaphragm is seen in some preparations but not in others. It could be either that
some techniques destroy a very delicate diaphragm or that other techniques result
in an artefactual appearance of a diaphragm, perhaps through condensation/
cross-linking and labelling of glycocalyx, other plasma proteins, or the outer
surface of the glomerular basement membrane. Another careful study demon-
strated that glomerular endothelial cells in the rat adult kidney, apart from a small
fraction, do not furnish diaphragms with their fenestrae; most glomerular
endothelial cells in the immature glomeruli of rat embryos have diaphragmed
fenestrations and the number of glomerular endothelial cells with diaphragmed
fenestrations is increased in the glomeruli of Thy-1.1 nephritis rats, presumably
reflecting a process of restorative remodelling of the glomerular capillary tuft after
injury [49]. Along with the appreciation that the intraglomerular portion of
efferent arterioles and direct tributaries may express fenestrated diaphragm [50],
this goes a long way toward clarifying the position. In our study, the fenestrations
of the glomerular endothelial cells of adult monkeys were clearly not closed by
diaphragms (Fig. 3A) which contrast to those observed in the choriocapillaris and
reported in one of our previous monkey studies (Fig. 6 in [19]). Since the same
technique was used in these two studies, technical artefacts can be excluded. The
glomerular changes observed in our study are not very extensive, but one has to
keep in mind, that in the present model anti-VEGF treatment was given only once
and the animals used have no overt renal pathology. Usually patients with e.g.
diabetic retinopathy get the anti-VEGF treatment on regular basis and as
proliferative diabetic retinopathy is a microvascular disesase, we have to assume in
these patients also microvascular disturbances in the kidney including micro-
albuminuria. Under this condition VEGFA secreted from podocytes is essential to
maintain proper cellular functions [51].
What might happen if VEGFA is affected in a stimulated system is speculative
and should be investigated. This might be a consequence of different antibody
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design. The immune complexes might be inductor of thrombotic microangio-
pathy in the kidney [52]. Caution is needed when patients which might also have
already renal disease get these substances locally, which have definitive systemic
effects.
Conclusions
In conclusion, we showed that intravitreal ranibizumab and aflibercept can escape
from the blood-retinal barrier and are also distributed to distant organ like the
kidneys. Our study demonstrated that a single dose of intravitreally injected
aflibercept already decreases the VEGF level in the glomeruli one and seven days
after treatment whereas ranibizumab did not affect the glomerular VEGF level. In
clinical practice, it is therefore important to monitor patients receiving intravitreal
injection of VEGF inhibitors for possible systemic side-effects, particularly kidney
injury, which may not be immediately apparent. Because of the increasing use of
intravitreal anti-VEGF agents in the treatment of age-related macular degenera-
tion, as well as for other indications such as diabetic retinopathy, further studies
are highly needed to elucidate the effects of repeated anti-VEGF injections on
VEGF concentrations in distant organs.
Supporting Information
Figure S1. Demonstration of the systematic uniform random sampling
protocol (SURS) on a multiple image arrangement (MIA). Transmission
electron microscopy, magnification63000. Probe: Aflibercept day 1, Glomerulus
1. Asterisk marks starting position (first picture), double asterisks mark end
position (last picture), arrows mark direction into which SURS was performed.
doi:10.1371/journal.pone.0113701.s001 (DOCX)
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